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Do but consider what an excel lent thing sleep is: 
it is so inestimable a jewel that, if a tyrant 
would give his crown for an hour's slumber, it 
cannot be bought: of so beautiful a shape is it, 
that though a man I ie with an Empress, his heart 
cannot beat quite ti I I he leaves her embracements 
to be at rest with the other: yea, so greatly 
indebted are we to this Kinsman of death, that we 
owe t~e better tributary, half of our I ife to him: 
and there is good cause why we should do so: for 
sleep is the golden chain that ties health and our 
bodies together. Who complains of want? of 
wounds? of cares? of great men's oppressions? 
of captivity?. whi 1st he sleepeth? Beggars in 
their beds take as much pleasure as kings: can 





Recent.research has suggested that clozapine, a 
psychotropic agent, may have sleep inducing pro-
perties. However, no research has yet attempted 
to systematically determine the effects of low 
·doses of clozapine (J2,50mg-25mg) upon the sleep 
patt~rns and REM dream content of normal young 
adults. In addition, contradictory findings 
exist in the 1 iterature at present. as to whether 
the administration of a placebo influences the 
sleep patterns of normal young adults. 
The present study makes significant contributions 
to the field of psychopharmacology in that results 
suggest that clozapine may have important thera-
peu~ic imp I ications for the treatment of insomnia 
as we! I as disorders of slow wave sleep. 
Moreover, the experiments conducted indicate that 
the administration of a placebo has no significant 
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Hypnotic and sedative drugs have been regarded as the most ex-
pedient method for the treatment of insomnia in contemporary 
western culture and their prescription has increased dramat~-
cal ly (KaracanandWilliams 1971; Oswald 1968). However, many 
of these drugs suppress REM sleep (Oswald 1968), cause death 
when taken in overdose (Johns 1975), produce dependence (Kales 
and Kales 1973), become relatively ineffective in the treatment 
of insomnia after chronic administration (Johns 1975) and the 
abrupt withdrawal after continuous administration may result in 
a drug withdrawal insomnia characterised by difficulty in falling 
asleep, an increased vividness in REM mentation as wel I as the 
occurrence of nightmares (Kales et al 1968(a)(b), 1969(a)(b)). 
Recent research has suggested that clozapine, a psychotropic 
agent, may have pronounced sleep inducing properties (Hemphill 
et al 1975; Ruch et al 1976; Gross and l,.angner 1966,1969; 
Berzewski et al 1969). However, its role as an hypnotic agent 
has yet to be systematically investigated. In the prese.nt 
study, therefore, the effects of clozapine upon the sleep 
patterns of twenty normal young adults were investigated during 
both short- and long-term administration at two different dose 
rates (25mg and 12,50mg/night respectively). In addition, the 
short-term effects of 12,50mg clozapine/night upon REM dream 
content were also investigated. The present study required a 
total of 2190 hours of recording over a period of 219 nights. 
Th~ first major aim of the present study was to elucidate the 
effects of the short-term administration of 25mg clozapine upon 
xvii 
the sleep patterns of seven normal young adults. The experi-
ment employed an additional group of seven control subjects. 
This research strategy pe rmi tte.d the use of a. d·oub.I e b 1.i-nd cross-
over design and, in addition, enabled the investigator to assess· 
the effects of the short-term administration of placebo upon the 
sleep patterns of normal young adults. Contradictory evidence 
exists in the literature at present as to whether the administra-
tion of a placebo influences the sleep patterns of normal young 
adults CDavis and Hartmann 1973(a)(b); Zung 1973; Adam et al 
1975,1976). The second major aim of the present study was, 
therefore, to determine the effects of the short-term adminJstra-
tion of placebo upon the sleep patterns of normal young adults. 
The subjects slept for nine consecutive nights in a sound 
attenuated, temperature regulated sleep laboratory while EEG's 
and EOG 1 s were monitored continuously throughout the night. 0 
The first two nights served purely an adaptive purpose and no 
recordings were made. Baseline sleep patterns were-obtained 
from nights three and four. On night$ five, six and sevenJ 
subjects received 25mg clozapine or 25mg.placebo. Nights eight 
and nine were used to assess any drug withdrawal effects. 
Measures of mood and performance, as wel I as a questionnaire 
concerning possible side-effects of drug administration, were 
administered each morning to the subjects in the laboratory 
fifteen minutes after awakening for the entire duration of the 
study. 
The short-term administration of 25mg clozapine suppressed 
stage 4 sleep on the second and third nights of administration. 
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This finding suggests that clozapine may have important thera~: 
peutic imp I ications for the treatment of disorders of slow wave 
sleep. The short-term administration of clozapine also appears 
to-have important therapeutic imp I ications for the treatment of 
insomnia. This conclusion is supported by the following find-
ings: (i) Total sleep time was significantly increased on the 
first and second nights of clozapine administration.despite th~ 
attempt to control for the duration of time spent in bed. (ii) 
The number of body movements was significantly reduced on al I 
' three nights of clozapine administration. (iii) The number of 
body movements/minute of sleep was also significantly reduced 
on al I three nights of clozapine administration. (iv) The short-
term administration and withdrawal of 25mg clozapine/night had( 
no significant effect upon stage REM sleep. 
However, the indices of stage REM sleep were significantly 
affected. The mean burst length, the density/minute REM slee~ 
and% motility were significantly increased on the third night 
of clozapine administration and this increase persisted on the 
first night of clozapine withdrawal. In addition, the total 
number of bursts and the number of bursts/REM period increaseq 
significantly on the first night of clozapine withdrawal. It 
is tentatively suggested that these findings may reflect the 
antipsychotic properties of clozapine (Blum and Glrke 1974). 
Finally numerous psychological and physiologi_cal side-effects 
including the impairment of intellectual performance, nausea, 
difficulty in writing and talking, hypotension and drowsiness 
were reported and this finding may represent a major I imitation 
In the possible use of clozapine as an hypnotic agent. 
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The administration of placebo had no systematic effect upon any 1 
of the monitored sleep parameters. This finding does not appear 
to hold true for psychological parameters as the administration 
of placebo resulted in a significant increase in the subjective· 
estimation of drowsiness on the morning following the second 
night of administration. 
The third major aim of the present study was an attempt to deter-
mine the effects of the long-term administration of 12,50mg 
clozapi~e upon the sleep patterns of six normal young adults, 
This investigation employed a 25 night single blind cross-over 
design. The subjects received 12,50mg placebo on the first and 
last five nights. On the intermediate fifteen nights, subjects 
received 12,50mg clozapine. Subjects reported to the laboratory 
on the third and fourth nights in order that baseline sleep re-
cordings could be obtained. To determine the effects of 12,50mg 
clozapine on sleep patterns, subjects slept in the laboratory on 
the eighth, twelfth, sixte~nth and twentieth nights. Nights 
twenty one and twenty five were used to determine whether the 
withdrawal of clozapine after fifteen consecutive nights of 
administration would result in an altered sleep pattern. Subjects 
completed a home log each morning throughout the twenty five days. 
Prior to the commencement of the study, subjects slept for two 
nights in the laboratory. This was done in order to adapt the 
subjects to the laboratory environment, experimenter and experi-
mental routine. 
The long-term administration of 12,50mg clozapine significantly' 
reduced the number of minutes spent awake during the second three 
xx 
hours of the record, the percentage of time spent in stage I 
sleep, the number of body movements during sleep as wel I as 
movement time. This evidence appears to suggest that clozapine 
may have sleep inducing properties. Additional support for the 
above assumption was provided by the finding that no rebound of 
stage REM sleep occurred, despite the fact that a smal I but S'ignl-
ficant reduction in stage REM sleep occurred d~ring the admi~i-
stration of clozapine. This finding is in markeq contrast to 
the effects of many hypnotics which produce a REM rebound on 
withdrawal characterised by difficulty in falling asleep, an· 
increased vividness in REM mentation as wel I as the occurrence 
of nightmares (Kales et al 1968(a)(b), 1969(a)(b)). 
However, numerous side-effects such as depression, apathy, tired-
ness, lack of vitality, resentfulness and lack of physical and 
mental energy were reported. In addition, the drug identi flea-
tion rating indicated that a rapid tolerance to clozapine may 
develop. These findings represent further limitations in the 
possible use of clozapine as an hypnotic agent over an extended 
p e r i o d of t i me . Further research on insomniac subjects should 
therefore be carried out to determine whether the administration 
of 12,50mg clozapine wi I I enhance sleep duration over an ext~nded 
period of time. 
The fourth major aim of the present study was to explore the: 
. I effects of the short-term administration of 12,50mg clozap1ne: upon 
the REM dream content of six normal young adults. This investi-
gation comprised a four night single blind cross-over deslf!n, the 
subject being unaware of the experimental condition. Each subject 
xxi 
spent a total of four recording nights in the sleep laboratory 
each within the space of six days of one another. This inter-
mediate period permitted the subjects to recover from the we! I 
documented REM rebound phenomenon incurred by repeated labora-
tory awakenings. Prior to the commencement of the study, the: 
Subjects were issued with coded tablets and were instructed to' 
take specific tablets at home on the two nights preceding each-
of the four laboratory recording nights. In addition, the 
subjects were issued with a home log which they were asked to 
complete upon awakening on the two mornings prior to each 
laboratory recording night. 
The first recording night was used to adapt the subjects to the 
laboratory environment, experimenter and laboratory routine .. 
Only one laboratory night was effected, as pl I the subjects par-
ticipating in this investigation had previously taken part in a 
sleep research program. Baseline REM dream reports were ob-
tained on the second recording night. The third recording night 
was used to determine the effects of the short-term administration 
of 12,50mg clozapine upon REM dream content-whereas the fourth 
recording night endeavoured to trace any possible withdrawal 
effects. The subjects were woken ten minutes into their second, 
third and fourth REM periods. 
The short-term administration and withdrawal of 12,50mg clozapine 
I 
had no systematic effect upon REM dream content. This finding 
is in marked contrast to the effects of many hypnotic agents 
which produce an increased vividness in REM mentation character-
ised by nightmares upon withdrawal (Kales et al 1969(b)p1974; 
xxi i 
Oswald and Priest 1965). This evidence provides additional 
support for the assumption that clozapine may have therapeu-
tic implications for the treatment of insomnia. 
The present study makes a number of significant contributions 
to the field of psychopharmacology, a rapidly developing 
discipline within the domain of psychology. The findings of 
the present study suggest that clozapine may have important 
therapeutic imp I ications for the treatment of insomnia as wel I 
as disorders of slow wave sleep. However, further research 
should be carried out on i~Somniac subjects to extend and sub-
stantiate the present findings. 
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1.0 THE AIMS AND OBJECTIVES OF THE PRESENT INVESTIGATION 
Insomnia is one of the most prevalent disorders encountered in 
general medicine today (Johns 1975) (see section 4.1) and is 
generally treated by the prescription of hypnotic and sedative 
drugs (see section 4.3}. 
REM sleep (Oswald 1968; 
However, many of these drugs suppress 
Freemon 1972; King 1972), cause death 
when taken in overdose (Johns 1975), produce dependence (Kales 
and Kales 1973), and become relatively ineffective after chronic 
administration (Johns 1975). The abrupt withdrawal of an 
hypnotic after chronic administration usually resu_lts in a drug 
withdrawal insomnia characterised by difficulty in fal I ing 
asleep and an increased vividness in REM mentation with the 
occurrence of nightmares (Kales et al 1968(b), 1969(b), 1970(e), 
1974). These findings suggest that many of the hypnotic and 
sedative drugs prescribed at present produce numerous undesirable 
side-effects and that a definite need exists for the development 
of more effective and safer sleep inducing medications. 
Clozapine (Leponex) is a psychotropic agent which has been used 
in many countries over the past five years. It appears to be 
effective in the treatment of a wide variety of psychiatric 
disorders including delusional states, schizophrenic affective 
disturbances, mutistic delusions, behaviour disorders, 
aggressiveness and affective inadequacy (Angst et al 197(). 
CI ozap i ne, un Ii ke the phenoth i az in es, does not cause 
extrapyramidal side-effects (Stille et al 1971). In addition, 
recent findi_ngs suggest that cloza·pine may have pronounced sleep 
induci_ng properties (Hemphi 11 et al 1975; Ruch et al 1976; 
Gross and Langner 1966, 1969; Berzewski et al 1969). However, 
its role as an hypnotic agent has yet to be systematically 
investigated. In the present study, therefore, the efficacy 
of low doses of clozapine (12,50mg-25mg/night) as a sleep 
inducing agent was examined by monitoring its effects upon sleep 
parameters of norma I young adu I ts in a rigorous I y contro I I ed 
laboratory environment. 
The investigation was carried out in three phases. The first 
experiment set out to determine the effects of the short-term 
administration of 25mg clozapine/night for three consecutive 
nights upon the sleep patterns of a group of seven normal young 
adults. Contradictory evidence exists in the I iterature, at 
present, as to whether the short-term administration of placebo 
affects the sleep parameters of normal healthy subjects 
<Zung 1973; Davis and Hartmann 1973; Adam et al 1975, 1976). 
The experiment thus employed an additional group of seven control 
subjects. This research strategy permitted the use of a double-
blind cross-over design and, in addition, enabled the 
investigator to assess the short-term influence of a placebo upon 
sleep parameters. Psychological and physiological side-effects 
were also quantified. 
The initial study demonstrated marked and significant effects of 
the 25mg/night dosage of clozapine upon stage 4 sleep and indices 
of stage REM sleep and the second experiment,therefore, investi-
gated the effects of a lower dose of clozapine (12,50mg/night) 
employing a single-blind cross-over design in a group of six 
normal young adults. In addition, the long-term administration 
of the lower dose was assessed over a period of fifteen 
consecutive nights In this experiment. P~ychological and 
physiological side-effects were a]so assessed by means of a 
number of psychological tests. 
The administration of many hypnotic agents results in a marked 
reduction of stage REM sleep, whereas their withdrawal often 
results in an increased vividness in REM mentation with the 
occurrence of nightmares (Kales et al l968(b), l969(b), l970(e), 
1974). The aims of the third experiment were therefore to 
assess the influence of the short-term administration and 
withdrawal of 12,50mg clozapine/night u.pon the REM dream 
content of six normal young adults: 
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Z.O THE NATURE OF SLEEP 
2. I The · 1 nit i at ion of Mode.rn Sleep Resea·rch 
The scientifi~ investigation of sleep began a I lttle more than 
a c e n t u r y a go • B u rd a c h ( I 8 3 0 ) , o n th e b a s i s o f h i s n at u r a I i .s t i c 
observations, predicted that "~ .. sleep is in i·ts beginning deepest, 
in its continuation smooth and quiet, towards its end slightest" 
(Snyder and Scott 1972, p.646). The first systematic attempt 
to quantify the depth of sleep in human subjects was described 
by Fechner (1860) in his Elemente der PsythophfSik but was 
credited to Kohlschutter, the founder of the experimental 
psychology of sleep (Fechner 1860; Snyder and Scott 1972; 
. . 
Williams etal 1974; Wohlisch 1957). Kohlschutter ( 1862) 
produced a sleep depth curve by plotting the figures for the 
intensities of sound required to awaken the sleeper at different 
times of the night. This curve was characterised by a sub- 1 
stantial increase in threshold unti I the end of the first hour 
of s I eep which was fo I I owed by a rapid and then grad ua I decrease. 
Michelson <1897) reported that the first ho.ur of sleep was indeed 
the deepest but that the remaining hours of sleep were 
characterised by random fluctuations in the arousal threshold in 
contrast to the gradual decrease reported by Kohlschutter (1862). 
Johnson and Swan (1930) elucidated this discrepancy by pointing 
out major methodological pitfal Is in Kohlschutter's design. 
Kohlschutter (1862) awakened his subjects as many as seventeen 
times per night which possibly explains why sleep was so 1.ight 
after the first few hours. He also .fulfi I led Fechner's 
expectation as to the smooth progression of the .curve by 
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disregarding many of his calculations. Subsequent studies 
progressively altered the remainder of Kohlschutter 1 s curve, 
having found the arousal threshold to be higher and less regular 
than Kohlschutter (1862) anticipated (Czerny 1891; De Sanctis 
and Neyroz 1902; 
Lambranzi 1900; 
Endres and Von Frey 1930; 
Mullin et al 1937). 
Hass 1923; 
The continuous monitoring of the sleeping subject's brain was 
soon to replace the investigation of behavioural correlates of 
sleep such as the arousal threshold technique. 
2.2 The Classification of Sleep into Sleep Stages 
2.2. I The Discovery of the Electroencephalogram (EEG) 
Berger ( 1929) recorded the first human electroencephalogram -
(EEG) and at the time wondered whether " ••. one would be able 
to demonstrate a difference of the electroencephalogram in 
wakefulness from that of sleep" (Berger 1969, p.72). Subsequent 
studies have revealed that differences do exist between the 
awake and sleep EEG (Gibbs et al 1935; Loomis et al 
Blake 1937; Knott et al 1939; Diaz-Guerrero et al 
1935{a)(b); 
1946). 
Loomis et al ((937), on the basis of all night monitoring of the 
EEG and ~lectro-oculogram CEOG), classified sleep into five 
different stages <A-E) thus dispel I ing the previously held notion 
that sleep was a homogeneous stage which only varied in depth 
(Johnson 1973). The authors reported that a continual shifting 
of sleep stages occurred during the night and attributed this to 
either exogenous or endogenous stimulation. 
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2.2.2 The Di~~dvery of Rapid Eye Movement (REM) Sleep 
In 1953 Eugene Aserinsky made a remarkable discovery which was 
to dramatically alter the future of sleep research (Aserinsky 
and Kleitman 1953). Aserinsky, while studying the sleep 
patterns .of infants noted that there were periods ~hen the 
eye[ ids were quiescent and times when they exhibited bursts of 
activity. Aserinsky and Kleitman (1953, 1955) attempted to 
systematically study this newly discovered phenomenon by 
monitoring the sleep EEG and EOG of adult subjects. They 
reported that jerky, binocularly conjugate rapid eye movements 
(REMS) occurred periodically every 90 minutes beneath the closed 
eye! ids of the sleeping subjects. 
conjunction with a low voltage EEG. 
(1955) found that vivid dreams were 
These REMS occurred in 
Aserinsky and Kleitman 
frequently recalled when 
subjects were awakened in the midst of a REM period. This 
psychophysiological parallelism was anticipated by Ladd ()892) 
and Griesenger (1869) who remarked " ... that with vivid dreaming 
movement of the eyes occur". (Snyder 1971, p.3[). 
Dement and Kleitman ((957), on the basis of. the presence or 
absence of rapid eye movements, divided sleep into two distinct 
categories, rapid eye movement (REM) sleep and non-rapid eye 
movement CNREM) sleep (Table I). They further subdivided NREM 
sleep into four stages (stages 1-4). 
Hartmann (1965) referred to wakin~ sleep as W, NREM sleep as S 
and REM sleep as D. These capital letters W,S,D might depict 
the waking state; slow wave, synchronised or spindle sleep; 
and desynchronised or dreaming sleep. The W-S-D nomenclature 
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Tabla I The classlf1~ation of sleep into sleep stages on the 
basis of the pre~ente or absence of rapid. eye move-









This stage is characterised 
by the absolute lack of 
spindle activity, low 
voltage, relatively fast 
EEG activity corresponding 
to the B stage of Loomis 
et al (1937) and includ-
ing what the Loomis group 
cal led the A or interrupted 
alpha stage. 
This stage is characterised 
by the presence of sleep 
spindles and K complexes. 
This is an intermediate 
stage containing 20% but 
le~s than 50% 6f high 
voltage slow wave ~ctivity 
(delta waves). 
This stage is characterised 
by large voltage CIOOuv) 
slow wave activity (delta 
waves) which comprise more 
than 50% of the record. 
This stage resembles 
stage I but is 
ch~racterised by ~he 




































system (Hartman 1965), desplte its simple descriptive propertles, 
has not been readi [y ~ccepted by the scientlf.(~ communlty 
CFreemo n 1972) . 
The great proliferation of I iterature on sleep research in the 
late 1~60 1 s (.Webb 1973) produced an array of terms for REM and 
NREM sleep. REM sleep was also referred to as paradoxical 
C.Jouvet 1965), para-sleep (lwamura et al 1967), rhombencephalic 
(Jouvet 196), Buendia 1963), desynchronised (Dunlop and Waks 
1965), LVF (Berger and Meier 1966), D (Hartmann 1965), 
activ<;:ited (Dement 1958), active (Parmalee et al 1967), restless 
(Cadilhac et al 1961), irregular (Wolff 1959), light (Karacan 
et al 1970) and deep (Carli and Zanchetti 1965) whereas NREM 
sleep was often referred to as orthodox (Oswald 1970), 
orthodoxical (Jouvet 1965), slow wave (Jouvet 1967), ortho-sleep 
tlwamura et al 1967), te]encephalic {Jouvet 196.f), high voltage 
(Buendia et al ·1963), slow CAiiison 1965), synchronised {Dunlop 
and Waks 1965}, HVS (Berger and Meier [966}, ordinary {Dem~nt 
1958) quiet (Parmalee et al [967, Cadi lhac et al 196.J), 
regular (Wolff 1959), deep CKaracan et al 1970), and light 
CCarl i and Zanchetti .(}965). This prompted a committee under 
the leadership of Rechtschaffen and Kales (196.8) to develop a 
standardised terminology, technique and scoring system for 
human sleep stages (see section 5.4.J). This system was based 
on the findings of Loomis et al (l937) and Dement and Kleltman 
. CI957). 
Despite attempts to standardise terminology relating to sleep 
parameters CClemente 1967, Rechtschaffen and Kales 1968), 
confusion stll I reigns as to the interchange of the physiological 
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concept of REM sleep wi.th the psychological concept of dreaming, 
as can be seen from the f:ol lowl.ng .quotati.on: "Dreaming occurs 
most frequently during REM states, but it can also occur during 
NREM states of sleeping and even waking" {Freemon 1972, p.23). 
Malcolm {1959) has suggested that the Jabe[ "dreaming" should 
only be used in a phenomenological context and it has so been 
employed in the present study. 
2.3 Sleep Cycle~ 
The architecture of a night's sleep is a well documented 
phenomenon (Dement and Kleitman 1957; Berger 1969; Feinberg 
et al 1967; Freemon 1972; Hartmann (973(a); Foulkes 1966; 
Williams et al 1974; Oswald l970(a); Webb 1968; Kamiya 196[; 
Snyder and Scott 1972). The cyclical fluctuations In cerebral 
and oculomotor activity during sleep implies that sleep is 
neither a h~mogeneous nor random state but a state characterised 
by the cyclical recurrence of distinct stages. 
2.3. I The Sleep Cycle of the Young Adult 
The initial descent into stage I sleep from wakefulness is 
ch~racterised by the disappearance of alpha activity in the EEG 
and the appearance of slow rolling eye movements In the EOG 
CRechtschaffen and Kales 1968). The appearance of sleep 
spindles {see section 5.4.J) her.aids the o·nset of stage 2 sleep. 
As sleep progresses, high voltage .slow wave delta activity 
to,5~2,0hz) becomes more prominent and the sleeper enters NREM 
stage 3 sleep. When the greater part of the EEG record is 
dominated by delta activity, .the sleeper is said to be in NREM 
stage 4 sleep. 
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After approximately seventy minutes of predomlnantly stage 3 
and 4 (slow waVel sl~ep, the ftrst REM period generally occurs 
(Berger )969(b11. The ftrst REM perfod rs usually preceded 
by a series of body movements and a brief return of the EEG to 
stage 2 activity. It can be distinguished from later REM 
periods by its short duration and fewer rapid eye movements 
( Fe i n berg et a I I 9 6 7 ; Goodenough et a I I 9 6 5 ; Verdone I 9 6 5 ) . 
REM sleep is accompanied by a decrease in tonic chin muscle 
activity (Berger 1961). 
The above sleep cycle is usually repeated four to six times 
during the might depending on the total time spent asleep 
(Foulkes 1966). The presence of stage 4 sleep diminishes and 
that of stage REM sleep increases as the night progresses 
<Dement 1965(b)). As a resul~ the latter sleep cycles do not 
contain stage 4 sleep and consist of an alternation of stage 2 
and stage REM sleep (Johnson 1973). The duration of the sleep 
cy c I e is 90 minutes. 
The young adult spends about six percent of his sleep in stage I, 
fifty percent in stage 2, seven percent in stage 3, sixteen 
percent in stage 4 and twenty percent in s~age REM; about one 
percent of his sleep is occupied by body movements (Johnson 1973). 
A decrease in slow wave sleep occurs with increasing age whereas 
REM sleep remains constant (Agnew et al 1967Ca); Feinberg et al 
1967; Wi 11 iams et al 1974; Roffwarg et al 1964). 
Numero.us factors .such as thirst CBokert 1965; Koulack 1970), 
exercise (Hauri 1968, 1969; Baekeland .and Lasky 1966; Horne 
and Porter 1975; Shapiro et al 1975), stressful films (Witkin 
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narcolepsy 1 (Dement and Gui I leminault 1973; Dement et al 1966(b); 
Roth and Bruhova 1969; Mitler et al 1975; Fenton 1975; Shapiro 
1975; Rechtschaffen et al l963(c); Wi 11 iams et al 1974; 
Rechtschaffen and Dement 1969; Zarcone 1973; Guilleminault et al 
1974), in subjects deprived of REM sleep for prolonged periods 
(Dement et al l973(a)) as wel I as in subjects placed on a 30-60 
minute sleep-wakefulness schedule (Carskadon and Dement 1975; 
Dement et al 1972). 
Foulkes and Vogel (1965), on the basis of EEG and EOG recordings, 
classified sleep onset into four consecutive periods: awake 
alpha rhythm with rapid ~ye movements, alpha rhythm with slow 
ro I Ii ng eye movements, stage I and stage 2 s I eep. They found 
that mental activity was elicited from 95 percent of awakenlngs 
from the four sleep onset periods and that on occasion this 
mental activity resembled that foun~ during REM awakenings 
(Foulkes et al 1966; Vogel et al 1972(a)). 
Mental activity showed an orderly progression across the four 
sleep onset periods changing from fragmentary visual material 
during the awake alpha rhythm to extended and more self-
involved mentation during stage 2 sleep (Foulkes et al 1966). 
The authors reported that vast individual differences existed 
with regard to the occurrence and content of mental activity 
during sleep onset periods. 
Foulkes ( 1966) concluded that mental activity at sleep onset 
was a " ... temporary expedient adopted by the organism to al low 
it to pass, undisturbed and with its mental apparatus relatively 
1Narcolepsy is a disease character.lsed by the uncontrollable 
desire to sleep. 
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intact, from wake.fulness to sleep." (Foulkes 1966, p.137). 
2.4.2 Mental ActiVlty TI~~iri~ NREM Sl~ep 
Dement and Kleitman (1957) found that vivid dream reports were 
obtained 74 percent of the time when subjects were awakened 
during REM periods but only seven percent of the time during 
NREM awakenings. Subsequent studies have confirmed that the 
majority of REM awakenings produced vivid dream reports but 
failed to obtain consistent findings for NREM awakenings (Table 
2) • 
Goodenough et al (1959) were able to elicit dream reports 
53 percent of the time during NREM awakenings compared to the 
~even percent reported by Dement and Kleitman ()957). They 
attributed this flnding to traces of mental experience which 
occurred in preceding REM periods. Subsequent studies, however, 
found that dream reports were elicited from NREM sleep prior to 
the commencement of a REM period thus dispel I ing the notion that 
NREM dream reports were the reminiscences of previous REM 
periods (Foulkes 1966, 1967; Rechtschaffen 1973). 
Foulkes ( 1962) obtained 74 percent dream recal I from NREM 
awakenings. He ascribed this finding to his broader cate-
gorisation of cognitive activities used to define dream reports. 
These cognitive activities included fragmentary reports of 
mental activity which resembled everyday thinking. 
1.t has generally been establ tshed that NREM dream reports are 
less ela~orate, more .everydayish, shorter in duration, consist 
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Table 2 Percentage recctl I of dream reports followi~g REM 
and NREM awakenings. 
Authors 
Aserinsky and Kleitman (1955) 
Dement <1955) 
Dement and Kleitman (!957) 
Wolpert and Trosman (1958) 
Goodenough et a I ( 1959) 







Rechtschaffen et al ( 1963(.a)) 
Foulkes and Rechtschaffen (1964) 
Goodenough et al (1965) 
Hobson et al (1965) 
Ka I es et a I ( 1967) 
Larson and Foulkes (1969) 






















of fewer characters other than the dreamer, are more conceptual 
and comprise more recent events from daily routine than REM 
dream reports (Foulkes and Rechtschaffen 1964; Goodenough et al 
1965; Foulkes 1966; Rechtschaffen et al l963(a)). Foulkes and 
Vogel (1974) reported that NREM dream reports were elicited less 
frequently than REM dream reports which were elicited on most 
awakenings. The authors also found that NREM dream reports, 
like REM dream reports, increased in vividness as the night 
-progressed. 
Goodenough et al (1965) investigated the effects of gradual 
versus abrupt awakenings to determine the extent to which NREM 
dream reports might be the product of awakening. They found that 
gradual awakenings resulted in "thinking" dream reports more often 
than did abrupt awakenings. 
Rechtschaffen et al (1963) proposed that NREM mentation was 
incorporated into REM periods and that REM periods thus 
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••• emerge as the most vivid and memorab I e part of a I arger 
fabric of interwoven mental activity during sleep" (Rechtschaffen 
et al 1963, p.546). Some confirmation of this hypothesis has 
been provided by Foulkes ( 1962) who found that pre-REM stage 2 
mentation comprised routine "everyday 11 topics as well as un-
distorted events which resembled Freud's concept of the day 
residue from which Freud presumed dreams to develop. 
2.4.3 Mental Activity During REM Sleep 
The world of dreams has fascinated mankind since antiquity: 
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And Joseph dreamed a dream .•••. For behold, 
we wete binding sheaves in .the~field, and lo, 
my ~heat arose, and also stood uptight; and, 
behold, your sheaves stood round about, and 
made obeisance to my sheaf. And his 
brethren said to him, shalt thou indeed reign 
over us? 
Genesis 37 
It seems likely that it is REM sleep mentation that has been 
associated with vivid and distorted mental themes cal led dreams 
(Table 2). The sleep research community has yet to reach con-
census on a definition of dreaming. "A meeting of psychologists 
attempted to formulate a definition of dreaming, but -0nly reached 
the unhelpful consensus that each investigator should use his 
own definition" <Freemon 1972, p.23). Thus in the present 
study a REM dream report is defined as the" ... mental activity 
which occurs during REM sleep and is sampled by waking the sleeper 
during the REM state and asking him what was going through.his 
mind" (Freemon 1972, p.23). 
Dement and Kleitman (1957(b)) found that the length of a REM 
dream report increased as the duration of the REM period 
increased prior to awakening. REM periods that occurred earlier 
in the night were found to have a lower profusion of rapid eye 
movements (Goodenough et al 1965; Aserinsky 1969, 1971) and 
dream reports elicited from these REM periods were found to be 
less perceptual, active and dramatic than those elicited from 
later REM periods (Domhoff and Kamiya 1964; Foulkes 1966, 1967; 
Shapiro et al 1963). 
It was previously hypothesised that a psychophysiologlcal 
parallelism existed between the profusion of rapid eye movements 
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during REM sleep and the vi.sual imagery recalled upon awaken-
i~g (Dement and Wolpert 1958~ Dement and Kleitman 1957(b}; 
Berger and Oswald 1962; Roffwarg et al 1962). This supposition, 
known as the "scanning hypothesis" <Firth and Oswald 1975), was 
supported by the finding that rapid eye movement profusion was 
positively related to various aspects of the REM dream report 
such as bizarreness (Goodenough et al 1965; Verdone 1965), 
emotionality (Karacan et al 1966; Verdone 1965), intensity 
(Pivik and Foulkes 1966) and vividness (Verdone 1965). 
Additional support for the "scanning hypothesis" was provided 
by the finding that congenitally blind people lacked visual 
imagery in their dreams and did not appear to produce rapid eye 
movements during REM sleep (Berger et al 1962; Offenkrantz and 
Wo I pert 1963). 
Recent research, however, has questioned the validity of the 
"scanning hypothesis". Recent studies have demonstrated the 
existence of rapid eye movements in congenitally blind subjects 
by the use of mechanical 1 rather than electrophysiological 
recording procedures (Amadeo and Gomez 1966; Gross et al 1965). 
Further contradictions of the possible isomorphic relationship 
between rapid eye movement profusion and the visual imagery of 
dreams were provided by the findings that kittens which were 
reared in the dark (Fishbein et al 1966) as well as newborn 
infants (Delange et al 1962; Monod et al 1964; Weitzman et al 
1965; Roffwarg et al 1966) produced rapid eye movements during 
REM sleep. 
1 Th~ cornea-retinal potential has been found to be either 
diminished or absent in most bl ind subjects and the usual 
electrophysiological recording techniques would thus fail 
to detect eye movements. · 
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,The rate and distrlbutlon of rapid eye movement bursts (section 
5.5.2). have been found to b~ constant within ~ubjects from REM 
period to REM period and from n[ght to night (Spreng et al 1968; 
Aserinsky and Cady 1967). Spreng et al (1968) reported that 
indivi.dual differences ~xlsted with regard to the direction of 
eye movements during REM sleep and that a consistent relation-
ship existed between rapid eye movement bursts and autonomic 
activity. Thus it appears unlikely that the profusion of rapid 
eye movements during REM sleep are directly related to the 
visual imagery recalled upon awakening. 
In view of the above contradictory evidence, the notion of a 
constant psychophys i o I og i ca I para I I e Ii sm between rapid eye move-
ments and visual imagery appears to be questlonable (Firth 1973, 
1974; Hauri and van de Castle 1973; Jacobs et al 1970; Koulack 
1972; Moskowitz and Berger 1969). Koulack (1972) concluded; 
"The initial hypothesis of a constant isomorphic relationship 
between REM's and visual imagery seems to be untenable, although 
it is quite possible that from time to time eye movements and 
the visual imagery of dream might be related". CKoulack 1972, 
p.157). It has been suggested that a neurophysiological mechanism 
might be associated with the profusion of eye movements and 
' autonomic changes which accompany REM sleep CAserinsky 1965; 
Johnson 1973). 
It has generally been established that visual, auditory and 
somesthetic stlmul I become 1ncorporated into ongolng REM 
mentatlon. Dement and Wolpert (1958) found that spraying water 
on exposed skin; soundl_ng a tone or flashing a light during 
REM sleep resulted in the incorporation of these stimuli into 
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the REM dream report. Koulack (1969) sti.mulated the sleeper$ 
wrist with a mi Id .electri.cal current durlng REM sleep and found 
a significant incorporation of this stimulus in the REM dream 
report. He obtained the highest incorporation when the stimulus 
was app Ii ed three minutes after the commencement of a REM s I eep 
period and the sleeper awakened three minutes later. Castaldo 
and Holzman (1967, 1969) found that playing a tape recording of 
the sleeper's own voice during REM sleep produced a REM dream 
report in which the central character of the drama· was active 
and dogmatic whereas the tape recording of another person's voi~e 
saying the same words produced a REM dream report in which the 
central character played an impassive role. Freud (1900) 
proposed that the incorporation of internal (bladder distention, 
stomach aches etc) as we I I as extern a I st i mu Ii into the ongoing 
dream process acted as a guardian of sleep by preventing the 
sleeping person from awakening. 
Another notable finding has been the discovery that the gross 
body movements which occur during REM sleep, demarcate the, REM 
dream r19port into several episodes Ololpert and Trosman 1958; 
Dement and Wolpert 1958). 
2.5 Physiological Characteristics of Sleep 
Several studies have investigated the physiological concomitants 
of sleep and as a result"··· we can now predict with a high 
degree of certainty that any virginal physiological activity wi I I 
show distinct changes with the onset of REM sleep, compared with 
i ts I. e v e I a n d p a t t e r n d u r ln g N REM s I e e p " ( Be r g e r I 9 6 9 (a ) p . 6 6 ) • 
The transition from NREM to REM sleep and vice versa has been 
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found to be a_ gradual rather than an abrupt process (Shapiro 
1967). 
2.5.1 Electro~ncephalbg~~~hy 
Modern technology has evolved techniques whereby it is now 
possible to record the activity of single neurons or the inte-
grated activity of groups of neurons by means of microelectrodes. 
Berger (1969(a) reported that the rates of neural discharge during 
REM sleep resemble~ those during wakefulness. The groups of 
neurons however tended to fire simultaneously in synchronised 
patterns during NREM sleep in contrast to the asynchronous 
pattern of firing during wakefulness. 
It has genera I I y been es tab Ii shed that the rate of firing of 
groups of neurons throughout most areas of the brain increased 
during REM sleep to levels found during wakefulness (Arduini et 
al 1963; Evarts 1962, 1964; Huttenlocher 1961; Benoit 1964; 
Bizzi et al 1964; Podvoll and Goodman 1967; Rougeul et al 1966). 
This increase in neural activity during REM sleep is accomp~nied 
by an increase in cerebral blood flow (Kanzow et al 1962; Kety 
1967, Reivich et al 1968) and by an "increase in the temperature 
of the brain (Kawamura and Saywer 1965; Rechtschaffen et al 1965; 
Kawamura et al 1966). Kety (1967) reported that the blood flow 
to the cortex practically doubled during REM sleep in comparison 
to NREM sleep. 
It had been previ.ously thought that the increased brain tempera-
ture during REM sleep was the result of an increased metabolic 
20 
activity in the brain. Baker and Hayward (1967} have produced 
findings ~hich hav~ cast some doubt upon th[s as.sumption. 
They found that the rise In the brain temperature .of the rabbit 
during REM sleep originated in a temperature rise in the cerebral 
arterial blood. 
The EEG characteristics of the various stages of sleep have been 
discussed in sections 2.3.I and 5.4. I. 
2.5.2 Heart Rate, Blood Pressure, Respiration ~nd 
Met~bol ic Activity 
Heart rates, systolic blood pressure and respfration rates have 
been reported to be higher during REM than NREM sleep (Aserinsky 
and Kleitman 1953; Kamiya 1962). It has genera I I y been 
est~bl ished that with the onset of REM sleep the above vegetative 
activities became increasingly irregular (Johnson and Lubin 1967; 
Shapiro et al 1964; Snyder 1960; Snyder et al 1963, 1964; 
l<hatri and Freis 1967; Richardson et al 1964). 
Hobson et al (1965) reported that a correlation existed between 
the number of rapid eye movements and the respiration rate during 
REM sleep. Aserinsky and Houseknecht (1965) found that a 
decrease in the respiration amp Ii tu de was associated with REM 
bursts. This decrease in the respiration amp I i~ude was associa-
ted with an increase in the frequency of respiration (Aserinsky 
I 965). 
It has genera I ly been es tab I ished that a gradua I decrease in 
oxygen consumption and body temperature occurs during sleep 
(Brebbia and Altshuler 1965; Kreider et al 1958). During REM 
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sleep, ho~ever, an increase In oxygen consumption and carbon 
dioxide production has been observed tBrebbia and Altshuler 
1965). Aserinsky .(1965) found that during intense bursts of 
rapid eye movements, the blood oxygen tension tel I to extremely 
I ow I eve Is. 
Biochemical assessments h.ave revealed that an increase in the 
osmolal ity of urine (Mandel I et al 1966) as wel I as increases 
in the circulating levels of plasma 17-hydroxycorticoids and 
catecholamines (Mandel I and Mandel I 1965; Weitzmann et al 1966) 
occur during REM sleep. It thus appears that an activation of 
the anterior and posterior lobes of the hypophysis occurs during 
REM sleep (Mandel I and Mandel I 1965). 
The evidence points overwhelmingly to the conclusion that REM 
sleep is accompanied by an increase in most autonomic parameters. 
2.5.3 Electrodermal Phenomena 
Slow wave sleep (stages 3 and 4) has usually been considered to 
be the least active stage of sleep during which "all functions 
are depressed and the lowest level of vigilance and alertness i~ 
reached" (Johnson and Lubin 1966, p.8). However, spontaneous 
~alvani~ skin responses are more prominent during stage 3 and 
stage 4 sleep than during REM sleep (Asahina 1962; Broughton 
et al 1965; Burch 1965; Johnson and .Lubin 1967). This finding 
contrasts with the autonomic ftinctions ~uch as the fi~ger 
:plethysmograms and fi.nger temperature (Johnson et al 1965), heart 
rate, blood pressure and respiration rate (Kamiya 1961; Snyder 
et al ·1964) which have been reported to be el.evated during REM 
and not NREM sleep. 
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Johnson and Lubin (196~) have attempted to provide an explana-
tion for the contradictory finding that an increase ln the 
spontaneous electrodermal activity occurred during the least 
active stage of sleep. They proposed that if a rhombencephal ic 
electrod~rmal Inhibitory centre existed, which was actlve durlng 
REM sleep but inactive during slow wave sleep, little or no 
electrodermal activity would occur during REM sleep. 
2.5.4 Slow Eye Movement Activity 
Dement (1964) reported that direct observation of sleeping 
subjects revealed that slow eye movements appeared as rhythmical, 
oscillating swings of the eyebal I from one side of the orbit to 
the other. The greatest proportion of movement was found to 
occur in the horlzontal plane. When these slow rolling eye. 
movements are recorded polygraphical ly, they resemble a sine wave 
and have a maximum frequency of between ten and twenty cycles per 
minute. Slow rolling eye movements are most prominent at the 
onset of sleep (Foulkes 1966). Dement (1964) found that the 
slow eye movements preceded the discontinuity of the EEG alpha 
activity and were thus a more sensltive lndex of sleep onset. 
Slow eye movements also occur throughout the night immediately 
fol lowing gross body movements (Dement 1964). On occasion the 
slow eye ~ovements precede the body movements by a few seconds. 
Dement (1964) noted that slow eye movements resembl Ing those at 
sleep onset occurred when a subject briefly awoke and returned 
·to sleep during the n_lght. The duration of these eye movements 
was however shorter than the duratlon at sleep onset. 
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2.5.5 Rapid Eye Mov~m~nt Activity 
Rapid eye movements are binocularly synchronous and resemble the 
waking eye movements of visual fixation in man <Dement 1964(b); 
Aserin~ky and Kleitman 1953). They occur with similar speeds 
in all directions. Antrobus et al (1969) reported that the 
majority of rapid eye movements occurred in the horizontal plane. 
Spreng et al (1968) found that individual biases existed in the 
predominance of rapid eye movements in the horizontal or vertical 
plane. 
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The rapid eye movements occur in clusters or bursts for long 
periods of time, or are exceedingly sparse, in the same individual. 
(Dement and Kleitman 1957(b); Mouret and Jeannerod 1964; 
Aserinsky 1965;. Spreng et al 1968; Snyder 1967). In man, the 
number of rapid eye movements have been found to be relatively 
constant from night to night (Spreng et al 1968). Aserinsky 
and Cady (1967) reported that the number of rapid eye movements 
per REM period increa~ed with each successive REM period of the 
night. 
2.5.6 Body Movement 
Oswald et al (1963) found that gross body movements occurred 
during al I stages of sleep. He reported that the highest 
incidence of gross body movements occurred during REM sleep and 
the lowest incidence during stages 3 and 4 sleep. 
Several studies have reported the pres~nce of irregular twitch-
ing and trembling movements of muscles of the face and hands in 
human subjects during REM sleep <Baldridge et al 1965; 
Dement and Kleitman 1957(.a); Stoyva 1965; Wolpert. 1960). 
Newborn infants have been found to stretch, smile, frown and 
cry during stage REM sleep (Delange et al 
al 1964). 




The periodic occurrence of penile erections during human sleep 
was reported by Ohlmeyer et al (1944, 1947). Aseri nsky ( 1953) 
suggested that a temporal relationship existed between the sleep 
erection cycle and stage REM sleep. Oswald (1962) was unable to 
demonstrate the existence of this temporal relationship. How-
ever subsequent studies have confirmed the existence of a REM-
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tumescence correlation in human subjects (Morita 1975; Hursch et al 
1972; Karacan 1965, 1970; Karacan et al 1965, 1966, 1972(a) (b) (C), 
1975; Fisher et al 1965; Jovanovic 1967, 1968; Kahn and 
Fisher 1969) as wel I as in monkeys (Karacan 1966; Karacan and 
Snyder 1966). 
Karacan ( 1970) reported that the wel I known phenomenon of a 
penile erection upon awakening in the morning was not precipitated 
by bladder distention but was related to the occurrence of a REM 
period. He also found that less anxiety was evident in the REM 
dream reports which were obtained following awakenings from ful 
erections than those obtained fol lowing awakenings from partial 
erections or in the absence of erections. 
Karacan et al Cl972Cc)) proposed that nocturnal penile tumescence 
and stage REM sleep were related but not entirely interdependent 
phenomena. The evid~nce for this hypothesis has been provided 
by the fol )owing findi~gs: The authors found that REM sleep 
did not nec.essari ly precede penile tumescence; penile tumescence 
occurred during NREM sleep; the first night effect (Agnew et al 
1966) resulted in a decrement in stage REM sleE?p without 
influencing tumescent time; temporary sexual abstinence 
affected tumescence but failed to influence stage REM sleep; REM 
sleep deprivation did not totally inhibit tumescence. 
Thus,the available evidence points to the conclusion that REM 
sleep usually precedes penile tumescence but ·that on occasion REM 
sleep or penile tumescence can occur independently of one another. 
2.5.8 Growth Hormone Secretion 
It has genera I I y been es tab Ii shed that s I ow wave s I eep is often 
accompanied by a rise in the human growth hormone concentration 
in the plasma of most healthy individuals (Hunter and Bigal 1966; 
Quabbe et al 1969; Takahashi et al 1968; Honda et al 1969; 
Sassin et al 1969(a)(b); Underwood et al 1971; Beck et al 1975; 
Karacan et al 1971(a), 1973(a); Parker et al 1969). 
Subsequent research has confirmed the assumption that an associa-
tion between slow wave sleep and the human growth hormone 
concentration in the plasma exists. The deprivation of slow wave 
sleep was found to result in a significant but incomplete 
suppression of the plasma human growth hormone ctincentration 
shortly after sleep onset CKaracan et al 1971(a); Sassin et al 
1969(a)). Karacan et al Cl971(a)) found that the significant 
decrease In the human growth hormone plasma levels was restricted 
to the first third of the night when slow ~ave sleep would have 
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predominated if Jt had not been suppressed. Further confirma-
tion for this ass~mptlon has been provided by the findings that 
acute fasting (Karacan et al 1973(a); Parker et al 1972) as wel I 
as the interruption ~f the sleep cycle (Beck et al 1975; Takahashi 
et a I I 9 6 8 ) b o t h res u I t e d I n a n i n c re as e i n s I ow w a v e s I e e p a s 
wel I as an increase in the human growth hormone concentration in 
the plasma. 
It has been suggested that slow wave sleep and human growth 
hormone may serve an anabolic restorative functio~ (Beck et al 
1975; Oswald 1970(a),(b); MacFayden et al 1973; Dunleavy et al 
1974; Adamson et al 1974). 
2.5.9 Tonic and Phasic Concomitants of REM Sleep 
The physiological activities that occur during REM sleep have 
been divided into phasic and tonic events (Hartmann )967(a); 
Moruzzi 1963; Molinari and Foulkes 1969). Tonic events are 
those physiological activities which persist for the entire dura-
tion of the REM period. Toniy events include an activated EEG, 
electromyogram suppression, an increase in brain temperature and 
the presence of hippocampal theta waves of five cycles per second 
(Grosser and Siegal 1971). 
Phasic events are those physiological activities that are short 
lasting and do not persist for the entire duration of the REM 
period. Phasic events include the rapid eye movements (Aserinsky 
27 
1965), cardiovascular irregularities ,(Snyder et al 1964), myoclonic 
twitches and Increased fine muscle activity (Baldri~ge et al 1965), 
changes in pupil diameter (Berlucchi et al 1964), fluctuations in 
nocturnal penile tumescence (fisher et al 1965; Karacan et al 
1965, 1972(a)(b)(c1, 1975; Jovanovic 1967, 1968; Morita 1975) 
I and finally .bursts of monophasi c sharp waves that are character-
istic of the electrical activity of the pons, oculomotor nuclei, 
lateral genlculate nuclei and the occipital cortex (Brooks 1967; 
Brooks and Bizii 1963; Michel et al 1964; Pompeiano 1967). 
Dement et al (1970) proposed that the PGO spikes were the trigger-
ing mechanism for the commencement of phasic events during REM 
sleep, especially the rapid eye movements. These PGO spikes 
occur in the cat, squirrel monkey as wel I as the rhesus monkey 
but as yet have not been observed in man (Dement et al 1970). 
It has been suggested that the reason for this could be the result 
of the restricted use of implanted electrodes in man (Dement et 
al 1970). It has genera I I y been suggested that the sawtooth 
waves ( Be r g e r et a I I 9 6 2 ), seen i n the EEG of h um an s u b j e ct s d u r i n g 
stage REM sleep, could be analogous to the PGO spikes seen in the 
cat (Dement et al 1970; Schwartz 1962). 
The PGO spikes normally precede the commencement of a REM period. 
These spikes have been found to show a reduction in amplitude, 
a rise in frequency and an increased probabi I ity of occurring in 
clusters or bursts. During NREM sleep, the PGO spike has been 
reported to occur as a unitary, high amplitude discharge at equi-
distant intervals <Thomas and Benoit 1968; Dement et al 1970). 
The termination of a REM period is characterised by the cessation 
of spike activity. 
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1These monophasic sharp waves are known as PGO Cpontine-geniculate-
occipital) spikes. .The PGO spikes occur at a fairly ~onstant 
daily rate of .::14000 per day int.he cat (Jouvet 1969). They 
always pr~cede stage REM sleep by ±}0 ~econds and ~ccompany bursts 
of rapid eye movements. 
Delorme et al :(J9fr5) reported that tonic and phasi.c events 
could be dissociated from one another. They tound that high 
doses. of reserpine totally suppressed REM :sleep in the cat 
without influencing the discharge of PGO spikes. On the basis 
of this finding, Dement et al (1970) have postula~ed that at 
least two distinct neurological mechanisms were responsible for 
the production of REM sleep. 
2.5. 10 REM SLEEP As An Activated State 
REM sleep has been found to be accompanied by an increase in 
heart rate, blood pressure and respiration rate (section 2.5.2), 
an increased neural activity in the sensory and motor areas of 
the brain (section 2.5.1), an increased cerebral blood flow and 
brain temperature (section 2.5.1) as well as an increased 
activity in the anterior and posterior lobes of the hypophysis 
(section 2.5.2) whereas a decrease in the tonic chin muscle 
activity (Berger 1961), the number of spontaneous galvanic skin 
responses in relation to slow wave sleep (2.5.3), the spinal H 
reflex (Hodes and Dement 1964) as well as a reduced neural 
activity in the hippocampus (Mi~k et al 1967) and fibres of the 
corpus cal losum CBerlucchi 1965) occur. In viaw of these find-
ings "··· the notion that there are active and quiet periods of 
sleep must be abandoned. Each state of sleep has its own 
unique pattern of physiological activity." (Johnson and Karpan 
1968, p.444). Berger (1969) ~6st~l~ted that each sleep stage . . 
had a distinct f~hction and as a result was characterised by a 
different conglomeration of physiological activities. 
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2.6 Sleep Depr.ivation 
2.6.I Total Sleep Deprivation 
Several studies have investigated the psychological, neurological 
and biochemical effects of prolonged sleep deprivation in human 
s u b j e ct s ( G u I e v i c h et a I I 9 6 6 ; Ro s s I 9 6 5 ; Pa s n. a u e t a I I 9 6 8 ; 
Kollar et al 1966; Tyler 1955 and Kupfer et al 1970(b)). The 
psychological investigations have revealed that extended sleep 
loss has resulted in dramatic behaviour such as fatigue, irrita-
bi I ity, feelings of persecution and disorientation. John'.>on 
( I 9 7 3 ) reported th at ha I I u c i n at i on s co u I d occur a ft e r ext en de d 
sleep loss but that they would be primarily visual and tactile 
in contrast to the auditory hallucinations usually found in 
schizophrenic patients. However,subjects have also been found 
to perform adequately on performance tasks during extended sleep 
deprivation when the task had a high incentive value and was of 
short duration (Wilkinson 1964; Lubin 1967). 
Neurological examination revealed that extended sleep loss 
resulted in the slurring of speech, inability to concentrate, 
loss of ocular convergence, immediate memory loss and episodes 
of disorientation to time (Ross 1965; Kollar et al 1968) as 
well as a decrease in alpha abundance (Johnson 1969; Freeman 
1972). Biochemical changes such as a rise in serum creatinine 
phosphokinase (Kupfer et al 1970(b)) and circulating levels of 
glucose and cortisol (Kollar et al 1969) have been reported after 
sleep deprivation. Kuhn et al ()967) reported that a consider-
able decrease in plasma iron levels occurred as well as a 
moderate fall in plasma cholesterol. It has generally been 
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established that these n.eurologlcal, psychological and bio-
chemical ~hanges are transient phenomena and disappear once the 
subject returns to his usual ~Jeep habits (Freemon 1972). 
In studies where psychotic behaviour has been reported follow-
ing sleep deprivation CBrauchi and West 1959; Bliss et al 1959; 
Katz and Landis 1935; Luby et al 1960) some predisposition of 
the subject to psychotic or bizarre behaviour under conditions 
of stress were evident (Johnson 1969). Thus it would appear 
that each subject's response to sleep deprivation would depend 
on his age, premorbid personality, motivation, physical health 
and the expectation of the experimenters (Freemon 1972). 
In view of the above findings, the previously held notion that 
extended sleep loss would result in a psychosis can now be dis-
missed (Johnson 1969). 
The recovery from total sleep deprivation has been characterised 
by a dramatic increase in total sleep time on the first recovery 
night. This dramatic increase was associated with a marked 
increase in slow wave sleep as well as an increase in the arousal 
threshold during al I sleep stages (Berger and Oswald 1962; 
Williams et al 1964(b)). Kales et al (1970(f)) reported that 
although REM sleep time increased on the first recovery night, 
the REM sleep percentage either remained unchanged or showed a 
slight increase. It Is on the second recovery night that REM 
sleep has been found to show its greatest rebound (Dement 1965(a); 
J oh n s on I 9 6 9 , Be _r g e r an d 0 s w a I d I 9 6 2 ) , a I t h o u g h s t u d i e s h a v e 
reported the REM rebound to 6ccur on the first ~ecovery night as 
wel I (Gulevich et al 1966; Johnson et al 1965). The increase 
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in stage 4 and stage REM sleep during the recovery from sleep 
deprivation was found to be associated with a substantial de-
crease in stage 2 sleep CFreemon 1972). 
2.6.2 Differential Sleep Deprivation 
The question often asked ls one of whether a specific sleep stage 
meets a particular need? (Johnson 1973). Shakespeare's Macbeth 
described sleep as "labour's bath, balm of hurt minds ..•.. chief 
nourisher at life's feast". It has been suggested that slow 
wave sleep replenishes the body after labour (Backeland and Lasky 
1966; Oswald 1970) and that REM sleep soothes hurt minds 
(Hartmann 1973(a)). 
Differential sleep deprivation has been achieved by the prevention 
of a subject obtaining a particular stage of sleep but permitting 
al I the other sleep stages (Webb 1969(b)). Stage 4 deprivation 
has not received as much attention as stage REM deprivation has 
amongst the sleep research community (Webb 1969(b); Johnson 
1973) . 
Agnew et al (1964) repo~ted that itage 4 deprivation was associa-
ted with a rebound of stage 4 during recovery sleep. In a 
subsequent investigation they found that no consistent performance 
differences existed between stage 4 and stage REM deprived 
.subjects (Agnew et al 1967(b.)). They did however find that stage 
4 deprived subjects displayed hypochondriacal and depressive 
Symptoms whereas stage REM deprived subjects showed an increase 
i.n irritabi I ity and emotional labi I ity. 
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Lubin et al (.1974)_ found that when performance was impaired by 
the complete loss of sleep, recovery sleep was. found to be equally 
effective regardless of the ~uant(ty of stage 4 or stage REM sleep 
p e rm i t t e d d u r i n g t h i s p e r i o d . J oh n s o n et a I Cl 9 74 ) . d e p r i v e d 
seven subjects of stage 4 sleep and seven subjects of stage REM 
sleep for three consecutive nights which-were followed by one night . . 
of total sleep deprivation. They found that no changes in waking 
behaviour occurred in either the stage 4 or the stage REM deprived 
subjects. 
The earlier REM deprivation investigations found that REM depriva-
tion resulted in the occurrence of deleterious psychological 
abnorma Ii ti es in human subjects (Dement and Fi sher l 963; Sampson 
1965). Subsequent studies have fa i I ed to rep Ii cate the above 
finding (Greenberg et al 1970; Vogel 1968; Kales et al 1964; 
Snyder 1963; Foulkes et al 1968). Recent studies have reported 
that REM deprivation may be of therapeutic value to some depressed 
patients (Vogel and Traub 1968(a)(b); Vogel et al 1968). 
In view of the evidence against the deleterious psychological 
effects of REM sleep deprivation, Dement ( 1965(a) remarked that 
" ... it seems likely that the psychological changes observed in 
the earlier studies were an artifact of the experimental 
procedures and the expectations of the experimenters'' (Dement 
1965(a) p.599). Vogel (1975) reported that the earlier studies 
had methodological ]nadequacies which would have had an influence 
on the results obtained. They failed to use NREM control 
awakenings, the subjects were aware of the expe~imental and 
control conditions, the researchers were not bl ind to the 
experimental conditions and psychological ~ssessment had in fact 
revealed that no consistent changes had taken place. 
Does REM deprivation eliminate dreaming? Before the discovery 
that mental ~ctlvlty ticcurred throughout sleep (Foulkes 1962, 
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1966; Foulkes and Vogel 1965), REM sleep deprivation was considered 
to be synonomous with the elimination of dreaming. In. view of 
the above finding, it was thought the only methodological pro-
cedure to eliminate NREM and REM dreaming would be total sleep 
deprivation. Recent research has indicated that this assumption 
may not be entirely valid (Foulkes and Scott 1973; Foulkes 1974). 
Foulkes and Scott (1973) found that subjects frequently reported 
hallucinatory experiences during relaxed wakefulness which s~owed 
a marked resemblance to nocturnal dreaming. These hallucinatory 
experiences occurred without drugs or prior sleep deprivation. 
Vogel (1975) concluded that " ..• dreaming, similar to and often 
indistinguishable from REM reports, occurs in al I other conven-
tional natural states of consciousness that sleep researchers 
recognise, eg. wakefulness, sleep onset and NREM sleep". (Vogel 
1975 Pp 753-754). 
2.6.3 Pa~tial Sleep De~~ivation 
Partial sleep deprivation has been achieved by preventing subjects 
from obtaining their normal ~uota of sleep within a twenty four 
hour period (Webb 1969). Webb and Agnew ( 1974) su~:igested that 
partial .sleep deprivation may in. fact be differential sleep 
deprlvation because when sleep duration was reduced to as I ittle 
as three hours per night, no reduction In stage 4 sleep occurred 
(Webb and Agnew 1965; Dement and Greenberg 1966; Rush et al 
1968). This occurred because stage 4 sleep predominates In the 
first third of the night and ls thus insensitive to the restric-
tion of sleep duration. 
Several studies have investigated the effects of restricted 
sleep schedules on sleep stages and performance tasks (Sampson 
1965; Dement and Greenberg 1966; Rush et al 1968; Webb and 
Agnew 1965, 1974; Wilkinson 1969; Frazier et al 1971; Johnson 
and Macleod 1973). The restri~tion of the duration of sleep 
resulted in I ittle or no decrement in stage 4 sleep and some 
studies have even reported a sl i~ht incr~ment in stage 4 sleep 
(Dement and Greenberg 1966; Webb and Agnew 1974; Rush et al 
1968). The most surprising result was that of a stage 4 rebound 
during recovery sleep despite the fact that no stage 4 sleep 
decrement occurred during the restricted sleep schedule (Webb ahd 
Agnew 1965; Rush et al 1968). 
REM sleep which occurs predominantly in the last third of the 
night was found to show a marked decrease during the restriction 
of sleep duration (Webb and Agnew 1965, 1974; Rush et al 1968). 
It did however show a compensatory response by occurring earlier 
in the night (Webb and Agnew 1974(b); Johnson and Macleod 1973). 
Restricted sleep schedules were found to have I ittle or no effect 
on performance tasks when they were of brief duration (Sampson 
1965; Webb and Agnew 1965, 1974(b)). Prolonged vigilance tasks 
however resulted tn ~marked reduction in perfdrmance after. 
partial deprivati:on of sleep.(Sampson 1965; Frazier et al 1971). 
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The above-mentioned &tudles .suffer from the llmltatlon that the 
restricted sleep schedules were Imposed for a I imlted time period 
(Webb l969(b.)). Re c e n t s. t u d i. es h a v e i n v es t i · g a t e d th e s I e e p 
patterns and personality trai.ts of normal individuals who con-
sistently sleep for long and short periods. They found that 
differences in sleep patterns existed between these two groups of 
individuals (Hartmann 1973(b); Hartmann et al 1971 (a), 1972; 
Webb and Agnew 1968, 1970; Baekeland and Hartmann 1970, 1971; 
Webb and Friel 1971). Hartmann ( 1973(a.)) reported that when 
sleep stages were expressed as percentages of total sleep time, 
short sleepersl had a greater percentage of stage slow wave sleep 
than long2 sleepers. The percentage of time spent in stage REM 
sleep was the same for both groups of subjects. The long 
sleepers however had significantly greater REM densities and 
recalled more dreams at home than did the short sleepers (Hartmann 
1973(a), Hartmann et al 1972). 
Contradictory findings have been reported as to whether long and 
short sleepers differ from one another on psychological dimensions 
(Hartmann 1973(a); Webb and Agnew 1971(a)). Hartmann et al 
(J97J(a)) reported that psychological test data indicated that 
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long sleepers scored in a more pathological direction than short 
sleepers on most of the MMPI, CPI and Cornell Medical Index scales. 
In contrast Webb and Friel (197.1) were unable to find any signifi-
cant differences between long and short sleepers on personality, 
i n t e I I e ct u a I p e r f o rm a n c e o r me d i ca I me as u re s • Taub ( 1972) has 
suggested that the a~ove discrepancy could be attributed to 
lnadequate samp I ing procedures. 
I . 
. Short sleepers had a mean sleep duration of. 5i hnurs. 
2 L· I h ong s eepers ad a mean sleep duration of 8 hours. 
2.6.4 .Chronic Sleep Deprivation 
Recent research has indicated that I lving in contemporary society 
may result In a chronic loss of sleep. The majority of people 
go to sleep when they wish to, but wake up when they have to. 
Webb (1969(a)) noted that 8-17 year old students in 1911 obtained 
an average of It hours more sleep than similarly aged students in 
1963. Kleitman et al (1937) using sleep diaries of six month's 
duration, noted that only one third of the subjects reported that 
they frequently awoke spontaneously and that half reported upon 
awakening that they had not had adequate amounts of sleep. 
Agnew (1974) reported that ina· questionnaire study involving one 
thousand students, I ess than a third reported that " ... they 
typically wake up in the morning feeling fresh and rested" (Webb 
1975, p.47). White (1915) carried out a study where 89 students 
kept sleep logs for fourteen consecutive days. He found that 
weekend sleep was an hour longer than their weekday sleep. This 
is consistent with the findings reported by Johns et al Cl971(a)). 
Webb and Agnew (1974Cal) placed 14 subjects on an ad I ib sleep 
schedule for fourteen days in an environment which offered no cues 
as to the time of day. Prior to the commencement of the study, 
subjects indicated that they had a mean sleep duration of 7t hours 
per night. The .subjects all significantly exceeded their 
anticipated sleep durations by an hour each night. Webb and 
Agnew Cl974Cb)) placed subjects on a strictly controlled sleep· 
schedule for ten days In which .the lights were switched off at 
11 pm and the subjects awakened promptly at 7 am. The subjects 
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had a mean sleep duration of seven hours and twenty four minutes 
per night. For the next ten nights subj~cts were permitted to 
sleep as long as they ~esired and under this experimental condition 
they had a mean sleep duration of eight hours and. fifty one minutes. 
More evidence as to the question of whether one is sleep deprived 
was provided by Webb and Agnew (1975(b)). Sixteen .subjects slept 
in a sleep laboratory, in which all cues as to the time of day were 
eliminated, for four consecutive nights. On the first three 
nights subjects were put to bed at I I pm and were woken promptly 
at 7 am. The mean sleep duration on the third night was found 
to be seven hours and thirty four minutes. On the fourth night 
subjects were unaware that they would be permitted to sleep unti I 
the EEG showed ten minutes of wakefulness in the morning. The 
subjects had a mean sleep duration of nine hours and forty minutes 
on this ad I lb sleep duration night. 
It has thus been general Jy estab I ished that when subjects are 
permitted to sleep in a time free environment, they significantly 
exceed their normal estimated sleep durations. Webb and Agnew 
(1975(b)) found that when sleep was experimentally restricted for 
a night, an increase similar to the amount restricted occurred 
on the following night. The authors concluded that " ... as in the 
case of eating, given uni imited amounts of food, we wl 11 eat more 
than we need. Our regular sleep diets may be simply and sensibly 
keeping us from being 'sleepfat"' (Webb and Agnew 1975(b) p.48). 
3.0 METHODOLOGICAL CONSIDERATIONS FOR SLEEP LABORATORY 
DRUG EVALUATION PROGRAMS 
3;1 The Adapt~tlci~ to The Sleep L~bcir~tciry EnVlrcin~~nt 
3.1.1 The "first night" effect 
Several studies have reported the existence of a "first night" 
adaptation effect in EEG sleep studies in normal subjects as wel I 
as in psychiatric outpatients (Agnew et al 1966; Schmidt and 
Kaelbling 1968, I 9 7 I ; R'e ch ts ch a f fen an d Ve rd on e I 9 6 4 ; Me n de I s 
and Hawkins 1967; Dement et al 1965; Antrobus 1962). The 
"first night" effect consists pri mari I y of a decrease in stage REM 
s I eep as we I I as an increase in tot a I ti me spent awake (Agnew 
et al 1966; Hawkins and Mendels 1966; Scharf et al 1975; 
Antrobus 1962; Rechtschaffen and Verdone 1964). In addition, 
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an increase in stage 4 and stage REM latency as wel I as an increase 
in the number of shifts in sleep stages occur (Agnew et al 1966; 
Hawkins and Mendels 1966). 
Recent studies have questioned the existence of this wel I documen-
ted adaptation phenomenon in norma I subjects as we 11 as in 
psychiatric inpatients (Coble et 
0
al 1974; Kupfer et al 1974; 
Toner et al 1975; Niimi et al 1968; Globus 1970; Williams et 
al 1972; Clausen et al 1974). 
Toner et al (1975) attempted to familiarise normal subjects to 
the experimental setting by taking them on an informal tour of 
the sleep laboratory. The subjects were also shown a documen-
tary f i Im which depicted the s I eep stages as we I I as the 
procedure used to secure the vari.ous electrodes. Subjects were 
also permitted to ass[st the experimenter ln w(rlng up tel low 
subj.acts. However, th[s fami lar[sation technique was unsuccess-
ful i.n eliminating the "first night" effect. 
Coble et al (f974) permitted subjects to sleep in private, 
comfortably furnished bedrooms. The subje~ts were al lowed to 
use kitchen facilities and had free access to a "denlike" 
television area until they were required to go to sleep. This 
laboratory environment resembled a good hotel in the middle price 
bracket. In addition, the laboratory personnel were friendly 
and helpful and explained the operation of the equipment to the 
subjects. There was a significant decrease in stage REM latency 
from the first to the second night, but no changes in any of the 
other sleep parameters occurred. 
Kupfer et al (1974) were unable to detect any significant "first 
night" effects in psychiatric inpatients. Mendels and Hawkins 
( 1967) noted that depressed inpatie~ts, with the exception of a 
decrease in stage 2 sleep, had similar sleep patterns on their 
first and second nights In the sleep laboratory. It has been 
suggested that the absence of an adaptation response shown by 
psychiatric inpatients may be a manifestation of a decreased 
ab i Ii ty to adapt to st res sf u I situ at i ohs (Kupfer et a I 1974). 
Contradictory evidence exists at present as to whether an 
initial adaptation night sh.ould be Incorporated into sleep 
research designs. ln conclusion, It seems advisable at present 
that sleep resear~h des.igns involving normal human subjects 
should comprise an Initial adapt~tion n.ight as most sleep 
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laboratories do not resemble a good hate.I in the mlddle price 
bracket. 
3.1 .2 Readaptatlon t6 The Sleep L~bor~t6ry 
Scharf et al ( 1969) analysed the data of eight subjects. who 
participated in a series of sleep research programs over a two 
year period to determine whether the first night effect persis-
ted throughout the series. They concluded that " ... regardless 
of the number of times previously adapted to the sleep laboratory, 
on a subsequent series there usually was a repeat adaptation or 
"first night" effect consisting of an increased sleep latency, 
and decreased percent sleep time and percent stage REM (Scharf 
et al 1969, p.263). The authors however failed to mention the 
time lapses between the successive series of experiments. 
Scharf et al ( 1975) reported that a readaptation effect existed 
in insomniac subjects when they were re-recorded in the sleep 
laboratory after spending seven nights at home. The authors 
found that the readaptation effect was si mi I ar to that seen in 
the initial adaptation period and included a decrease in stage 4 
and stage REM sleep as wel I as a decrease in the number of stage 
REM periods. These result~ should however be interpreted with 
caution as the adaptation effects appear to b~ confounded with 
drug effects. 
3.2 The Reliabi I ity of Sleep· Measures 
Several s~udles have reported ~iml far percentages Cn6rmative 
data) for the various sleep st~ges in n6rmal young adult subjects 
<Williams et al 1964Ca), 1972, 1974, Dement et al 1966; 
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Wi 11 [ams and Wi. I !lams 1966; .. Agnew and Webb 1968; Ni. i.mi. et al 
1968; Brebbla et al 1969; Hori et al 1969; Moses et al 1972; 
Scott .(972;. Johnson 1973; Cl.ausen et al 1964)(section 2.3.I ). 
However, lt has been as~umed that these values are consistent 
from one night to the next. Be~ger (1969(b}) reported that 
11 ••• the pattern of sleep from n.i.ght to night in a single 
individual remains relatively constant, ~xcept for the first 
night spent in the laboratory when the subject takes a longer 
time to fal I asleep, tends to awaken more frequently and has 
less REM sleep than on subsequent nights" (Berger 1969(b) p.21 ). 
Several studies have investigated the consistency and predicta-
bi I ity of sleep parameters for groups of subjects over several 
nights (Williams et al l964(a), 1966; Hartmann 1968(a), 
Weitzman et al 1970), but only a I imited number of studies have 
attempted to assess whether the sleep parameters of individual 
subjects are reliable over several nights (Moses et al 1972; 
Feinberg 1974; WebbandAgnew 1969; Webb 1974; Clausen et al 
1974). These studies differed from one another in that they 
employed different methodological techni.ques, variable sample 
sizes as wel I as subjects of different age groups. Despite 
these discrep~ncies the above studies arrived at similar con-
clusions as to the reliability of sleep parameters and these 
conclusions are discussed below. 
Webb and Agnew (1969) investigated the reliability .of sleep 
parameters In sixteen young adult subjects with an age range 
from 20-29 years. These subjects slept in the laboratory for 
four consecutive nights from II pm to 7 am in the morning. 
The data. from the last three nights r.evealed that stage 4 and 
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stage I reliabi Ii ties were consistently higher than stage REM 
rel iabi I ittes. In addition, stage awake was found to have a 
consistently low rel iabi I ity whereas the rel iabi I ity of stage 
3 sleep was found to be variable. The authors also found that 
stage 2 rel iabi I ities were lower than those of stage 4 or stage 
I sleep but were greater than those of stage REM sleep. Thus 
the NREM sleep stages had consistently higher reliabi I ities over 
the three recorded nights than stage REM sleep. 
Moses et al (1972) used twenty adolescent subjects with an age 
range from 17-21 years to determine whether sleep parameters 
were reliable. The subjects lived in the sleep laboratory for 
I I days and were only permitted to sleep during specified hours. 
The data from the third and fourth nights were used to determine 
the reliability coefficients. Two subjects were only monitored 
for 390 minutes as a result of technical difficulties. The 
author's results resembled those of Webb and Agnew (1969), but 
in addition it was noted that the number of body movements and 
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the number of sleep stage changes were consistent over the nights. 
Sassin and Johnson (1968) have previously reported that a relation-
ship existed between body movements and sleep stage changes. 
Webb <1974) reported the rel iabi I ity coefficients of the sleep 
parameters of eight young adult subjects with an age range from 
la-23 years. The subjects were studied under highly control Jed 
environmental ~onditlons for teri consecutive days. They I ived 
in a 12xl2 foot room that provided no external cues as to the 
time of day and they were permitted to sleep from II pm at night 
to 7 am ln the morning. The results of this s~udy resembled those 
obtained by Webb and Agnew (1969). 
Feinberg (1974) attempted to determine the reliability of REM 
sleep across three con~ecutive nights in 38 normal subjects with 
an age range from 16-34 years. He permitted a_ greater degree 
of variabi I ity both within the between .subjects in sleep dura-
ti on. The mean within subject variability across the three 
nights was 49,6 minutes. REM re Ii ab i Ii ty coeff i ci en ts were 
determined for a variable sleep duration; the sleep length 
adjusted to each subjects shortest sleep duration and sfeep 
duration I imited to six hours and three minutes for al I subjects. 
The author found REM sleBp was consi~tent across nights and that 
the reliability coefficients were higher when the nights w0re 
equated for total sleep time than when total sleep time was 
permitted to vary. The reliability coefficients across the 
three nights for NREM sleep were consistently higher than th?se 
for REM sleep. High reliability coefficients also existed for 
rapid eye movement activity! as well as for rapid eye movement 
density2 and were in accordance with the findings of de la Pena 
et al (1972). Clausen et al (1974) reported that rapid eye 
movement activity varied considerably amongst subjects but showed 
a consistent increase in individual subjects across four nights 
of study. 
In .summary, it thus appears that the inter-night reliability 
coefficients are higher for NREM sleep stages, especially stage 4 
sleep, than for stage REM sleep CWebb and Agnew 1969; Webb 1974; 
Moses et al 1972; Clausen et al 1974; Feinberg 1974). The 
n_lght to night variabl I ity of the sleep stages may be the result 
.of inadequate scorlng crtteria. "We should not forget that the 
I . . . . 
. The number of 20 second epochs displaying rapid ey~ movements. 
2
Rapid eye movement activity per twenty second e;·och. 
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stages of sleep are man made; devised by a committee based 
primarily upon an epiphenomenon of sleep, the EEG. These sleep 
stages, as defined have been useful and have provided an effec-
tive tool around which to orient our research. We should be 
careful not to reify these stages or to cast their rules in 
cement" (Johnson 1974, p.4). 
3.3 The Selection of Subjetts 
It may seem peculiar to remunerate subjects for sleeping in the 
sleep laboratory. However " ... although there is a small pool 
of interested volunteers, this pool is quite shallow, unreliable 
and dries up rapidly when subjects must be used over a number of 
successive nights or it is necessary to sharply modify their 
normal sleep routine" (Webb 1968, p.8). 
Hartmann and Cravens (1973(a)) have reported the advantages of 
using the same pool of subjects in sleep research programs. The 
subjects become fami I iar with the laboratory, experimenter and 
experimental procedure and as a result become increasingly more 
cooperative and reliable. 
Whitman et al (1963) reported.that subjects have been noted to 
wlthhold personal dreams from the experimenter and Keith(l962) 
indicated that the pres~nce of transference in the laboratory 
dream reports could not be ruled out. The subject may distort 
a dream in such a way as to .avoid embarrassment. Orne (1962) 
has emphasised the extremes to which subjects wi I go in order 
to comply ~ith the expectations of the experimenter. 
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Most sleep research programs require subjects to abstain from 
alcohol lc beverages, hallucinogenic drugs, brief sleep periods 
during the day and may require subjects to take prescribed 
medication on specified nights. The failure to comply with 
these requests could result in an altered nocturnal sleep 
pattern. 
Subjects should be selected within a narrow age range as slow 
wave sleep decreases with increasing age (Agnew et al 1967(a); 
Feinberg et al 1967; Feinberg 1969; Williams et al 1974). 
Female subjects should not be used in studies of extended 
duration due to the increase in stage REM sleep reported to occur 
prior to menstruation <Hartmann 1966(a); Sheldrake and Cormack 
1974). 
In view of the above findings, care should be exercised in the 
selection of subjects for sleep research programs and wherever 
possible subjects with previous sleep laboratory experience 
should be used. 
3.'4 The Nonindependence of Successive Nights 
Several studies have reported the importance of studying drugs 
Independently of one another in order to eliminate the carry over 
effects of one drug to another (Freemon 1972; Oswa Id 1968; 
Kales and Kales 1975; Kales et al 1975). If two different drugs 
are studied on con~ecutive nights, it becomes impossible to deter-
mine to what extent the drug administered on the first night would 
influence the one admi.nistered on the second. 
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3.5 The Control 6f Sleep Dtiration 
lt is a wel I documented phenomenon that stage REM sleep usually 
predominates in the early morning (Verdone 1968) and an extended 
sleep duration normally results in an increase in the number of 
minutes spent in stage REM sleep (Hartmann 1973(a)). The 
extended sleep duration may however have no influence on the 
percent of total sleep time spent in stage REM sleep (Hartmann 
1973(a); Johnson 1975 (Personal communication). Thus a 
pharmacological agent which increased sleep duration without 
having a direct influence on specific sleep stages might be 
regarded as an agent which increased stage REM sleep activity 
if absolute values (minutes) were considered. However if stage 
REM sleep was expressed as a percentage of total sleep time then 
the agent would most likely be considered to have no effect on 
stage REM sleep. 
In addition to expressing sleep stages as a percentage of total 
sleep time, several other methods such as curtai I ing al I the 
records to a specified length or to the length of the shortest 
sleep duration have been used to control for sleep duration 
<Freemon 1972; Webb 1974). 
3.'6 The Analysis of Smaller' Portions of the Night's Data 
Many scientists presently involved in sleep research programs 
h.ave recommended that portions of the night's sleep should be 
analys~d in addition to the data for the entire n_ight (Kales et 
al 1975; Freemon 1972; Hartmann and Cravens 1973(a.)). This 
type pf analysis is essential in determining whether sleep stage 
alterations 6ccur both throughout the night as wel I as within 
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only certain portions of the n_ight's sleep. Hartmann and Cravens 
Cl973(a.)) have .suggested that data from the first three hours, 
second three hours, first six hours of the record as wel I as the 
data from the entire night should be scored and analysed. This 
system of data analysis has been carried out in the present s~udy. 
3. 7 Summary 
The costly nature of sleep laboratory research has often culmina-
ted in the development of research designs which have consisted 
of a I imited number of nights and few subjects. The use of 
single subjects in tha evaluation of the effects of drugs on 
sleep has not been an infrequent phenomenon in the sleep research 
literature (Green 1965; Knowles et al 1968; Wyatt et al 1969). 
Freemon ( 1972) reported that " ..• the incomparabi I ity of resu·lts 
from different laboratories has driven many clinical scientists 
to despair the entire field of sleep pharmacology and to ignore 
important clinical correlations" (Freemon 1972, p.96). 
Many of the methodological inadequacies inherent in sleep 
laboratory drug evaluation studies have been reviewed in this 
chapter. The research designs employed in the present studies 
have been critically evaluated in terms of the above methodo-
logical inadequacies in sections 6.2. I, 7.2.1 and 8.2. I. 
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4.0 THE EFFECTS OF DRUGS ON SLEEP 
4.1 Insomnia 
Insomnia has usually been regarded as the inabi I ity to obtain 
an adequate night's sleep and has been found to be one of the 
most common disorders that exist in contemporary medical practice 
(Johns 1975). The prevalence rate of insomnia has been reported 
to be between five and ten percent in "healthy young adults" 
(Johns et al 1971 ), in twenty percent of patients treated at 
genei-al hospitals (Johns et al 1970) and in excess of eighty 
percent i n pat i en ts s u f fer i n g from acute psych i at r i c i I I n es s es 
(Ward 1968; Detre 1966). The incidence of insomnia increases 
with age and occurs more frequently in women than in men (Johns 
19 75) • 
Surveys taken in two Scottish cities revealed that about fifteen 
percent of the men and twenty five percent of the women over the 
age of 45 years, regularly took prescribed hypnotic medication. 
Karacan (1972) found that insomnia was evident in fourteen percent 
of the populati·on of Aluchua County. A survey in an urban area 
of Melbourne revealed that 9,4 percent of a sample of the popula-
tion reported suffering from moderate, severe or frequent 
insomnia. The phenomenal increment in the sale of hypnotics and 
tranquilisors in the United States during the last ten years has 
provided indirect information as to the widespread incidence of 
sleep disorders (U.S. Department of Health, Education and 
Welfare 1967). 
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Fenton (1975) reported that although Insomnia was "· .. very real. 
to the individual .sufferer ..••. lt was .curiously difficult to 
define and .evaluate cl inlcal ly" (Fenton 1975, p.122). Recht-
schaffen and Monroe (1969) indicated that the criteria which 
delineated the borderline between normality and insomnia were 
largely "guesswork". However insomniacs have been categorised 
into those individuals who experienced difficulty in fal I ing 
asleep (sleep onset insomnia), those who frequently woke up 
during the night for extended periods of time (sleep maintenance 
insomnia) and those individuals who consistently awoke in the 
early hours of the morning (terminal insomnia) (Wi 11 lams et al 
... t 974) • Various combinations of these disorders are evident in 
insomniacs. 
Numerous factors such as noise (Johns 1975), climatic conditions 
(Johns 1975), high altitudes (Williams 1959), age (Feinberg and 
Carlson 1968, Feinberg 1969), psychiatric illness (Kupfer et al 
1970(a); Takahashi and Gjessing 1972), left or r.ight heart 
failure (Rohmer et al 1967), thyrotoxicosis (Oswald et al 1972), 
Cushing 1 s syndrome (Krieger and Glick 1972), fever (Karacan et 
al 1968) and the last three months of pregnancy (Karacan et al 
1969) have been clinically associated with insomnia. Insomnia 
thus appears to be symptomatic of a variety of physical or m~ntal 
disorders and there has been considerable doubt as to whether 
insomnia exists as a distinct entity (Fenton 1975). 
However, several slee~ laboratory investigations have provided 
evidence in support .of the exist~nce of insomnia as an indepen-
dent di.sturbance (Tanaka 1975; Hartmann 1967Ca); Shimuzu et al 
1970; Karacan et al l971(b)). Monroe ()967) attempted to 
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determine whether healthy young adults who regarded themselves 
as good or poor sleepers would· differ from one another on psycho-
logical as we[ I as physiological dimensions. Poor sleepers had 
longer sleep onset latencies, more nocturnal awakenings, more 
stage 2 sleep and less stage REM sleep than good sleepers (Monroe 
1967). They also exaggerated the time needed to fal I asleep. 
The poor sleepers exhibited a high degree of arousal both before 
sleep onset and during sleep. This increased arousal was 
evident in higher heart rates, increased central body tempera-
tures, and more frequent vasoconstrictions in their fingers 
during sleep (Monroe 1967), higher levels of adrenocortical 
activity during the day and night (Johns et al l971(b)) as well 
as lower arousal thresholds to external stimulation during 
sleep (Zimmerman 1970). 
Rechtschaffen and Monroe (1969) indicated that this elevation 
in physiological arousal in the poor sleepers should be regarded 
as a failure of the rest-inducing mechanisms rather than a con-
tinuation of the elevated presleep arousal levels. Support for 
this assumption has been provided by Haurl (1968) who found that 
exercise prior to sleep resulted in increased presleep levels of 
heart rate and rectal temperature which showed a rapid decline 
after sleep onset. The increased rectal temperature and heart 
rate in poor sleepers failed to show asimilar decline after 
sleep onset. 
Rech+schaffen and Monroe (1969) reported that psychological 
di.fferences ~xisted between good and poor sleepers: poor 
sleepers were more anxious, depressed and displayed more 
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"pe.cularities .of tho.ught" than. good sleepers. Williams et al 
(1974) reported that the differences between good and .poor sleep-
ers were remarkable since none of the poor sleeper~ considered 
themselves to be insomniacs and usually slept for four or five 
hours per night. They had no Intention of seekin~ psychiatric 
assistance and did not take sleeping tablets. 
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Most of the research on poor sleep has been carried out on "healthy" 
subjects <Fenton 1975) and relatively few methodical studies of 
insomniac patients have appearsd in the literature. This could 
be due to the absence of an adequate definition of insomnia. 
It has :Jenera I ly been es tab Ii shed that i r.somn i acs have an increased 
slee~ latency, rsduced total sleep time and longer latencies of 
ari~ing (the time taken from awakening in the morning to getting 
out of bed) {Karacan et al 1971(b)), but were found to have normal 
quotas of stage REM sleep (Kales 1972; Snyder 1972). The nigh~ 
to night sleep patterns of insomniac patients revealed a great 
degree of variabi I ity and nights of poor sleep with reduced 
quantities of stage REM sleep were followed by nig.hts of good 
sleep with increased quantities of stage REM sleep <Kales 1969; 
Karacan et al 1973(c); Fenton 1975). 
Another important feature of the insomniacs sleep has been the 
discovery of abnormal EEG waveforms despite the occurrence of 
normal sleep patterns. These EEG waveforms consisted of inter-
mingled alpha and delta activity <Hauri and Hawkins 1973; 
Karacan et al 1973(c.)). 
Insomnia should not be equated with a reduction in total sle~p 
time ~ecause reduced sleep could represent either insuffici~nt 
sleep or a decreased need for .sleep. Jones and Oswald .(1968) 
reported that two indivtdu:aJs· we.re recorded who only· slept for 
three hours a day and yet I ived healthy, content, productive 
I Ives. Insomniacs have been found to differ from these healthy 
short sleepers in having a high incidence of psychopathology 
such as mi Jd depression, anxiety as wel I as psychosomatic sympto-
mology (Fenton 1975). Several studies have found that insomniacs 
fear losing control over their aggressive or sexual feelings and 
this could be instrumental in their difficulty in falling asleep 
(Kales 1972; Hartmann 1973(b)). 
Hypnotic and sedative drugs have been regarded as the most 
expedient method for the treatment of insomnia in contemporary 
culture and their prescription has increased dramatically 
CKaracan and Williams 1971; Oswald 1968). It has generally 
been established that these drugs have undesirable side effects 
such as drug dependence, self poisoning, changes in perceptual 
motor performance as well as mood changes (Oswald and Priest 
1965; Hartmann 1972). Several studies have indicated that the 
~htcihic use of hypnotic drugs should be avoided because of their 
relative ineffectiveness and the danger of both physiological 
and psychological dependence <Kales and Kales 1973; Johns 1975). 
Most hypnotic drugs have been reported to suppress stage REM 
sleep and this suppression has been associated with a reduction 
in the intensity and vividness of REM mentation (Carrol et al 
1969; Kales et al 1969(.a)(b.)). "···One thing we can declare, 
though, with incontrovertibl~ certitude, is that the REM rebound 
fol lowing withdrawal of .the chronic use of a dr_ug is one of the 
commonest causes of sleep dis.turbance'' (Fr~emon 1972, p. 127). 
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Drug withdrawal lnsomnia is associated with a difficulty In 
f a I I i .n g a s I e e p , a n I n c re as e d v I. v. i d n e s s i n REM me n tat i on as w e I I 
as the occurrence of nLghtmares (Kales et al 1968(a)(b), 
l969(a)(b). 
Several studies have advocated non-pharmacological treatm~nts 
for insomnia such as hypnosis (Hanley 1965; Fry 1963; Tiller 
1967; Todd and Kelley 1970), muscle relaxation training (Kahn 
et al 1968; Jacobson 1938; Paul 1969; Wolpe 1969; Hinkle and 
Lutke r I 9 7 2 ; Bork o v e c and F ow I es I 9 7 3 ; Bork o v e c et a I I 9 7 3; 
Wei I and Goldfried 1973; French and Tupin 1974; Gershman and 
Clouser 1974), systematic desensitisation (Geer and Katkin 1966; 
Evans and Bond 1969; Borkovec et al 1973; Gershman and Clouser 
1974), classical conditioning (Poser et al 1965; Evans and Bond 
1969), biofeedback (Raskin et al 1973; Budzynski 1973), 
electrosleepl (Rosenthal and Wulfsohn 1970; Rosenthal 1972; 
Feighner et al 1973; Weiss 1973; Hearst et al 1974; Frankel et 
al 1973; Frankel 1974) as well as expectation2 and attribution3 
(Nicholls and Silvestri 1967; Zaroslinski et al 1969; Storms 
and Nisbett 1970; Davison et al 1973). 
In view of the many undesirable side effects produced by the 
administration of hypnotics, these non-pharmacological methods 
should play an ever increasing role in the overal I management 
of insomnia. 
1
The transcranial appl.ication of a low Intensity electrical 
current. 
2
The powerful effects .of suggestion, therapist ~xpectation 
and placebo administration (Montgomery et al 1975). 
3~ttribution '~efers to the ~el iefs the subject has about the 
causes of his current physiological and psychological state" 
(Montgomery et al 1975, p.96). 
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4.Z ,The Effects of Placebo Administrati.on on Sleep Parameters 
Within the realm of cl iriical psycholo~y and p~ychopharmacol~gy 
the placebo effect has remained a poorly explained phenomenon 
and attempts at advancing a feas[,ble rationale have been notably 
few (Rachman and Phi I ips 1975). 
The placebo has been defined as '' ... a preparation containing no 
medicine, employed with or without some ritual, but always with 
the suggestion or implication of its power or helpful properties", 
and the placebo reaction as 11 ••• the physiologic and psychologic 
reaction to the administration and acceptance of the placebo, 
this reaction can be positive and beneficial or it can be negative 
and detrimental" (Fischer and Olin 1956, p.509; English and 
English 1958, p.393). 
The administration of placebo has been found to be effective in 
the treatment of a variety of physiological and behavioural dis-
orders such ~s headaches (Beecher 1955), seasickness <Beecher 
1955), severe post-operative wound pain (Keats and Beecher 1950; 
Beecher 1955), anxiety and tension (Wolf and Pinsky 1954) and 
pain tolerance (Gelfland et al 1963), but as yet there has been 
I ittle investigation into the direct effects of placebo on sleep 
patterns (Hartmann and Cravens 1973(a); Adam et al 1975). "The 
placebo effect is a much quoted but less often investigated 
assumption in sleep studiesll(Adam et al 1975, p.84). 
Placebo administration, in general, has been reported to produce 
p,ositive as wel I as negative effects (Shader and Di Mascio 1970). 
Beecher <1955) reported that the administration of placebo 
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resulted in the occurrence of side-effects .such as dry mouth, 
n.ausea, sensations of he.aviness, headache, and di.fficulty in 
concentrating. Such findings have resulted in the widespread 
tendency to compare a drug to asimilar appearing placebo when-
ever an attempt has been made to determine the pharmacological 
effect of the drug in contrast to its total effect on the subject 
<Hartmann and Cravens 1973(a)). The total effect of a drug has 
been reported to be its pharmacological effect as we! I as the 
placebo! effect (Stroebel 1972). 
Davis and Hartmann (1973(a)(b)) investigated the effects of the 
short-term administration of placebo on the sleep patterns of 
male subjects with an age range of 21-35 years as we! I as female 
subjects with an age range of 45-60 years. The male subjec~s 
spent significantly more time awak~ whereas the female subjects 
spent significantly more time in stage 3 and stage slow wave 
sleep during placebo administration. Hartmann and Cravens 
(1973(a)) suggested that the discrepancy in the responses of 
male and female subjects to placebo administration should be 
evaluated in terms of the subjects' expectations of the medication. 
They indicated that the older women may have had a positive 
expectation that any medication evaluated in a sleep laboratory 
would have a beneficial effect whereas young male subjects may 
have regarded their normal sleep as adequate and that medication 
would do little to improve this. 
Zung ( 1973) reported that the short-term administration of 
p I acebo resu I ted in an increase in stage 4 s I eep and a decrease 
in stage REM sleep in five healthy subjects. These findi.ngs 
1The expectation of the subjects (Stern~ach 1966) and/or the 
experimenter (Rosenthal 1965). 
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should be interpreted with caution as a result of methodological 
inade~uacies in research design .~uch as the absence of an initial 
adaptation period (~ection 3. I. I) and the non independence of 
successive nights (section 3.4). Hartmann and Cravens Cl973(a) 
found that the long-term administration and withdrawal of placebo 
resulted in a significant increase in stage REM sleep in normal 
young adult subjects. 
Several more. recent studies, however, have reported that the short-
term administration of placebo exerted no significant effect on 
sleep stages, quality of sleep or mood (Adam et al 1975, 1976; 
Touyz et al 1975(b). 
The evidence appears to favour the conclusion that the short~ 
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term administration of placebo does not markedly alter the sleep 
patterns of normal adult subjects (Adam et al 1975, 1976; Touyz et al 
1975{b)), but Nicolis and Silvestri (1967) have indicated that 
this conclusion may not be applicable to insomniac subjects whose 
sleep improved under placebo administration. Additional research 
is also required to confirm the findings of Hartmann and Cravens 
(1973(a)) that the long-term administration and withdrawal of 
placebo resulted in a significant increase in stage REM sleep. 
4.3 Sleep and Hypnotic DrOgs 
It has generally been established that many hypnotic drugs 
suppress REM sleep (Oswald 1968; Ki_ng 1972; Freemon 1972), 
cause death when taken in overdose (Johns 1975), produce depen-
d~nce (Kales and Kales 1973} and become relatively ineffective 
in the treatment of insomnia after chronic administration (Johns 
The abrupt withdrawal of an hypnotic after continuous 
administration may result in a drug withdrawal Insomnia (Kales 
and Ka I es I 9 73) . "It is ironic that insomnia should be caused 
frequently by the very drugs which have been prescribed to treat 
the sympton" (Johns 1975, p.464). 
The recent advances In p~hopharmacological sleep research have 
now made it possible for a more scientific approach to be adopted 
in the prescription of hypnotic agents in the treatment of sleep 
disturbance. The physician, provided with the Information as to 
the exact problem of his patient, wl I I now be able to prescribe 
a drug which has been scientifically shown to al levlate the 
specific sleep deficiency {Williams et al 1974). The trial and 
error method of prescribing hypnotic medication may soon be a 
phenomenon of the past. 
4.3.1 Barb.iturates 
The barbiturates, which are powerful hypnotic agents CSapelka 
1972), have been. frequently used and abused (Freemon 1972). 
Friend (1969) reported that secobarbital and pentobarbital were 
among the twenty most prescribed medications in the United 
States. The barbiturates are the most common chemical used to 
Induce death by suicide (Oliver and Hetzel 1975; Berger 1967). 
Sharpless (1970) reported that the barbiturates were rapidly 
absorbed from the gastr6intestinal tract and were distributed 
throughout the body, having a profound depressant effect upon 
the entl re centra I nervous system. Johns (1975) noted that the 
barbiturates were meta~ol ised at an increased rate by the hepatic 
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microsomal enzymes after only a few days of administration and 
i t h a s b e e n s .u 8 g e s t e d th a t t h i s i n c re a s e d rate o f me ta b o I i s m h a s 
been responsible for the rapid development of tolerance CRemmer 
1969; Sharpless 1970). 
The barbiturates reduce the latency to sleep onset as wel I as 
the frequency and duration of nocturnal awakeni.ngs (Johns 1975). 
It has generally been established that barbiturate administration 
resulted in the suppression of stage REM sleep CBaekeland 1967; 
Hartmann 1968(b); Kales et al 1968(b), 1970(e); Oswald 1970(b); 
Oswald and Priest 1965; Evans and Lewis 1968; Haider 1969; 
Haider and Oswald 1971; Davison et al 1970). This reduction in 
stage REM sleep has been found on occasion to return to base I ine 
levels (Evans and Lewis 1968; Kay et al 1972). The abrupt_ with-
dr~wal of barbiturates after chronic administration results in a 
REM rebound (drug withdrawal insomnia) characterised by frequent 
nocturnal awakenings as a result of disturbing dreams and night-
mares (Oswald and Priest 1965). Carroll et al (1969) found that 
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the barbiturates influenced dream content making it more conceptual 
less perceptual, more "thought-like" and less "dream-like". 'Kales 
et al (1974) reported that the barbiturates have often been con-
tinued to be taken to avoid the symptoms produced by the drug 
withdrawal insomnia, but the resultant sleep was found to be no 
better than that during the preadministration period. Whitlock 
(1970) found that the dosage was often increased in an attempt to 
improve sleep and resulted in intoxication with tremor and confusion 
during the day and insomnia at night. Oswald and Priest (1965) 
have shown that it takes up to five weeks to''·· .escape the sleeping 
plll habit 11 after chronic administration (Oswald and Priest 1965, 
p.1093). 
The barbiturates produce hangover effects on the day fol lowing 
. . 
administration (Johns 1975) as wel I as to impair performance 
tasks (Malpas et al 1974). Johns (1975) concluded .that in view 
of the many side-effects produced by the administration of bar·-
b it u rates they " •.. have ceased to have a I e g i t i mate r o I e i n the 
treatment of insomnia" (Johns 1975, p.467). 
4.3.2 Benzodiazepines 
The benzodiazepam derivative nitrazepam (5-IOmg/night) is 
extensively used as an hypnotic in Australasia, Europe and the 
United Kingdom, whereas a related drug, flurazepam (15-30mg/night) 
has been extensively used in the United States (Johns 1975; Taws 
et al 1975). These drugs are as equally effective as the bar-
biturates (Haider 1968; Morgan et al 1970; Haider and Oswald 
1971; Mathew et al 1969; Malpas et al 1970; Davies and Levine 
1967; Fisher and Gal 1969; Bordeleau et al 1970; le Riche et 
al 1966; Jick et al 1966; Hartmann 1968(b); Andersen et al 
1969) and non-barbiturates such as chloral hydrate (Jick 1967; 
Kales et al 1970(a)(b)),glutethimide (Jick 1967; Kales et al 
1970(e))and methaqualone (Kales et al 1970(d)). 
Low therapeutic doses of nitrazepam C5mg) and tlurazepam ( 15mg) 
h~d an Insignificant effect on stage 4, stage slow wave or stage 
REM sleep CGastaut et al 1967; Johns and Masterton 1974). The 
administration of higher doses of these drugs, however, had a 
much more consistent suppressant effect on stage 4 than on stage 
REM sleep <Kales and Scharf 1973; Dement et al 1973Cb); Kales 
et a I I 9 7 0 ( d ) ; Voge I et a I . I 9 7 2 (b ) ; 0 s w a. I d et a I I 9 7 3 ; 
Hartmann 1968(b)). Kales et al Cl970(d)) reported that 
flurazepam suppressed stage slow wave sleep to a greater extent 
60 
than did nitrazepam whereas nltrazepam reduced stage REM sleep 
to a greater extent than did tlurazepam. The withdrawal of 
n i t r a z e p a m a f t e r co n t i. n u o u s a d m i n i s t rat i o n res u I t e d i n a REM 
rebound which persisted for several weeks (Oswald and Priest 
1965; Haider and Oswald 1971). 
The benzadiazepines have distinct advantages over other tra-
ditional sleep inducing drugs in that they have been found to be 
innocuous whon taken in suicidal or accidental overdose (Barra-
clough 1974; Mathew et al 1969), and have a low dependence 
labi lity (Isbell and Chrusciel 1970; Greenblatt and Shader 1974). 
Flurazepam is unique in that its hypnotic efficacy has been found 
to persist after several weeks of administration (Kales et al 
1970(d); Greenblatt and Shader 1974). The benzodiazepines, 
however, produce hangover effects (Greenblatt and Shader 1974) 
as well as persistent psychomotor impairment (Malpas et al 1970; 
Bond and Lader 1972(a) (b); Sal kind and Silverstone 1975)) but 
these effects are reportedly of a lesser degree than those of the 
barbiturates (Bond and Lader 1972(a)(b); Johns 1975). 
In view of the above findings, it has been recommended that 
nitrazepam or f lurazepam should be prescribed in preference to 
other hypnotics in situations where sleep inducing medication is 
indicated (Greenblatt and Shader 1974; Johns 1975). 
4.3.'3 Non.JBarbiturate Hypnotics 
Chloral hydrate is one of the oldest hypnotic agents and has been 
extensively used throughout the world (Hartmann and Cravens 
1973(e); Johns 1975). It is an inexpensive and efficient 
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hypnotic agent .for the short-term treatment of insomnia CSapeika 
1972; Johns 1975). Chloral hydrate has an unpleasant taste with 
a tendency to irritate the upper gastrointestinal tract and should 
be taken with milk or brandy (Johns 1975). It is metabolised to 
trichloroethanol which exerts the potent neural suppressant effect 
<Hartmann and Cravens 1973(e); Sapeika 1972; Johns 1975; 
Marshal I and Owens 1954; Imboden and Lasagna 1956; Goodman and 
GI I Iman 1970). It has generally been estab I ished that the 
administration of chloral hydrate (500mg-1000mg) has no significant 
effect on sleep stages (Kales et al 1969(b); 1970(d); Hartmann 
and Cravens 1973(e). Chloral hydrate loses its hypnotic effect 
during long-term administration in insomniac subjects (Kales et 
al 1970(d)). Bare and Pepino (1961) found that chloral hydrate 
produced minimal hangover effects. 
Glutethimide is a sedative and hypnotic agent (Sapeika 1972). 
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The administration of glutethimide (500mg-lgm) results in a decrease 
in stage REM sleep (Rubin et al 1969; Williams and Agnew 1969; 
Kales et al 1969, 1970(a)(e}) and its withdrawal results in a REM 
rebound (Kales et al 1969, 1970(a)(e}). Johns (1975) reported 
that glutethimide has no advantages over the barbiturates either 
in its short-term or long-term use as it produces dependence and 
is toxic in overdose (Sapeika 1972; Kales et al l970(b); 
Goldstein et al 1971). 
Methyprylone is related chemically to glutethimide (Johns 1975). 
The administration of 300mg of methyprylone resulted in a decre-
ment of stage REM sleep and a REM rebound 6ccurred on withdrawal 
(Kales et al 1969(b}, 1970(e}). Methyprylone produces dependence 
and is toxic in overdose (Rickels and Bass 1963; Kales et al 
(1970(b)). 
Methaqualone, a synthetic non-barbiturate hypnotic, is a 
qu(nazolone derivative (Sapeika 1972). The admin1stration of 
methaqualone has no effect on sleep stages CW( I I lams and Agnew 
1969; Davison et al 1970; Evans and Ogunremi 1970; Kales et 
al 1970(d)). Dunlop (1970) reported that non-fatal side-effects 
occur with methaqualone administration. 
Carbromal is a brominated monoureide and has been regarded as a 
mild and relatively safe hypnotic (Johns 1975). Sharpless (1970) 
has warned that care should be exercised in the long-term admini-
stration of carbromal as its ingestion results in the release of 
free bromide which could cause bromism. As far as it could be 
ascertained, research has yet to be carried out to determine the 
effects of carbromal on sleep patterns. 
4.3.4 Antidepre~s~hts 
The tricycl le compounds and the monoamine oxidase inhibitors have 
been found to have a marked effect on the sleep patterns of normal 
subjects as wel I as in patients suffering from depression (Wyatt 
et al 1969, 1971(a); Zung 1969; Akindele et al 1970; Hartmann 
and Cravens 1973(c)). The tricyclic antidepressants imipramine, 
desipramine, clomipramine and amitriptyl ine increase total sleep 
time and reduce body movement activity (Johns 1915). It has 
generally been established,however,that these drugs have an 
initial inhibitory effect on stage REM sleep which results in a 
REM rebound on withdrawal <Hartmann and Cravens l973(c); Toyoda 
.1964; Ritvo et al 1967; Chernik et al 1973(b)). The admini-
stration of lprLndole and t~imlpramine however~ did not inhibit 
stage REM sleep (Baxter and Glukman (1969). 
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The monoamine oxidase inhibitors suppress stage REM sleep within 
a few days of chronic administration and this suppression of 
stage REM sleep persists for the entire duration of administration 
(Okuma et al 1974; Johns 1975; Wyatt et al 1969; Cramer and 
Kuhlo 1967; Ryba et al 196.6). Wyatt et al (1971(a)) indicated 
that a marked rebound of stage REM sleep occurs upon the cessa-
tion of administration of these drugs. 
4.3.5 Phenothiazihes 
The phenothiazine drugs such as chlorpromazine have seldomly 
been prescribed for the treatment of insomnia in the absence of 
psychosis (Johns 1975). Hartmann and Cravens (1973(d)) reported 
that chlorpromazine was the most extensively used major tran-
qui I isor in the world today. 
Several studies have investigated the effects of the administration 
of chlorpromazine and related phenothiazines on the sleep patterns 
of normal volunteer subjetts as wel I as of psychiatric patients 
(Toyoda 1964; Lester and Guerrero-Figueroa 1966; Feinberg et al 
1969; Lewis and Evans 1969; Sagales et al 1969; Lester et al 
1971; Kupfer et al 1971). The overall effect of chlorpromazine 
administration on sleep parameters was found to depend on the 
dosage administered. It has been established that low doses 
(25mg) increase stage REM activity (Lewis and Evans 1969), high 
dos~s (200mg) inhibit stage REM activity (Feinberg et al 1969) 
but increase total sleep time (Hartmann and Cravens 1973(d)) 
whereas intermediate doses C50mg) have no effect on sl~ep 
parameters (Hartmann and Cravens 1973(d.)). 
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Research has yet to be carried out on other phenothiazines such 
as ptomethazine and trimeprazine to ascertain whether they have 
an effect on sleep parameters (Johns 1975). 
4.3.6 Alcohol 
A I coho I is the most frequent I y used "psychoactive" agent in 
contemporary Western culture (Freemon 1972). It increases total 
sleep time (Freemon 1972) and decreases stage REM activity (Gresham 
et al 1963; Yules et al 1967; Knowles et al 1968; Maclean and 
Cairns 1975; Greenberg and Pearlman 1967). The withdrawal of 
alcohol after chronic administration results in a marked rebound 
of stage REM sleep (Yules et al 1967; Knowles et al 1968; Gross 
et al 1966; Johnson et al 1970). 
It has genera I I y been estab Ii shed that the REM rebound which 
occurs following the withdrawal of alcohol, is more profound 
than following the withdrawal of barbiturates or any other drug 
(Freemon 1972). The hal.lucinatory experiences associated with 
delirium tremensl may be related to the mechanisms underlying the 
REM state. 
4.3.7 Miscellaneous Drugs 
The amphetamines decrease stage REM sleep as wel I as total sleep 
time (Rechtschaffen and Maron 1964; Baekeland 1967; Lewis 1970). 
It has been established that the withdrawal of amphetamines after 
chronic administration results in a rebound of stage REM sleep 
(Oswald 1969(a), Lewis 1970). 
1
delirium tremens i.s an acute delirium precipitated by 
alcohol and Is characterised by great anxiety and tremors. 
Lithium carbonate, used to treat patients suffering from de-
pression, has also been found to reduce stage REM sleep (Kupfer 
et al J970(c); Chernik and Mendels 1972, 1974; Mendels and 
Chernik 1973) and to increase slow wave sleep (Kupfer et al 
1970Cc); Chernik et al 1973(a); Chernik and Mendels 1974). 
Tetrahydrocannabinol, the active ingredient of marihuana, 
suppresses stage REM sleep (Pivik et al )972; Moreton and Davis 
1973; Freemon 1974; Feinberg et al 1975) .. 
On the other hand, a variety of drugs enhance stage REM sleep: 
these include reserpine (Hartmann 1966(b); Tissot 1965; 
Hoffman and Domino 1969; Coulter et al 1971; Hartmann and 
Cravens 1973(b)), lysergic acid diethylamide (Muzio et al 1966; 
Green 1965, 1969), tryptophan and 5-hydroxytryptophan (Evans 
\ 
and Oswald 1966; Oswald et al 1966; Hartmann 1967(c); 
Hartmann et al 1971Cb); Wyatt et al 1971(b)). 
4.3.8 CloZapine 
Clozapine Cleponex), a new an·d powerful psychotropic agent, 
became avai I able in South Africa in 1974 (Hemphi 11 et al 1974) 
(section 5.2.4). Recent research has indicated that clozapine 
may have sleep inducing properties .(Hemphill et al 1974, 1975; 
Ruch et al 1976) but as yet only one investigation on the effects 
of clozapine on sleep patterns has been carried out (Blum and 
Girke 1974). The authors reported that the administration of 
clozapine resulted in a phe~omenal increase in stage REM sleep 
in four neurotic and one p~ychotic patient. The reported 
increase in stage REM sleep wa~ as high as B5% of total sleep 
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time. This result sh.ould however be Interpreted with extreme 
caution as many metho~ological inadequacies are evident in the 
research design. These included the absence of an adaptation 
night; the administration of a variable dose of clozapine with 
a range of more than 300mg; the criteria as to what constituted 
stage REM sleep were not specified, but it was reported that REM 
sleep occurred at sleep onset and that muscle tension was 
frequently recorded; REM awakenings were effected but no mention 
was made on which night or nights this was done; no statistical 
analyses were attempted and the ages of the subjects were not 
specified. In view of the above findings, the remarkable 
increase in stage REM sleep reported appears to be questionable. 
4.4 Summary and Contl~~idns 
Insomnia is one of the most prevalent disorders encountered in 
general medicine today (Johns 1975) and att~mpts at advancing a 
feasible definition have largely been unsuccessful. However, 
insomniacs have been categorised into those individuals who 
experience difficulty in falling asleep (sleep onset insomnia), 
those who frequently wake up .during the night for extended periods 
of time (sleep maintenance insomnia) and those individuals who 
consistently awake in the early morning (terminal insomnia). 
Wi 11 iams et al ( 1974) reported that various combinations of 
these disorders were evident in insomniacs. 
l t. has genera I I y been es tab Ii shed that insomniacs have an in-
creased sleep latency, reduced total sleep·time and have longer 
latencies of arising in the morning than normal subjects. 
Insomniacs were however found to have normal ~uotas of stage REM 
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sleep (Kales 1969(a); Kales 1972; Snyder 1972). The n.i ght to 
night sleep patterns were found to have a high degree of varia-
bl I lty and nights of poor sleep with reduced quantities of stage 
REM sleep were followed by nights of good sleep with increased 
.quantities of stage REM sleep <Kales 1969(a); Karacan et al 
1973(c); Fenton 1975). Abnormal EEG waveforms comprising 
Intermingled alpha and delta activity have been reported to occur 
in insomniac subjects (Hauri and Hawkins 1973; Karacan et al 
1973(c)). 
Hypnotic and sedative drugs have been regarded as the most 
expedient method of treatment of insomnia despite the fact that 
non-pharmacological treatments such as hypnosis, muscle relaxa-
tion, systematic desensitisation, biofeedback, classical con-
ditioning, electrosleep as well as the powerful effects of 
s u g g est i on a n d expect at i on ha v e. been advocated ( sect i on 4 • I ) • 
Nicol is and Silvestri (1967) have indicated that placebo adminis-
tration may enhance the sleep of insomniac patients(section 4.2). 
Thus, sleep laboratory investigations of the effects of hypnotic 
drugs on sleep patterns have indicated that a " ••• potential and 
largely unrecognised danger lies in their use" (Kales and Kales 
1970, p.2232). The intensely aggravating reactions associated 
with the withdrawal of many hypnotics after chronic administra-
tion have led to drug dependence (Kales and Kales 1969; Oswald 
and Priest 1965). Kales et al (1969(b)) proposed a number of 
recommendations for the treatment of drug dependent patients. 
The authors advocated that the drug should be withdrawn gradually, 
that the patient should be 1.nfdrmed that psycholo9ical distur-
bances such as Increased dreaming and nightmares may occur and 
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that these w6uld be of physiological rather than a psychological . . 
o r i g i n , a n d. f i n a I I y w h e re t h e tot a I w i th d raw a I o f a d r u g w a s n o t 
feasible, the drug should be replaced by an hypnotic which has 
been found not to suppress stage REM sleep. 
Freemon (1972) reported that th~ indiscriminate prescription of 
sleep inducing medication was the most ''· .. common error in 
medicine today" (Freemon 1972, p.128). 
Recent research in the United States has indicated that physicians 
and patients may be adopting a more responsible attitude to the 
use of hypnotic drugs and that "· •. in the great majority of cases 
the drugs are used for a relatively short period of time" ... and 
" .•. of all adults in the general population who reported a major 
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sleep problem in·a recent calender year, only a smal I minority were 
treated with hypnotic drugs". (Balter and Bauer 1975, p.291). 
The evidence favours the conclusion that hypnotic agents should 
be thoroughly investigated prior to being placed on the medical 
market. The investigations should include the following: the 
effects of the drug on sleep parameters, the short and long-term 
effectiveness of the drug as wel I as the side-effects produced. 
5,0 METHODOLOGY 
5.1 Subjects 
The subjects in al I phases of the present study comprised 20 
paid student volunteers drawn from approximately the same socio-
economic and educational background. They were al I English 
speaking, registered students at the University of Cape Town and 
ranged in age from 18-24 years with a mean age of 20,65 years. 
Prior to the commencement of the study, subjects completed legal 
consent forms, which was a Groote Schuur Hospital prerequisite 
for research on human subjects, a questionnaire concerning their 
normal sleep and drug taking habits and an Eysenck Personality 
Inventory (EPI) (Form A). Subjects were also required to under-
go a medical examination and in no instance was any obvious 
physical or mental abnormality found. The Neuroticism score on 
the EPI revealed a mean of 7,7 with a range of 4 - 16 whereas the 
Extroversion score was found to have a mean of 12,9 and a range 
of from 4 - 19. The mean Neuroticism and Extroversion scores 
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thus fell well within the normal range. (Eysenck and Eysenck 1964). 
The questionnaire concerning sleep and drug habits indicated that 
subjects normally had a mean sleep duration of 7,68 hours with a 
range of 7 - 9 hours per night, kept their sleep habits constant 
and were not habitual drug takers. Subjects were assured that 
they were free to withdraw from the study if they so desired; 
however the costly nature of sleep research with respect to time 
and money was pointed out to them. Subjects were paid on the 
completion of each investigation. The subjects were distributed 
across three separate investigations and some subjects took part 
in more than one investigation. 
Subjects were permitted to take part in more than one investi-
gation as the three investigations were carried out 3 months 
apart thus avoiding any possible contaminating effects of a 
drug upon subsequent drug periods (Hartmann and Cravens 1973(a)). 
The advantages of using the same pool of subjects clearly out-
weighed the disadvantages. The experimenter became familiar 
with subjects through repeated laboratory sessions and interviews. 
Likewise the subjects became fami I iar with the laboratory and 
experimental procedure and as a result became increasingly more 
cooperative and reliable <Hartmann and Cravens l973(a)). As far 
as could be ascertaihed, there was no dishonesty regarding the 
taking of medication (i.e. subjects took the coded tablet on the 
required night). In no instance did any subject fai I to arrive 
at the laboratory on a prescribed recording night. 
5.1.I Short-Term Clozapine Investigation 
This group originally consisted of 15 subjects - II males and 
4 females. The first male subject constituted a pilot study to 
test the intended dose of clozapine of 50mg per night. This 
dose was found to be unsuitable and was altered to 25mg per 
night. The initial intended dose was too strong to be of 
use as an hypnotic as it resulted in the subject sleeping for up 
to 14 hours. As a result, the data obtained for the above 
subject were excluded from the study. The remaining 14 subjects, 
10 males and 4 females with a mean age of 21,20 years and an age 
range of from 18-24 years participated in this investigation. 
The female subjects commenced the investigation on the fourth day 
of their menstrual cycles in order to control for the increase 
in REM sleep reported to occur prior to menstruation (Hartmann 
l966(a), Sheldrake and Cormack 1974). 
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The subjects were told that the alm of the &tudy was to investi-
gate the possible physiological and psychological ~oncomitants of 
a new sle~ping tablet. The majority of subjects were psychology 
students and were aware that placebos are often used in con-
junction with sleep medication in drug trials of this nature. 
Subjects were asked to abstain from al I medications (with the 
exception of those prescribed by the experimenter), cannabis, 
hallucinogens, alcohol and caffeine (after midday) two days prior 
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to and for the duration of the study. Subjects were ndt permitted 
to sleep during the day for the duration of the study. 
Al I the subjects participated on a volunteer basis and were paid 
R45 on the completion of the investigation. 
5. I .2 Long-Term Cloz~pine Investigation 
This group comprised 6 male subjects with a mean age of 19,67 
years and an age range of from 19-22 years. The duration of this 
investigation required the exclusion of female subjects because of 
the increase in REM sleep reported to occur prior to menstruation 
.<Hartmann 1966(a); Sheldrake and Cormack 1974). Prior to the 
commencement of this investigation, blood was drawn by venepuncture 
from each subject and analysed by the Department of Haematology at 
Groote Schuur Hospital. This procedure was repeated on the 
completion of the investigation. 
~ubj~cts were asked to abstain from alcohol, cannabis, hal lucino-
gens and caffeine (after midday) on the days of scheduled labora-
tory recordings. They were told that the aim of this study was 
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to investigate .the possible psychological, physiol~gical ~nd bio-
chemical concomitants of a new sleeping tablet .over an extended 
period of time. The subjects were each paid R85 on the comple-
tion of the investigation. 
5.1.3 REM Dream Recall ·investigation 
This group comprised 6 male subjects with a mean age of 19,83 
years and an age range of from 19-22 years. Prior to the 
commencement of the study, subjects completed the Rotter Incomplete 
Sentences Blank Test in addition to the EPI and were found to 
h a v e a me a n s co re o f I 2 2 , 6 7 a n d a r a n g e o f f r om I I 5 to I 3 5 ·f • Th e 
Rotter ISB provided additional information as to the normality of 
the subjects as studies have indicated the REM dream content in 
psychopathological states such as schizophrenia and depressi~n 
differ from those of normal subjects (Kramer 1970). The subjects 
were told that the aim of the study was to investigate the 
possible effects of a new sleeping tablet on dream content. The 
subjects were all volunteers and were paid R20 on the completion 
of the investigation. 
5.2 Apparatus 
5.2. I Sl~e~ Lab6r~tory 
Subjects slept in a private, sound attenuated, temperature regu-
lated sleep laboratory. The temperature was maintained at 74°F 
and approximately 50% humidJty, thus approaching ideal sleep 
conditions (Holdstock and Verschoor 1974). A buzzer was provided 
with which the subject could call the experimenter monitoring the 
I 
Rotter and Rafferty ( 195.0) reported that "· .• a cutting score 
of 13~ provided a very efficient separati6n of adjusted and 
maladjusted students" (Rotter and Rafferty 1950, p.10). 
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Figure I The Sleep Laboratory. 
d y no graph i n an adjacent e I e ctr i ca I I y sh i e I de d mo n i tori n g 
room. 
5.2.2 Electrophysiological Apparatus 
A Beckman type R Dynograph multipurpose laboratory recorder 
equipped to record four channels of information was employed. 
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It included 4 Type 481 B Preamplifiers, 2 Type 482 M8 Amplifiers and 
4 Type AN 3057-6 Amphenol size 14 leads. In addition, it incor-
porated a vertical (paper) chart drive with 8 possible chart 
speeds ranging from O, I to 25cm per second. The write out 
medium consisted of ink on prefolded Beckman No. 344-206569 
rectilinear paper. 
Beckman silver chloride disc electrodes were used to monitor the 
EEG and EOG. They were attached to the scalp and outer canthi 
of the eyes by means of co I I od ion adhesive. Col lodion is a 
quick drying adhesive which can be easily dissolved with acetone. 
DB electrode paste was used as a conducting paste. 
A Phi I ips PM 3200 single beam osci 1 loscope with a frequency range 
of 0-10 MHz provided an additional monitor of the ongoing EEG 
activity. This monitor, as a result of the negligible electron 
mass, had the distinct advantage over the paper printout of being 
a more sensitive index of EEG activity (Doxey 1975). This was 
particularly useful in identifying background interference at the 
commencement of the recording which did not appear on the paper 
record. 
5.2.3 Tape Recording Equipment 
A JVC Type 1610 V Novice portable cassette taperecorder with a 
bui It in electret-condensor microphone was used to record the 
subjects' dreams. 
5.2.4 Pharmacological Ag~nts 
Clozapine (Leponex): Clozapine differs in chemical structure 
from the major conventional tranqui I isors such as the pheno-
thiazines, thioxanthenes .and butyrophenone derivatives. It is· 
a tricycl ic compound with an asymmetric 7-member central ring 
and is the first substance with a halogen in position 8 instead 
of position 2 (Figure 2). 
Clozapine has been found to be void of cataleptogenic activity 
(Poldinger and Stille 1968) and is thus able to be clearly 
differentiated from anti psychotic agents which preferentially 
affect the extrapyramidal system. The extrapyramidal effects 
of known.major tranqui I isors are closely associated with their 
anti psychotic effects (Sti I le et al 1971 ). 
Major tranqui I isors increase the turnover of dopamine in the 
brain (Corrodi et al 1967; Roos 1965; Vogt 1965) and this 
increase has usu a I I y been associated with an increase in the 
homovanillic acid (hva) concentration in the corpus striatum 
(Anden et al 1963; Da Prada et al 1966; Laverty and Sharman 
1965; Sharman 1966). Clozapine however, has not been found 
to cause an increase in the hva concentration of the corpus 













8-chloro-11-'(4 methyl - 1-pi.peraziny.I) - 5H-dibenzo (b,e) 
.(1,4) diazepine. 
CLOZAPINE 
F_igure 2 The biochemical structure of clozapine showing 





Clozapine has been characterised by the lack of extrapyramidal 
side effects, decreased vigi.lance, increased muscular relaxation 
and its strong dampening action of peripheral autonomic functions. 
(Stille et al 1971). Clinically clozapine can be regarded as 
an antipsychotic agent (Berzewski et al 1969; De Maio 1968; 
Gross and Langner 1966) and has been ranked among the major 
tranquilisors (Stille et al 1971). In the series of major 
tranquilisors ranging from haloperidol to thioridazine, clozapine 
has been placed below thioridazine (Table 3} because of the 










antagonism and arousal 
inhibition 
Table 3 Pharmacological classification of some major 
tranqui I isors according to cataleptic effect, 
apomorphine antagonism and arousal inhibition 
(Stille et al 1971). 
Clbz~plne Plac~bo: Clozapine placebo was manufactured by Sandoz 
Drug Company and was used in the long-term clozapine investiga-
ti on. The tablet was Identical In size, colour and taste to 
the clozapine tablets. ~he constituents of clozapine placebo 




Aerosl I 200 (Degussa) 
Talcum · 
Magnesium Stearate 
Co I Ii don 30 (BASF) 
Ariavit Yellow 2.85 
CTartraziri> Water 
Soluble (Anstead) 
Ariavit Blue (lndigotin) 
Water soluble (Sandoz) 











Table 4 The constituents of clozapine placebo in mi I Ii grams. 
Ascorbit A~id: Ascorbic acid was used as a placebo in the short-
term clozapine investigation as well as in the REM dream recal 
investigation. Ascorbic acid (vitamin C) possesses an asym-
metrical C atom and is therefore optically active. L-ascorbic 
acid and L-dehydro ascorbic acid are the only known naturally 
occurring biologically active substances, the D component being 
inert (Harper 1971). Pure ascorbic acid is a white crystal I ine 
so I i d free I y so I u b I e i n water. It is a powerfu I reducing agent 
giving up two hydrogen atoms to become dehydro-ascorbic acid. 
This oxidation is reversible in the body. It is present in all 
body fluids and tissues (Bell et al 1968; Harper 1971). 
5.2.5 Psychological Te~t A~patatus 
Th~ Taylot Ma~if~~t A~~i~ty S~ale .(Taylor 1953) gives an indica-
ti on of the subjects habi.tual level of general or residual 
anxiety and consists of 50 items thought to be indicative of 
"manifest anxiety" (Appendix .1). .The 50 items were selected 
from the MMPI and 175 "buffer items" were added. The normative 
data on the test, which is presented under the title of 
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"Biographical Inventory" were obtained on a sample.of 229 psy-
chology students. The mean score was abo~t 12. Taylor (1953) 
reported a test - retest rel iabi I ity of 0,88 when a group of 
179 subjects were retested after a period of 4 weeks had elapsed. 
Anastasi (1961) reported that the validity of the above scale was 
sound and that favourable evidence had been obtained from studies 
that compared neurotic and psychotic patients with normal groups. 
The Eysenck Persona Ii ty Inventory (Eysenck and Eysenck I 964) 
measures two major dimensions of personality - extraversion and 
neuroticism. The EPI furthermore consists of two para! lei forms 
thus making it possible to retest subjects after an experimental 
treatment without interference from memory factors (Form A and 
Form 8). The means of the combined forms of the EPI obtained on 
a normal standardisation sample of 2000 subjects were as follows: 
approximately 27,5 for the "E" dimension and 9,1 for the "N" 
dimension. Eysenck ~nd Eysenck (1964) have reported test retest 
rel iabi I ities in the region of 0,84(N) and 0,94(E) for the com-
bined forms and between 0,80(N) and 0,97(E) for separate forms of 
the test over a period of a year. The split half rel iabi I ity of 
the combined scales was reported to be in the region of 0,85 to 
0,95. Eysenck (1962) and Eysenck and Eysenck ( 1963) have shown 
on numerous occasions that when independent judges are asked to 
rate subjects in terms of "introversion" and "extroversion" or 
stability or !ability, their ratings show a clear and predictable 
correspondence with the subjects' EPI scores. 
Th~ Attivati6n D~~ttiVati6h AdJettiv~ Ch~tk I i~t CAD~ACL) CThayer 
• 1967, 1970 and 1971) measures transient l.evels of mood and 
consists of 21 activation - descriptive adjectives which were 
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integrated with 27 no~activation mood descriptJve adjectives 
p rev i o us l y use d by Now I i s ( I 9 6 5 ) (A p pen d i x 2 ) . The non -
activation adjectives were incorporated as a means of disguising 
the aims of the test. Subjects were asked to describe their 
present feelings with their first response to each word. A 
four point scale, with symbols indicating definitely feel (vv), 
feels slightly ( v) cannot decide (?) and definitely .do not 
feel (no ) were used by the subjects as a rating scale for each 
adjective. The AD-ACL has been factor analysed (Thayer 1967, 
1970,1971) and yielded four orthogonal dimensions; General 
Activation (peppy, energetic, vigorous, I ively, activated, ful I 
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of pep, active); High Activation (jittery, intense, stirred up, 
fearful, clutched up); Deactivation Sleep (sleepy, tired, drowsy); 
and General Deactivation (placid, leisurely, calm, at rest, still, 
quiet, quiescent). General Activation, High Activation and 
Deactivation Sleep have been found to be relatively stable factor 
analytic dimensions whereas General. Deactivation has been found to 
be relatively unstable (Thayer 1971). The AD-ACL is purported to 
be reliable and that the mood factors are valid and sensitive 
indicators of transient levels of activation .CThayer 1967, 1970, 
I 9 7 I ) • 
. The Rotter Incomplete Sentences Blank CISB)(Col lege Form) method 
of sentence completion ls a semi-structured projective technique 
in which the subject Is asked to finish a sentence for which the 
first word or words are supplied. It is assumed that the subject 
reflects his· own wishes, desires, fears and attitudes in the 
sentences he makes (Rotter and Rafferty 1950). The ISB consists 
of. 40 items revised from a form developed by Rotter and WI I lerman 
(1947). This form was in turn a revision of blanks used by 
Shor Cl946), Hutt (1945) and Holzberg et al (19471. The lSB 
provides a technique tor objectively screening experimental 
subjects as wel I as inftirmation regarding the diagnosis of 
"mental" disorders for treatment purposes. Rotter and Rafferty 
(1950) found a corrected split half rel iabi I ity of 0,84 when the 
data were based on the records of 124 mal~ college students and 
0,83 when based on 71 female students. The scoring plan involved 
judgements and the matching of sentences against criterion 
sentences, so re Ii ab i Ii ty of scoring was an important factor. 
Rotter and Rafferty ( 1950) reported an inter-rater rel iabi I ity 
of 0,91 when based on 50 male records and 0,96 for 50 female 
records. 
The Brief Psychiatric Rating Scale CBPRS) (Overall and Gorham 
1973) comprises 18 symptom constructs which are rated on a seven 
point scale of severity which range from "not present" to 
"extremely severe" <Appendix 3). This scale was developed to 
provide a highly efficient, rapid assessment technique to evaluate 
change in psychiatric patients and provides a comprehensive des-
cription of the major symptom characteristics (Overal I and 
Gorham 1962). The authors recommend an interview duration of 
eighteen minutes and provide a schedule to assist the interviewer. 
The eighteen mi.nut~ schedule is subdivided into a three minute 
interval in which the interviewer establishes rapport with the 
patient, a ten minute period for non directive interaction and 
a five minute period for direct .questioning. Overal I and Gorham 
(19£2) have indicated that this schedule shou)d not be regarded 
as inflexible and can be modified wherever necessary. The BPRS 
has been reported to be reliable <Overall and Gorham 1962). 
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.The Stanford Sleepiness Scale <Hoddes et al 1972,19731 i.s a .self 
rating scale which is used to quantify subjective changes in 
sleepiness for any period of the day or night. The scale com-
prises seven statements (Appendix 4) which were selected on the 
following basis. Hoddes et al (1972) asked 95 subjects to sort 
52 statements of sleepiness into 7 categories denoting increas-
ing degrees of sleepiness. The final statements were selected 
using Thurston's method of equal appearing intervals (Thurstone 
and Chave 1929). An alternate form reliability check of the 
scale yielded an agreement of 0,88 for 10 subjects. 
5.2.6 Visual Analogue Scales 
It has been suggested that visual analogue scales may provide a 
sensitive index of feelings and mood, more so than category 
scales which fai I to grasp nuances of feelings (Aitken 1969; 
Zea I I y a n d A i t ken I 9 6 9 ) ; w o rd s o r s em an t i c p h r as es a re so met i mes 
inadequate media for descriptions of mood (Aitken 1969). 
"Feelings are states of self and incorporate mood and sensations. 
Although a person may appreciate precisely his state on a selected 
dimension, words may fai I to describe the exactness of the 
subjective experience" (Aitken 1969, p.989). Hayes and Paterson 
(1921) reportad that lines with their boundaries clearly defined 
as the extremes of feeling, served as a useful index of mood and 
feelings. The analogue method is thus particularly useful for 
sensitive comparisons between different occasions in the same 
person. The visual analogue scale has been .successfully employed 
in the measurement of mood changes in a .number of clinical drug 
trials (Firth 1971; Bond and Lader 1975). 
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Al I the visual analogue scales used in this study consisted of 
IOOmm I ines and were scored to the nearest mi 11 imeter (Aitken 
1969). Four visual analogue scales were employed In the short-
term clozapine investigation :-
( i) depression C very depressed - not depressed at 
a I I ) 
Ci i) anxiety (very anxious - not anxious at al I) 
Ci ii) drowsiness (very drowsy - not drowsy at a 11) 
(iv) ability to concentrate Cable to think clearly -
not able to think clearly at all) 
The fol lowing three analogue scales were used in the REM dream 
recall investigation :-
Ci) quantity of dreaming (dreaming al I the time -
little or no dreaming) 
Ci i) qua I ity of dreaming (very everydayish ordinary 
dreaming - very vivid, bizarre dreaming) 
(iii) activity in dream (very active - very passive) 
The Dream Activity - Passivity Scale: The development of this 
analogue scale was based on the finding of Berger and Oswald (1962) 
that there was a direct relationship between the eye movements 
depicted on the EOG and the visual content of one's dream. 
Berger and Oswald ( 1962) awakened 8 volunteers from periods of 
rapid eye movement sleep on 103 occasions during 37 nights. 
Dream reca 11 occurred in 89 instances and was recorded on magnetic 
tape. The double blind procedure was adopted and an independent 
scorer who had never been present during the nocturnal recording 
sessions and who had never seen the relevant electroencephalo-
graphic or eye movement recordings classified the dream reports 
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as "active" or "passive". The dream reports were classified as • 
"active" or "passive" according to the nature of .the events 
• 
described and especially if it was felt that such .events would 
have been accompanied by many shifts of gaze, had .they occurred 
in real life. The rapid eye movement periods were then 
classified as "active" or "passive" according to the frequency 
and size of the eye movements. Berger and Oswald (1962) found 
a significant association (x2 = 16,18 p<0,001) between the nature 
of the dream content and the amount of movement of the eyes, thus 
confirming the hypothesis of Dement and Wolpert ( 1958) that eye 
movements during rapid eyemovement sleep were directional responses 
to the events of the dream. These criteria of "activity" and 
"passivity" appear quite generalised and the broad approach of 
rating dreams as etther active or passive is questionable. 
Thus as a result of the above criticism, a visual analogue scale 
was developed in the present study to enable the rater to assess 
the "activity" or "passivity" of the dreams. This enabled 
raters to express their own nuances of judgement. 
5.2.7 Dream Report Rati~g Scales 
The Dream Report Rating Scales were selected on the basis of 
their previous use in sleep research programs of this nature 
(Carrol et al 1969, Firth 1974). These·scate-s have not been 
published and are difficult to obtain and as a result the develop-
ment and rationale of these tests has bee~ covered in much detai I 
below. 
Th~ L~~so~ lntervie~ Sch~dule (1969) comprises a series of 
questions which wera used as a standard format for eliciting 
dream recal I throughout the experiment and consequently across 
al I rating scales. A copy of thi$ interview schedule appears 
in Appendix (5). 
The Dream I Ike Fantasy (OF) Scale (Foulkes, Spear and Symonds 
1966) focuses on the formal properties of dreams such as the 
presence of visual imagery and hallucinatory quality and only 
secondarily considers content properties such as realistic or 
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bizarre happenings. Foulkes and Vogel (1965) originally developed 
the OF scale to differentiate mental thought-I ike activity at 
sleep onset from .pictorial, hallucinatory dreamlike imagery 
occurring during REM periods. The scale contains 8 points 
with assigned values from 0 - 7 (Foulkes 1970) (Appendix 6). 
Recal I is defined as the mention of at least one item of specific 
content, for example not "I saw images" or "I had feelings" but 
11 1 saw a car" or "I felt sad" (Foulkes 1970). 
Two special methodolological procedures should be taken into 
account when using this scale. Firstly the OF scale was designed 
to be used in conjunction with the Larson Interview Schedule 
(1969) and can probably only be used in this context <Foulkes 
1970). Secondly the OF scale was constructed primarily to 
differentiate various stages of NREM sleep or to contrast NREM 
and REM mentation. It has a I imited value for scaling REM 
mentatlon a~ most REM dreams are visual and hallucinatory. 
The use of the OF scale In the present study was restricted to 
its purported content properties, i.e. the progression from 
"th.ought-I ike" mentation' to pictorial mentation to hallucinatory 
imagery was seen as providing an index of dream intensity. 
lnten~ity of dream experience was construed as a function of 
distortion, dramatisation and vividness. Foulkes .tl970) 
indi~ated the poss(~( lity of using the a~ove scale in this 
particular way. Carrol et al (1969) and Firth .(1974) have 
since used this scale in the above way. Pivik et al (1969) 
found the inter-rater rel iabi I ity of the DF scale to be 0,94. 
The Physical Aggression CPA) Scale (Foulkes and Rechtschaffen 
1964) concentrates on overtly physically aggressive behaviour. 
The PA scale is a seven point ordinal scale (0 - 6) (Appendix 7). 
Each point on the scale is characterised in terms of one or more 
general classes of dream events. The PA scale should be used 
to rate individual dream reports and not a collection thereof 
and should be assigned the highest score that could be attributed 
to any particular part of the dream. Foulkes and Rechtschaffen 
(1964) applied the scale separately to physical aggression "need" 
(dreamer as agent) and physical aggression "press" (others as 
agents). A factor analytic study (Hauri et al 1967) revealed 
the usefulness of distinguishing between physical and verbal 
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aggression but not between the "need - press" distinction. Fo u I kes 
et al (1969) have used the PA scale as a unitary entity without 
distinguishing whether the dreamer was the object, agent or 
bystander. The scale has been used in the above context in the 
present study. The inter-rater rel iabi I ity of the PA scale, in 
evaluating REM dream reports, using a sample of 78 dreams obtained 
from 14' male adolescents was r = 0,91. Weisz and Foulkes ((970) 
rated 38 dream reports which were obtained from 12 male adults. 
Twenty dreams were obtained in the laboratory while eighteen were 
recorded at home. They reported an inter-rater rel iabi I ity of 
0,88. 
The M~nifeSt S~x~ali~y Sd~le (Swanson and Foulkes 1968) focuses 
upon overt sexual behaviour and manifest sexual feel Ing. It 
is a seven point scale CO - 6) and is assumed to be ordinal. 
Higher ratings are given to the self as a dream character than 
when similar events are seen in other dream characters. The 
Manifest Sexuality Scale is used to rate individual dream reports. 
Manifest sexuality is def.ined both in terms of physical intimacy 
as wel I as other forms of sexual interaction such as dating, 
joking and teasing. Physical intimacy receives the highest 
ratings whereas socialised sexual encounters receives intermediate 
ratings. Symbolic or suppressed sexual behaviour receive low 
ratings and where no sexual behaviour is present, a score of 0 is 
assigned, (Appendix 8). Only heterosexual behaviour is ever 
'scored. Swanson and Foulkes Cl968) have reported Pearson 
product moment inter-rater reliabilities coefficients of 0,71 
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(40 dreams), 0,79 (34 dreams), 0,51 (38 dreams) and 0,84 (39 dreams). 
A 11 the dream protoco Is rated were obtained from I aboratory REM 
awakenings. The above scale differs from the Sexual ity-lnteraction 
Scale (Hal I and Van de Castle 1966) in the fact that it is ordinal 
rather than nominal, results in a single score per dream report 
and is less exclusively "physical" in its definition of sexuality. 
The Active Participation Scale (Foulkes et al 1969) is a five 
po i n t s ca l e ( I - 5 ) an d i s ass u med to be or d i n a I (Append i x 9 ) . 
Each point on the scale i~ characterised by the degree of 
participation by the dreamer in his own dream. This scale 
should be applied to each individual dream rather than a collection 
of dreams. Foulkes et al (1969) reported an inter-rater 
rel iabi I ity of 0,80 when 2 raters independently evaluated 78 
laboratory monitored REM dream reports obtained from 14 male 
adolescents. Weisz and Foulkes <1970) rated 38 dream reports 
which were obtained from 12 young male adults. They reported 
a Pearson Product moment correlation of 0,76. 
The Verbal Aggression CVA) Scale (Foulkes and Rechtschaffen 
1964) is a seven point ordinal scale (0 - 6) and centres around 
overt verbal aggressive behaviour (Appendix 10). Higher values 
are given to "more intense and explicitly malicious episodes of 
interpersonal derogation" and lower values are given to "teasing 
or other indirect forms of derogation of the person" (Foulkes 
and Rechtschaffen 1964). Verbal threats of physical aggression 
are regarded as physical aggression and not as verbal aggression. 
Hauri et al <1967) reported that factor analysis had revealed the 
fruitfulness of distinguishing between verbal and physical 
aggression but suggested that verbal aggression "need" (dreamer 
as agent) and verbal aggression "press" (others as agents) should 
be ~egarded as a unitary entity. Foulkes et al (1969) and Weisz 
and Foulkes (1970) have reported inter-rater reliabilities of 
0 , 9 2 (n = 7 8 ) a n d 0 , 9 7 Cn • 3 8 ) re s p e ct i v e I y • 
The Hedonic Tone C0~ple~s~~tness) Scale (Foulkes Spear and Symonds 
1966) was developed to quantify the distinction betw~en "good'' and 
"bad" dreams. The scale is a seven point ordinal scale Cl - 7) 
(Appendix I I). The lower portion of the scale Cl~ 3) quantifies 
degrees of pleasantness whereas the upper portion quantifies 
degrees of unpleasantness (5 - 7). The middle position on the 
scale (4) is used to score hedonically neutral or unscorable 
dreams. Dreams are rated on their.overall hedonic tone .. When 
the dream consists of p I easant and unp I easant .events (he don i ca I I y 
mixed dreams) a special adjustment procedure must be carried out. 
89 
The rater obtains the maximum P score and the maximum UP score 
when rating the dr~am. The UP score is then doubled and the 
P score is then added to this value. The total is now divided 
by 3 to obtain a weighted average. Al I fractions are rounded 
off to the next highest digit if it is over 5, and to the next 
lower digit if it is below 4, for example:-
Max. UP Max. p Weighted Scale 
element element average value 
7 I 5 5 
7 2 5.3 6 
6 3 5 5 
5 I 3.7 3 
When events depicted in the dream are either pleasant or un-
pleasant (hedonical ly unmixed dreams) the rater assigns the_ most 
extreme score that is given· to any dream event, for example:-
I + 2 + 3 = I 
5 + 6 + 7 = 7 
These special weighting procedures are purported to increase the 
reliability of the scale with respect to raters assigning their 
own overal I rating to the dream report. The scale relies on 
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the rater's subjective judgement of what is pleasant and unpleasant 
and does not attempt to define the above terms. Foulkes et al 
(1966) and Weisz and Foulkes (1970) have reported inter-rater 
rel iabi I ities of 0,78 Cn=14) and 0,86 (n=38) respectively when 
rating dream reports obtained from REM dream awakenings and 
morning arousals respectively. 
The Distortion Scale (Foulkes and Rechtschaffen 197.0) was 
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originally developed to determine the subject's own subjective 
estimate of the degree of distortion and fantasy which occurred 
in the previous night's dreams. This is a six point scale Cl - 6) 
ranging from "not at al I distorted" to "extremely distorted" 
(Appendix 12). The authors report that an inter-rater rel iabi I ity 
of 0,85 was obtained when a sample of 127 REM dream reports were 
evaluated; however a low correlation of 0,44 was obtained when 
the ratings of the experimenters were compared to those of the 
subjects. Foulkes and Rechtschaffen (1970) express reservations 
concerning the value of self rating techniques when compared to 
other rater orientated techniques. With regard to the present 
study, the above scale, despite its "skimpy formal properties" 
provided a simple subjective estimate as to the qua I ity of 
dreaming. 
5.2.8 Sleep Logs 
Sleep logs were used in each of the three studies as fol lows: 
(i) Short-term investigation. A home sleep log 
developed by Hartmann and Cravens (1973(a)) was 
used as a laboratory sleep log in the present 
study. This log provided useful information 
regarding estimated sleeping time, events of the 
previou~ day which could h~ve influenced the 
night's sleep, dreams recalled, naps taken and 
any unusual psychological or physiological feel-
ings that occurred (Appendix 13). 
(ii) Long-ter~ inv~stigation. The home sleep log 
of Hartmann and Cravens (I 973(a)) used in the 
short-term study was adapted to meet the demands 
of the present study. It provided additional 
information with regard to side-effects and the 
identification of +he nature of the medication. 
The Stanford Sleepiness Scale (described in 
section 5.2.5) formed part of this home log 
(Appendix 1-4). · 
(iii) REM Dream recall investigation. This home log 
comprised two visual analogue scales which 
provided information concerning the quantity 
and qua I i~y of the subject's dreams (~action 
5.2~6). Th~ Rechtschaffen and Foulkes 
Distortion Scale (1970) also formed a part of 
this home log (Appendix 15). 
5.2.9 M~ntal Speed Test 
A mental speed test comprising 258 simple addition problems 
derived from a table of random numbers (Edwards 1968) was con-
structed to assess the speed and accuracy of performance 
(Appendix 16). 
5.3 Procedure 
5.3. I Electrophysiological Recording Procedure 
Subjects reported to the laboratory one hour before their normal 
retiring times which were established on the basis of a question-
naire concerntng their sleeping habits (section 5. I), completed 
before the commencement of the study. The subject then un-
dressed and changed into his sleeping apparel. ·It was essential 
for subjects to do this as tight fitting clo~hing would either 
dislodge or totally remove the electrodes when taken off. The 
subject was then comfortably seated and the appropriate electrode 
attachment sites were thoroughly cleaned with cotton wool which 
had previously been immersed in alcohol. DB electrode paste was 
then rubbed into these electrode attachment sites to faci I itate 
electrical conduction. Co I I od ion adhesive paste was used to 
secure the Beckman silver chloride disc electrodes to the scalp 
and to the outer canthus of each eye. In addition,each · 
electrode attached to the outer canthus of the eye was taped to 
the skin with No. 1530 micropore surgical tape. A ground 
electrode which was common to al I transducers was placed on the 
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forehead. A blunted hypodermic needle· attached to a syringe 
ti I led with DB paste was then inserted into the hole in the 
centre of the electrode. The scalp was gently scratched to 
remove dead hornified cells which were poor conductors and the 
electrode was then f i I led with DB conducting paste. 
Electrode placements were kept constant for al I subjects. 
Bipolar EEG recordings were obtained from the central and occi-
pital areas. The C3 and C4 as wel I as the 01 and 02 positions 
( J as p e r I 0- 2 0 s y s ,t em I 9 5 8 ) we re us e d to re co r d th e E E G ( F i g u re 3 ) . 
The EOG;recordings of horizontal eye movements were obtained from 
electrodes placed l-2cm lateral to the outer canthus of each eye. 
The dynograph settings were kept constant for al I subjects. The 
time constant of the Type 9806 A A/C coupler was set at 0,3 and the 
high frequency filters at 3. For the EEG records, the Type 481 B 
Preamp I ifier setting was at 0,5 mi II ivolts per centimeter whi 1st 
the setting for the Type 482 M 8 amplifier was at XO,) (ie. 
O, IX0,5 mi 11 ivolts per centimeter} giving a net resultant 
amplification of 50 microvolts per centimeter on the recording 
paper. For the EOG recordings the Type 481 B Preamplifier 
setting was at I mi 11 ivolt per cm whi 1st the setting for the 
Type 482 M 8 Amplifier was at 0,1 (ie. IXO,I millivolts per 
centimeter) giving a net resul~ant amp I ification of 100 microvolts 
per centimeter on the recording paper. 
The subject then retired and tince he was comfortable in bed, both 
the EEG and EOG electrodes were attached via electrically shielded 
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adjacent monitoring room. The experimenter then thoroughly 
checked the EEG and EOG activity on the oscilloscope as wel I 
as on the recording paper and wherever ~ecessary made adjust-
ments to the ele~trodes ot monitoring apparatus. It was 
essential to obtain artifact free recordings from the ·onset 
in order to avoid arousing a subject once the recording had 
commenced. The subject was then asked to look to his left 
and right to determine whether these eye movements would be 
detected by the EOG channel on the dynograph. The subject then 
received the coded table~ and the sleeping room I igh~s were 
switched off. The interleading door was closed and the record-
ing was terminated in the morning either by a spontaneous 
awakening or by the experimenter at a time specified by the 
subject's sleeping habits. 
5.3.2 Short-Term Clozapine lnvestig~tion Proced~re 
This study comprised a nine consecutive night, double blind 
cross-over design <Touyz et al 1975(a))(figure 4). The first two 
nights served a purely adaptive purpose to control for the "first 
night" effect (Agnew et al 1966; Hartmann 1967(b), Scharf et al 
1969; Schmidt and Kaelbling 1971; Kupfer et al 1974; Coble et 
al 1974). It has been suggested that a first night adaptation 
might not be sufficient (Agnew et al 1966; Dement and Kleitman 
1957; Rechtschaffen and Verdone 1964; Wi 11 lams et al 1964; 1966) 
and as a result two nights were used for subjects to adapt them-
selves to the laboratory conditions. These two nights were also 
used to exp I a in the workings of a I I the equipment which the 
subject would ~ncounter during the course of the study. In 





























































































































































































































































































misapprehensions subjects may have had concerning the experiment. 
Although the full electrophysiological recording procedure was 
carried out, (section 5.3.1) no al I night recordings were made. 
Baseline sleep parameters were obtained from nights three and 
four. On nights five, six and seven, subjects received upon 
retiring, either 25mg clozapine or 25mg placebo (ascorbic acid) 
administered in tablet form. Nights eight and nine were used 
to assess any withdrawal effects. The double blind technique 
was employed as both the experimenter and subject were unaware 
of the drug condition. The sleep log (section 5.2.8), the 
visual analogue scales (section 5.2.6) as well as measures of 
mood (section 5.2.5) and performance (section 5.2.9) were 
administered to the subjects each morning fifteen minutes after 
awakening for the entire duration of the study. 
5.3.3 Long-Term Cloz~pine l~ve~tigation Prcicedure 
This study comprised a twenty five night, single bl ind cross-
over design (Figure 5), the subject being unaware of the experi-
mental condition. Subjects received 12,50mg clozapine placebo 
(section 5.2.4) on the first and last five nights. On the 
intermediate fifteen nights, subjects received l2,50mg clozapine 
(section 5.2.4). Subjects reported to the laboratory on the 
third and fourth nights in order that baseline sleep recordings 
could be obtained. To determine the effects of 12,50mg 
clozapine on sleep patterns,subjects slept in the laboratory on 
the eighth, twelf~h, sixteenth and twentieth nights. Nights 
twenty one and twenty five were used to determine whether the 
withdrawal of cloz~pine after fifteen consecutive nights of 










































































































































































































































































































































































Subjects completed a home log (section 5.2.8} each morning through-
out the. twenty five days. 
Prior to the commencement of the study, subjects slept for two 
nights in the laboratory. This was done in order to adapt the 
subjects to the laboratory, experimenter and experimental routine 
(section 5.3.2). The electrophysiological recording procedure 
(section 5.3. I) was carried out with two exceptions; (i) subjects 
received no medication upon retiring and (ii) all-night monitoring 
was not carried out. On the morning prior to the commencement of 
the study, subjects reported to the laboratory, underwent a 
medical examination (section 5.3.8) and had 5cc 1 s of blood taken 
<section 5.3.9). Subjects also ~ompleted the Taylor Manifest 
Anxiety Scale (section 5.2.5) and were rated on the Brief Psy-
chiatric Rating Scale (section 5.2.5) by the experimenter. The 
subjects were then given their coded tab lets, home logs and a 
calendar depicting the nights they were expected to report to the 
sleep laboratory. The entire electrophysiological recording 
procedure (section 5.3.1) was carried out on each recording night. 
On the final morning of the study,5cc's of blood were once agaln 
taken from each subject. Subjects once again completed the Taylor 
Manifest Anxiety Scale and were rated on the Brief Psychiatric 
\ 
Rating Scale by the experimenter. 
5.3.4 REM Dream Recall .Investigation Procedure 
This study comprised a four night single blind, cross-.over 
design (Figure 6), the subject being unaware of the experimental 
condition. Each subject spent a total of four recording nights 




















































































































































































































































































































another. This intermediate period permitted the subjects to 
recover from the wel I documented REM rebound phenomenon i.ncurred 
by repeated laboratory awakenings (Oswald 1970(c)). Prior to 
the commencement of the study, the subjects were issued with coded 
tablets and were instructed to take specific table~s at home on 
the two nights preceding each of the four laboratory recording 
nights. In addition, the subjects were issued with a home log 
(section 5.2.8) which they were asked to complete upon awakening 
on the two mornings prior to each laboratory recording night 
<Figure 6). 
Placebo Cl2,50mg/night) was administered on the two nights prior 
to the first, second and fourth laboratory recording nights whereas 
clozapine Cl2,50mg/night was administered on the two nights prior 
to the third laboratory recording night. In addition, 12,50mg 
placebo was administered on the first, second and fourth record-
ing nights,whereas 12,50mg clozapine was administered on the third 
recording night. This design enabled the experimenter to deter-
mine the short-term effects of three consecutive nights of 12,50mg 
clozapine administration upon REM dream content. 
The first recording night was used to adapt the subjects to the 
. ' 
laboratory environment, experimenter and laboratory routine. Oniy 
one. laboratory night was affected, as al I the subjects participating 
in this study had previously, taken part in a sleep research program. 
Baseline REM dream reports were obtained on the second recording 
The third recording night was. used to determine the 
effects of the short-t~rm administration of 12,50mg clozapine 
upon REM dream content wher~as the fourth recording night 
endeavoured to trace any possible withdrawal effects. 
-
5.3.5 REM Awakening Pt6t~dure 
Subjects were briefed about the awakening procedure for each 
laboratory night to dispel any fears or misapprehensions they 
might have had concerning the possible detrimental effects often 
associated with REM sleep deprivation (Dement 1960; Kales et al 
1964 and Glemes and Dement 1967). Awakenings were made by the 
experimenter cal I ing the subject by name a~~/or gently touching 
his body. On all laboratory recording nights three awakenings 
were effected. Subjects were woken ten minutes into their 
second, third and fourth REM periods. The first REM period was 
excluded because of its short and variable duration (Feinberg et 
al 1967; Goodenough et al 1965: Verdone 1965). On the adapta-
tion night three random awakenings were effected. A standard 
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interview format, the Larson Interview Schedule (1969) was used to 
elicit dream reports (Appendix 5). The interviews were all tape-
recorded for later transcription and analysis. Once the dream 
had been tape-recorded the subject was permitted to sleep again. 
5.3.6 Mental Speed Test Procedure 
This procedure commenced 15 minutes after the subject had woken 
up. The subject was seated in a comfortable chair and was given 
two minutes to complete as many problems as accurately as possible 
C$ection 5.2.9). The two minute duration was measured by the 
experimenter using a stopwatch accurate to a hundredth of a 
second. 
5.3.7 AD - AGL, Visual Analo.gue and Sleep Log Pr6tedure 
The subject was given the AD-AGL check list (section 5.2.5), visual 
analogue scales (sectlon 5.2.6) and sleep log (sect(on 5.2~8) to 
complete in his own time once the mental speed test procedure had 
been completed during the short-term clozapine investlgatlon. 
The subject~ completed the sleep logs (section 5.2.8) fifteen 
minutes after awakening during the long-term and REM dream recal 
investigations. 
5.3.8 Medical Exa~iriaticiri Prcit~dure 
A I I of the subjects who pa rt i c i pated in each of the three studies 
underwent a medical examination at Groote Schuur Hospital. Th~ 
medical examination was performed by a p~ychiatric registrar one 
day prior to the commencement of the study. In no instance was 
any obvious physical or mental abnormality found. 
5.3.9 Veriepunttur~ Prcid~d~re 
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In addition to their medical examination, the .subjects participating 
in the long-term study, (section 5.1.2) had a sample of blood taken 
on the morning prior to the commencement of the study. This 
procedure was repeated on the final morning of the study. Five 
cc 1 s of bloodweretaken from an upper limb vein and placed in a 
tube containing a standard anticoagulant. The blood sample was 
then coded and sent to the Department of Haematology, Groote Schuur 
Hospital for analysis. This procedure was necessitated by the 
fact that clozapine administration has been associated with the 
occurrence of agranulocytosis in clinical patients (Goodson 1976 -
~ersonal communication) and was carried out as a precautionary 
measure to en.sure that .the subjects participating in the study 
suffered no i I I-effects from long-term drug administration. The 
occurrence of agranulocytosls ha~ been rare and only when 
I 
exceptionally high doses have been admlnlstered for exceedingly 
long periods (Goodson 1976 - personal communication). 
5.4 Storing sy~tem 
The epoch by epoch scoring procedure advocated by Rechtschaffen 
and Kales (1968) was strictly adhered to throughout the scoring 
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of the data. The most convenient interval to use as an epoch was 
a page of recorded data, which in this case was 30cm. This 
interval had the additional benefit that at a paper speed of lcm 
per second, each page would be the equivalent of 30 seconds. 
This epoch duration also fal Is within the Rechtschaffen and Kales 
(1968) recommendation. Each epoch however was not scored in total 
isolation but preceding and succeeding polygraphic features were 
taken into consideration when assigning a sleep stage to an epoch. 
In no instance were two epochs ever combined to create a new epoch 
as only one sleep stage score was permitted for each epoch. On 
occasion when more than one sleep stage was present in an epoch, 
the sleep stage which occupied the greatest portion of the epoch 
was assigned to the particular epoch. Al I the sleep stages as 
well as movement time were scored according to the criteria set 
out by Rechtschaffen and Kales (1968). 
5.4. I C~ite~i~ to~ Scoring Sl~~p Stages 
(i) Stag~ ~~~ke. An epoch is scored as stage awake when more 
than half the epoch is characterised by alpha or i?w voltage 
mixed fre~uency activity. Some indivi.duals termed "alpha 
producers" are able to generate virtually conti.nuous streams 
of alpha activity whereas other subjects may show I ittle or 
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no alpha actlvlty In the waking record. Th.is stage ls 
frequently hut not always accompanied b~ rapid eye move-
ments and eye blinks in the EOG channel. 
Ci i) St~g~ I ~leep. An epoch is scored as stage I when the 
alpha activity occupies less than half the epoch. The 
scoring of an epoch as stage I requires the complete 
absence of clearly defined K complexes! and sleep spindles 2 . 
Stage I, when it follows wakefulness is characterised by the 
appea ranee of s I ow ro I Ii ng eye movements which a re of 
several seconds duration. These slow eye movements have 
a wave-I ike appearance and are usually more conspicuous 
during the early portion of this stage. Prominent vertex 
sharp waves which may reach amp I itudes of 200 microvolts also 
occur during this stage. 
( i 11 ) Stage 2 s I eep. An epoch is scored as stage 2 by the 
presence of sleep spindles and/or K complexes and the absence 
of high amp I itude, slow wave activity which constitute the 
presence of either stage 3 or stage 4. Sleep spindles and 
K complexes are transient phenomena and long periods of time 
may elapse between the occurrence of a sleep ~plndle and/or 
K complex. If this duration exceeds 3 minutes, without any 
indication of body movement activity, the interval ls scored 
as stage I, but if the appearance of a sleep spindle and/or 
1K complexes are defined as EEG waveforms which have a wel I 
delineated negative sharp wave which is immediately fol lowed 
by a posltiv~ component. K complexes can occur as a result 
of endogenous stimulation in the absence of any detectable 
sti.mul~s or in response to a sudden stimulus (Johnson and Karpan 
1968). 
2A sleep spindle is defined as 12 ~ 14 hz.activity of at least 
0,5 seconds duration. The term spindle relates to a spindle-
shaped envelope of this sigma paroxysm. Sleep spindles are 
characteristic of stage 2 sleep (Rechtschaffen and Kales 1968). 
K complex occurs before 3 minutes., the interval is scored 
stage 2. 
(iv) Stage 3 Sl~ep. An epoch is scored as stage 3 sleep when 
at least 20% but not more than 50% of the epoch consists 
of waves of 2 hz.or slower. The ampli~udes of these waves 
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should be greater than 75~microvolts measured from peak to 
peak, (the distance between the extreme negative and positive 
pofhts of the wave). Sleep spindles may or may not occur 
during this stage. 
(v) St~ge 4 sleep. An epoch is scored stage 4 sleep when half 
the epoch or more comprises waves of 2 hz.or slower which 
have amp I itudes in excess of 75 microvolts peak to peak. 
Sleep spindles may or may not occur during stage 4 sleep. 
The apparent eye movement activity present in the electro-
oculogram recording is merely a "spillover" of brain wave 
activity into the eye movement record (Foulkes 1966). 
(vi) Stage REM. An epoch is scored as stage REM sleep when 
rela~ively low voltage mixed frequency EEG activity and 
episodic rapid eye movements predominate the EEG and EOG 
recordings respectively. Stage REM activity differs from 
stage I activity in the following ways. Firstly the 
vertex sharp waves which occur in stage are not as 
conspicuous in stage REM. Secondly in stage REM distinct 
"sawtooth" waves (Berger et al 1962) frequently but not 
always appear iri conjunction with rapid eye movements. 
Alpha activity iS more pronounced during stag~ REM than 
during st_age I and is characteristically I - 2 hz.slower 
than during wakefulness (Johnson et al 1967). Stage REM 
is also characterised by a total absence 9f sleep spindles 
and K complexes. An exception to the rule however is the 
6ccasional appearance of sleep spindles during the first 
REM period of the n.ight. 
5.4.2 Criteria for' Scoring Body Movements Indices Dufing Sleep 
( i ) Bo d y move me n· ts • Th e f o I I ow i n g c r i t e r i a h a d to b e met 
before muscle activity appearing on the EEG or EOG records 
was scored as body movement (Rechtschaffen et al 1963). 
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(i) Fast muscle potential of at least 30 microvolts had to be 
present in one of the EEG channe Is as we 11 as on the EOG 
channe I. (ii) The burst of muse I e potenti a I had to be 
at least 4 seconds in duration. (iii) Amplifier blocking 
of I second or longer on at least one of the channels was 
required. (Iv) Periods of muscle tension artifact which 
were separated by at least 4 seconds of EEG record contain-
ing no trace of muscle tension artifact were counted as 
separate body movements. (v) Periods of muscle tension and 
amp I ifier blocking which occurred prior to and upon awaken-
ing were counted as body movements occurring during sleep. 
(ii) Movement ti me <MT). The score "MT" was assigned to epochs 
in which the EEG and EOG tracings were obscured in more than 
half the epoch as a result of muscle tension an~/or amp I ifier 
blocking caused by the movement of the subject. Whenever 
an epoch was obscured by muscle ten~ion and/or am~f ifier 
blocking artifacts but was immediately preceded and followed 
by wakefulness, the epoch was scored as stage awake rather 
than MT CRechtschaffen and Kales 1968). 
5.4.3 Ptcitedure for Stciting Dream Rating .S~ales 
The dreams were al I transcribed and coded before they were given 
to raters who were unaware of the aims of the experiment. The 
raters were al I psychologists involved in the scientific study 
of dreams. 
5.4.4 Procedure for Storing Sleep Reccirds 
The names of the subjects, the dates of the recordings as wel I 
as the experimental conditions were systematically deleted from 
a I I of the s I eep records which we re then coded. The recordings 
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were then scored "b Ii nd" as the experimenter was unaware as to 
whether the records were of base I ine, drug administration or with-
drawal origin. 
Several prominent sleep researchers have recommended that the sleep 
record should be evaluated for smaller portions of the night as 
well as for the entire night (Kales et al 1975; Hartmann and 
Cravens 1973(a); Freemon 1972). In addition to the total night's 
analyses, the major sleep stages (section 5.4.1) as wel I as indices 
of body movement activity (section 5.4.2) were analysed for the 
first three hours, the second three hours as wel I as the first 
six hours of the record as recommended by Hartmann and Cravens 
(1973(a)). 
5.4.5 Prcitedure for Stciti~~ Sleep Lcigs 
The short-terrri clozapTne investigation: This sleep log consisted 
of ~I.even questions of which the answers to questions.six, seven, 
nine and ten were evaluated for each day of the study (see 
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appendix 13). These ~uest(ons referred to the subject's sub-
jective estimation of the ~ual ity and .quantity of the previous 
night's sleep as we! I as any physiological or psychological side-
effects experienced shortly after awakening. 
The long-term clozapine investigation: This sleep log consisted 
of sixteen questions as wel I as the Stanford Sleepiness Scale 
(see appendix 14). These questions referred to the subject's 
estimation of the quantity and qua I ity of the previous night's 
sleep as wel I as any physiological or psycholo~ical side-effects 
experienced shortly after awakening. In addition, the sleep log 
assessed the subject's abi I ity of correctly identifying the nature 
of the previous night's medication i.e. clozapine or placebo. 
The answers to questions five, six, seven, ten and thirteen as 
well as the Stanford Sleepiness Scale were evaluated. 
The duration of the long-term clozapine investigation was twenty 
I 
five nights and was divided into 5 five night periods to 
faci I itate statistical analyses. These included an initial 
baseline period, a first, second and third clozapine administra-
tion period as wel I as a clozapine withdrawal period. Mean 
scores of the answers to the questions of each 5 five night 
period were subjected to statistical analyses. The psychological 
side-effects (question twelve) were I isted for each 5 five night 
period. 
The REM dream r'ecall investigation: The subjects completed home 
logs on the two mornings prior to each laboratory recording 
n.ight (Figure 6). Mean scores were thus obtained for the 
baseline, clozapine administration and withdrawal conditions on 
al I of the visual analogue scales (section 5.2.6) as we.I I as of 
the Distortion Scale (section 5.2.7) .. 
5.5 Def iriitions and Ter~inology 
A standardised system for the scoring of human sleep stages has 
been formulated by a numbet of prominent sleep research workers 
(Rechtschaffen and Kales 1968). Wherever possible the defini-
tions and terminology developed by this committee have been 
strictly adhered to. However many other additional indices of 
sleep parameters have been included in this study and are defined 
be I ow. 
5.5. I Sleep Stage Activity 
(i) Total recording time (TRT). The time from when the 
subject was comfortable in bed with the electrodes attached 
and the I ights switched off, ti I I the recording was termina-
ted in the morning. This included the time taken for the 
subject to fall asleep as well as the time he lay awake in 
bed in the morning before he buzzed the experimenter to 
terminate the recording. 
(ii) Total waking time CTWT). The total time in minutes 
subjects spent awake from the time of drug administration 
(recording commencement) unti I awakening the next morning. 
Ci i i ) Tota I s I eep ti me < TST). The total ~ime in minutes 
I I 0 
during which recordings were made minus the total waking time. 
(iv) Petcerit ~t~ge ~W~ke. The total waking time expressed as 
a percentage of total recording time. 
( v) Percent stage I :s I eee. The total number of minutes of 
stage I sleep expressed as a percentage of TST. 
(vi.) Percent stage 2·s1eee. The total .number of minutes of 
stage 2 sleep expressed as a percentage of TST. 
(vi i ) Percent stage 3 ·sieee. The total number of m i.n utes of 
stage 3 sleep expressed as a percentage of TST. 
(vi i i ) Percent stage 4 sleee. The total number of minutes of 
stage 4 sleep expressed as a percentage of TST. 
(ix) Percent stage slow wave sleee. The total number of 
minutes of stage 3 and stage 4 sleep expressed as a 
percentage of TST. 
(x) Pertent ~tage REM sleee. The total number of minutes of 
stage REM sleep expressed as a percentage of TST. 
5.5.2 REM Indices 
( i) Mean REM duration. The total time in minutes spent in 
REM sleep divided by the number of REM periods. 
(ii) REM burst. A REM burst is defined as one or more rapid 
eye movements in which two successive eye movements are 
separated by less than 8 seconds (Aserinsky 197)). 
I I I 
<iii) Tota I number of REM bursts. The total number of REM bursts 
occurring throughout al I REM periods. 
Civ) The nurriber of bursts eer REM eeriod. The tot a I number of 
REM bursts divided by the number of REM' periods. 
(v) Burst length. The distance from the first to the last 
rapid eye movement pf each burst measured to the nearest 
second (Aseri nsky 1971). 
(vi) Total burst length. The duration in seconds of al I burst 
lengths occurring throughout al I the REM periods. 
(vii) Mean burst length. The total burst length divided by 
the number of REM periods. 
(viii) REM den~ity. The total number of rapid eye movements that 
occur during the total time spent in REM sleep. The cri-
terion for a rapid eye movement was an out of phase 
deflection of at least 60 microvolts. 
(ix) Derisity/min.REM ~leep. REM density divided by the number 
of minutes of REM ~leep. 
(x) % Moti I ity. % moti I ity is defined as the percentage of 
REM periods occupied by REM bursts (Aserinsky 1971). 
5.5.3 Sleep St~ge L~terities 
Ci) Stage latericy. The number of minutes from the commence-
ment of recording to the appearance of the firit stage I 
period leading to stage 2 activity. 
(ii) Stag~ 2 l~tehcy. The number of minutes from the commence-
m~nt of recording to the appearance of the first sleep 
spindle. 
(iii) Stage 4 latency. The number of minutes. from the onset of 
sleep to the appearance of the first stage 4 activity. 
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Ci v) Latency to I st REM period. The number of minutes from the 
onset of sleep to the appearance of the first stage REM 
period. 
(v) Latency td 2nd REM p~riod. The number of minutes from the 
onset of sleep to the appearance of the second stage REM 
period. 
(vi) Latency to 3rd REM p~riod. The number of minutes from the 
onset of sleep to the appearance of the third stage REM 
period. 
5.5.4 Sleep Stage lncid~nce 
( i) Number of awakenings. The total number of times the sub-
ject awakened after sleep onset but excluding the finaJ 
awakening. 
(ii) Number of stage 4 periods. The total number of stage 4 
periods, each perfod being separated by at least 15 mf nutes 
' from preceding stage 4 activity. 
(iii) Number of stage REM periods. The total number of stage 
REM periods, each period being separated by at least 
15 ~inutes from the preceding REM period. 
5.5.5 Sleep Cycle Duratidns 
Ci> ·1st cycle. The .number of minutes from the end of the 
first REM period to the end of .the second REM period 
(Hartmann and Cravens 1973(a)). 
Ci lJ 2n'd eye I e. The number of minutes from the end of the 
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second REM period to the end of the third REM period 
(Hartmann and Cravens 1973.(a)). 
5.5.6 Btidy MoVem~~t Activity 
( i) Tota I number 6f btidy rri6vements. The total number of body 
movements occurring during sleep. 
(ii) Body moveme~ts/minute sleep. 
movemSnts divided by TST. 
The total number of body 
(iii) Movement time. The total number of 30 second epochs of MT 
occurring during sleep. 
5.5.7 Blood Parameters 
The following blood parameters were defined according to Ganong 
(1969). 
( i ) Wh i te b I oo d ce I I s. In man there are normally 4000 - 11000 
white blood cells per cu.mm.of blood. Of these the granu-
locytes or polymorphonuclear leukocytes are the most 
numerous. Fifty to seventy percent of the granulocytes 
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are neutrophi Is, 1-4% are eosinophi Is and 0,1% are basophi Is. 
Lymphocytes (20 - 40%) and monocytes (2 - 8%> are also 
normally found in the peripheral blood. 
(ii) Red blood cells. The red blood eel Is or erythrocytes 
carry haemoglobin in the circulation. They are biconcave 
discs that ar~ manufactured in the bone marrow. The mean 
"normal" red blood cell count is 5.4 x 103/cu.cm.in men and 
4.8 x 10 3/cu.cm.in women. 
< i l i) Haerriog lob in. Haemoglobin is the red oxygen carrying 
pigment in the red blood eel Is. It has a molecular weight 
of approximately 68000. Haemoglobin is a globular mole-
cule made up of 4 subunits and each subunit contains a heme 
moiety conjugated to a polypeptide. 
(iv) Haerriatoctit. Haematocrit is the percentage of the volume 
of blood occupied by red blood cells. 
<v> Mean corpu~c~lat volume <MCV). The volume of a red blood 
corpuscle expressed in cubic microns. 
(vi) Mean corpuscular haemoglobin (MCH). The amount of 
haemoglobin per red blood corpuscle expressed in mmg's. 
(vii) Mean corpustular haemoglobin conce~tration <MCHC). The 
concentration of haemoglobin per red blood corpuscle. 
5.6 Statistical Methods 
The data were analysed according to the statistical procedures 
outlined in Roscoe (1969), Winer (1962) and Kirk (1968) and 
processed by a Hewlett Packard (HP2114B) computer. The fol low-
ing statistical procedures were carried out : 
(i) one way analysis of variance with repeated measures 
(Winer 1962, Roscoe 1968). 
(ii) two way analysis of variance (Winer 1962, Roscoe 1968). 
(iii) two way analysis of variance with repeated measures on 
one factor (Winer 1962, Roscoe 1969). 
(iv) Pearson Product Moment Correlation (Roscoe 1968). 
(v) Dependent t test (Roscoe 1968). 
The experimental design employed in the short-term clozapine and 
I I 5 
placebo investigation involved the comparison of the two_ groups 
of subjects on baseline, drug administration and withdrawal 
conditions on a given variable. This required a two factor 
design where the subjects were recorded on seven consecutive 
nights. The appropriate statistical analysis employed was the 
two factor analysis of variance with repeated measures on one 
factor CWi ner 1962). 
The experimehtal designs employed in the long-term cfozapine and 
REM dream recal I investigations involved the comparison of one 
group of subjects on base I ine, clozapine administration and 
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withdrawal conditions on a given variable. These were one factor 
designs where the subjects were monitored repeatedly, and the 
appropriate analysis employed was the one way analysis of va~iance 
with repeated measures (Winer 1962). 
Wherever the two way analysis of variance revealed significant 
Interaction effects,simple main effects analyses were carried 
out (Kirk 1968, p.263) before comparisons between means were 
attempted. This procedure provided useful information regarding 
those levels of factors where such comparisons would prove to be 
fruitful. Finally, significant simple main effects analyses 
were fol lowed up by comparisons between eel I means using the 
Tukey HSD procedure (Kirk 1968, p.292). The F Max test was 
used to determine the homogeneity of variance. 
5.6. I Z Score Ttah~ftit~~titins 
It was decided to transform the visual analogue scores to normali-
sed scores using a Z score transformation computer program which 
was deve I oped by G i I bert ( 1976 - persona I communication) for 
this purpose (see Appendix 16 for details of the computer 
program). This was done in order that each subject's data 
would receive equal statistical weight. This was necessitated 
by the fact that some subjects rated themselves on a very 
narrow range on the I 00 mm ana I ogue sea I es ( i . e. between 40mm 
and 60mm) whereas others rated themselves using the extremities 
(i.e. between Omm and lOOmm). The formula for Z score trans-
formations which formed the basis of the computer program was 
as fol lows: 
z • x - x 
SD 
Where Z = Z score 
X • raw score 
X • arbitrary mean of 50 
SO z arbitrary standard deviation of 10 
The Z score transformation removed individual differences and as 
a result analysis of variance with repeated measures was not the 
appropriate statistical procedure to be employed in the analysis 
of the visual analogue scales (Gilbert 1976 - personal communi-
cation). The one and two way analyses of variance without 
repeated measures were employed in the analysis of the visual 
analogue scales. 
5.7 lnterscorer Rel iabi 1 itx:_ 
5.7.J.Major Sleep Stage lnterscorer Reliability 
Al I of the sleep records were coded and then scored by the 
experimenter according to the recommendations of Rechtschaffen 
and Kales ()9·68). In orde.r to assess the re 1 i ab i I ity of scoring 
the sleep stages, six records were scored independently by a 
I I 7 
second experienced sleep researcher and the results were compared 
by .the Pearson product moment coefficient of correlation. The 
correlation coeff [cients and means of the major sleep stages 
scored by the two researchers are shown in Table 5. There were 
no systematic differences between the means. 
Table 5 Estimates the agreement in the scoring of the major 
sleep stages i~ human subjects by tw6 experienced 
sleep researchers according to the criterion of 
Rechtschaffen and Kales (1968) (6 records). 
Researcher I I 
x mean(minutes) y mean(minutes) r 
stage awake 12,92 14,33 0,99 
stage I 40,67 40,25 0,99 
stage 2 198,00 192,67 0,56 
stage 3 39,08 45,42 0,84 
stage 4 71, 33 67,75 0,74 
stage REM 88,42 89,25 0,97 
5.7.2 lnterscorer Rel i~bi lity for the Dre~m Report Rating Scales 
All ~he dream rating scales were evaluated independently by two 
experienced dream researchers. The Pearson product moment 
coefficient of correlation was used to assess the interscorer 
reliability. The correlation of coefficients and means of the 
various dream rating scales are shown in Table 6. 
Table 6 Estimates of agreement in the scoring of the dream 
report rating scales by two experie~ced dream 
researchers according to specified criteri~ (45 REM 
dream reports). 
Researcher I I 
x mean y mean r 
Dreamlike Fantasy Scale 5,02 3,98 0,81 
Physical Aggression Scale 0,47 0,76 0,67 
Verbal Ag~ression Scale I, 07 0,58 0,80 
Activit~~Passivity Scale 5,00 5,40 0,71 
Manifest Sexua I i ty Scale 0,78 0,40 0,76 
Hedonic Tone Scale 4,71 4,64 0,88 
Active Participation Scale 3,44 3, I 3 0~76 
I 18 
I 19 
There were no systematic differences between the means. 
5.7.3 lnterscorer ReTiabi llty for the REM Indices 
In order to assess the re Ii ab i I i ty of the exp er i mente r in scoring 
the indices of REM sleep, 10 five minute periods of REM sleep 
were scored independently by a second experienced sleep researcher 
and the results were compared by the Pearson product moment 
coefficient of correlation. The correlation coefficients and 
means of the REM indices scored by the two researchers are shown 
in Table 7. The agreement between the scorers was except i ona I I y 
high. Al I of the correlation coefficients were above 0,95 and 
there were no systematic differences between the means. 
Table .7 Estimates of agreement in the scoring of the REM 
indices in human subjects by two experienced 
sleep researchers according to specified criteria. 
Researcher I I 
x mean y mean r 
Number of bursts 5,60 5,90 0,95 
Mean burst length (seconds) 9, I 7 8,27 0,99 
Number of rapid eye move-
men ts 21, 30 28,00 0,98 
5.7.4 lnterscorer Rel iabi I ity for the Body Movement Indices 
In order to assess the rel iabi I ity of the experimenter in scoring 
the body movement indices, 10 fifteen minute periods of a sleep 
record were scored independently by a second experienced sleep 
researcher and the results were compared by the Pearson product 
moment coefficient of correlation. The correlation coefficients 
and means of the body movement indices scored by the two 
researchers are shown in Table 8. 
Table 8 Estimates of agreement in the scoring of body 
movement indi6es in human subjects by two 
experienced sleep researchers according to 
specified criteria (10, fifteen minute periods 
of a sleep record). 
Researcher x mean 
I I 
y mean r 
Movement Time (number of 
30 second epochs) 0,40 0,50 0,95 
Number of body movements 0,80 0,90 0,76 
120 
6.0 THE SHORT-TERM CLOZAPINE INVESTIGATION 
6.1 Results 
The short-term, long-term and REM dream recal I investigations 
required a total of 2190 hours of electrophysiological recording 
over a total of 219 nights. One hundred and twenty six analy-
ses of variance were carried out to analyse the data. The data 
of the major sleep stages and body movement indices were analysed 
for the first three hours, second three hours and first six hours 
of the record in addition to the analysis of the data of the 
entire night. This procedure generated a very large number of 
statistical summary tables, and in the interests of concision 
only the data for the entire night are presented in the tables. 
In al I other cases, the F ratios, degrees of freedom and p values 
are indicated in the text. 
The convention used to indicate the two way analysis of variance 
interaction effect was as follows: FCAXB). Means and standard 
errors are tabulated throughout the thesis. 
6.1.1 Total Sleep Time 
The effects of the administration of clozapine and placebo_ upon 
the duration of total sleep time are presented in Table 9 and 
significant findings are i I lustrated in Figure 7 <F<AXB) = 3,42; 
df 6,72; p<0,01 ). Closer examination of the data through 
simple main effects analysis revealed a significant difference 
between the clozapine and placebo groups on the first night of 
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3 4 5 6 7 8 9 
LABORATORY RECORDED NIGHTS 
., 
Ftgure. 7 ·The mean duration of total sleep time (minutes) for 
the· cl'ozap·ine and .p lac.ebo groups over .the laboratory 
recorded ni~hts. Total s!aep time was significantly 
i'ricreased on the first and second nights of clozapine 
administration •. The administration of placebo had 
no signifJcant effect. Nights 3-4 and nights 8-9 
were bas~I ine and withdrawal co~ditions. respectively. 
i. 
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difference over the laboratory recorded nights for the clozapine 
g r o up ( F = 6 , 0 7 ; d f 6 , 4 I ; p< 0 , 0 0 I ) , b u t not f o r the p I a c e b o g r o up 
(F = 0,22; df 6,41; p>0,25). 
The Tukey HSD comparisons indicated that sleep duration was 
markedly increased on the first night of clozapine administration 
(Figure 7). The mean sleep duration on the first night of 
124. 
clozapine administration was longer than on either the first (p<0,05) 
or second (p<0,05) baseline nights as well as the third night of 
clozapine administration (p<0,05). The mean sleep duration o~ 
the first night of clozapine administration was also significantly 
I o n g e r t h a n th e me a n s o f t h e f i rs t ( p < 0 , 0 I ) a n d s e con d ( p< 0 , 0 I ) 
withdrawal nights. Finally, the mean sleep duration on the second 
clozapine administration night was longer than the second night of 
w i t h d raw a I ( p< 0 , 0 I ) . 
6.1.2 Major Sleep Stages 
As previously described (section 5.5.4) the major sleep stages 
were analysed for the first three hours, the second three hours, 
the first six hours of the record as wel I as for the entire 
night, expressed as a percentage of total sleep time. Stage 
awake was expressed as a percentage of 'total recording time 
( s e c t i o n 5- • 4 • I ) • 
St~ge Awake. The admi.nistration of clozapine and placebo 
had no significant effect upon the percentage of time spent 
aw a k e ( F ( AX B ) = I , 2 3 ; d f 6 , 7 2 ; p> 0 , 2 5 ) ( Ta b I e 9 ) . T h e w i t h i n -
night analyses also revealed no significant differences for the 
first three hours CFCAXB) = 1,92; df 6,72; p<0,10), the second 
125 
.. 
three hours <FCAXB) = 0,51; df 6,72;·p>0,25) as well as the first 
six hours CF<AXB) = 1,54; df 6,72; p<0,25) of the record. 
Stage I. The administration of clozapine and placebo had 
no significant effect upon the percentage of time spent in stage 
sleep (F(AXB) = 0,25; df 6,72; p>0,25) (Table 9). The within-
night analyses also revealed no significant differences for the 
first three hours (F(AXB) = 0,41; df 6,72; p>0,25), the second 
three hours (F(AXB) = 0,29; df 6,72; p>0,25) as wel I as the first 
six hours <F<AXB) = 0,10; df 6,72;· p>0,25) of the record. 
Stage 2. The administ~ation of clozapine and placebo had 
no significant effect upon the percentage of time spent in stage 2 
s I e e p ( F ( AX 8 ) = I , 9 6 ; d f 6 , 7 2 ; p< 0 , I 0 ) ( Ta b I e 9 ) . The within-
night analyses also revealed no significant differences for the 
first three hours <F<AXB) = 1,14; df 6,72; p>0,25), the second 
three hours (F(AXB) = 1,47; df 6,72; p<0,25) as well as the first 
s i x h o u rs ( F ( AX B ) = 0 , 9 4 ; d f 6 , 7 2 ; p> O , 2 5 ) o f t h e re co rd . 
Stage 3. The administration of clozapine and placebo had no 
significant effect upon the percentage of time spent in stage 3 
s I e e p ( F ( AX 8 ) . = 0 , 7 2 ; d f 6 , 7 2 ; p> 0 , 2 5 ) ( Ta b I e 9 ) . The within-
night analyses also revealed no significant differences for the 
first three hours <F<AXB) = 0,65; df 6,72; p>0,25), the second 
three hours (FCAXB) = 0,69; df 6,72; p>0,25) as wel I as the first 
six hours (F(AXB) = 0,83; df 6,72; p>0,25) of the record. 
Stage 4. The effects of the administration of clozapine 
and placebo upon the percentage of time spent in stage 4 sleep 
are presented in Table 9 and significant findings are i I lustrated 
i n F i g u re 8 ( F (AX B) = 3, 2 7; d f 6, 7 2; . p< 0, 0 I ) . Closer examination 
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LABORATORY RECORDED NIGHTS 
9 
Figure 8 The mean percentage of time spen+ in stage 4 
sleep for the clozapine and placebo groups 6ver 
the laboratory recorded nights. Stage 4 sleep 
--~I 
·was significantly suppressed on the second and 
third nights of clozapine administration. The 
administration and withdrawal of placebo had no 
significant effect. Nights 3-4 and nights 8-9 
were baseline and withdrawal conditions respectively. 
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·of the data through simple main effects analysis revealed a 
significant difference over the laboratory recorded nights for 
the clozapine group (F 4,31; df 6,41; p<0,01), but not for the 
placebo group (F = 0,55; df 6,41; p>0,25). 
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The Tukey HSD comparisons indicated that stage 4 sleep was marked-
ly suppressed on the second and third nights of clozapine admini-
stration (Figure 8). The mean percentage of time spent in stage 
4 sleep on the second night of clozapine administration was lower 
than on either the first (p<0,01) or second (p<0,01) baseline 
nights. The mean percentage of time spent in stage 4 sleep on 
the third night of clozapine administration was also lower than 
o n t h e f i rs t b a s e I i n e n i g h t ( p< 0 , 0 5 ) . 
The within-night analyses revealed no significant differences for 
the first three hours <F<AXB) = 1,78; df 6,72; p<0,25) and second 
three hours (F(AXB) = 1,96; df 6,72; p<0,10) of the record. The 
analysis of variance of the first six hours of the record yielded 
a significant variance ratio (F(AXB) = 3,18; df 6,72; p<0,01). 
Closer examination through simple main effects analysis revealed 
a significant difference over the laboratory recorded nights for 
the clozapine group (F = 3,58; df 6,41; p<0,01 ), but not for the 
placebo group (F = 0,63; df ?,41, p>0,25). 
The Tukey HSD comparisons indicated that stage 4 sleep was 
markedly suppressed during the first six hours of the second and 
third nights of clozapine administration and remained at low levels 
during the first six hours of the first night of drug withdrawal. 
The mean stage 4 duration during the first six hours of the second 
.. ······· .. 
night of clozapine administration was significantly lower than on 
either the first (p<0,01) or second (p<0,01) baseline nights. 
In addition, the mean stage 4 duration during the first six hours 
of the third night of clozapine administration was also signifi-
c a n t I y I owe r t h a n o n e i t h e r t h e f i rs t ( p< 0 , 0 I ) o r s e con d ( p < 0 , 0 I ) 
baseline nights. Finally, the mean stage 4 duration during the 
first six hours of the first night of clozapine withdrawal was 
significantly lower than on the first baseline night (p<0,05). 
Stage Slow Wave. The administration of clozapine and 
placebo had no significant effect upon the percentage of time 
spent i n stage s I ow wave s I e e p ( F ( AX B) = I , 9 6 ; d f 6 , 7 2 ; p< 0, I 0) 
(Table 9). The within-night analyses also revealed no signifi-
cant differences for the first three hours (f(AXB) 1,37; 
df 6,72; p<0,25), the second three hours (f(AXB) 1,09; df 6",72; 
p> 0 , 2 5 ) a s we I I a s t h e f i rs t s i x h o u rs ( F ( AX B ) = I , 8 0 ; d f 6 , 7 2 ; 
p<0,25) of the record. 
Stage REM. The administration of clozapine and placebo 
had no significant effect upon the percentage of time spent in 
stage REM sleep (f(AXB) = 1,90; df 6,72; p<0,10) (Table 9). 
The within-night analyses also revealed no significant differ-
ences for the first three hours (f(AXB) = 1,21; df 6,72; p>0,25), 
the second three hours (f(AXB) 0,66; df 6,72; p>0,25) as wel I 
as the first six hours (f(AXB) 
record. 
6.1.3 REM Indices 
0,89; df 6,72; p>0,25) of the 
The effects of the short-term administration of 25mg clozapine and 
placebo upon the mean indices of stage REM sleep over the 
128 
laboratory recorded nights are i I lustrated in Fi.gure 9. 
Mean REM Duration. The administration of clozapine and 
placebo had no significant effect upon the mean duration of stage 
REM sleep (F(AXB) = 1,35; df 6,72; p<0,25) <Table 10). 
Tota I Number of Bursts. The effects of the administration 
of clozapine and placebo upon the total number of bursts are 
presented in Table 10 and significant findings are illustrated 
in Figure 9 <F<AXB) = 2,64; df 6,72; p<0,05). Closer examina-
tion of the data through simple main effects analysis revealed 
a significant difference between the clozapine and placebo groups 
on the first night of drug administration (f = 12,11; df 1,84; 
p<0,001) and a significant difference over the laboratory recor-
ded nights for the clozapine group <F = 5,33; df 6,41; p<0,0~1 ), 
but not for the placebo group <F = 0,31; df 6,41; p>0,25). 
The Tukey HSD comparisons indicated that the total number of 
bursts increased markedly on the first night of clozapine with-
drawal (Figure 9). The first night of clozapine withdrawal 
contained significantly more bursts than either the first base I ine 
<p<0,01) or first (p<0,01) and third (p<0,05) clozapine admini-
stration nights. The second night of clozapine withdrawal 
contained significantly more bursts than the first night of 
clozapine administration (p<0,05). 
Number of Bursts pe~ REM period. The effects of the 
administration of clozapine and placebo upon the number of bursts 
per REM period are presented in Table 10 and significant findings 
are illustrated in Figure 9 <F<AXB) = 2,60; df 6,72; p<0,05). 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































analysis revealed a significant difference between the clozapine 
and placebo groups on the first night of drug administration 
(F = 9,40; df 1,84; p<0,01) and a significant difference over the 
laboratory recorded nights for the clozapine group (F = 4,46; 
df 6,41; p<0,01), but not for the placebo group (F = 0,62; df 6,41; 
p> 0' 2 5) • 
The Tukey HSD comparisons revealed that the number of bursts per 
REM period increased markedly on the first night of clozapine 
withdrawal <Table 10). The first night of clozapine withdrawal 
conta~ned significantly more bursts per REM period than either 
the first baseline (p<0,05) or the first night of clozapine 
administration (p<0,01 ). The second night of clozapine withdrawal 
also contained significantly more bursts per REM period than the 
first night of clozapine administration (p<0,05). 
Mean Burst Length. The effects of the administration of 
clozapine and placebo upon the mean burst length are presented 
in Table 10 and significant findings are i If ustrated in Figure 9 
(F(AXB) = 2,63; df 6,72; p<0,05). Closer examination of the data 
through simple main effects analysis revealed significant 
differences between the clozapine and placebo groups on the first 
CF= 4,80; df 1,84; p<0,05) as well as the second CF= 8,19; 
df 1,84; p<0,01) baseline nights and a significant difference over 
the laboratory recorded nights for the clozapine group (F = 3,09; 
df 6,41; p<0,05), but not for the placebo group (F = 1,40; df 6,41; 
p<0,25). 
The Tukey HSD comparisons indicated that the mean burst length 
increased significantly on the third night of clozapine 
Figure 9 
. ;i::,"~ e CLOZAPINE GROUP 
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LABORATORY RECORDED NIGHTS 
--~~-- ·----~ 
The effects of the short-term administration of 25mg 
clozapine and placebo upon the mean indices of sta~e 
REM sleep over the laboratory recorded nights. The 
density/minute REM sleep, the mean burst length and 
% mot:ili·ty increased significantly on the third night 
of clozapine administr~tion and this increased activity 
persisted on the first night.of clozapine withdrawal. 
In addition, the total number of bursts and the number 
of bursts/REM period increased dramatically on the 
first night of clozapine withdrawal. The administra-
tion of placebo had no significant effect. Nights 
3-4 and nights 8-9 were baseline and withdrawal 
conditions respectively. 
!32 
administration. The mean burst. length on the third night of 
clozapine administration was significantly longer than on either 
the first (p<0,05) and second (p<0,05) baseline nights as well 
as the first night of clozapine administration (p<0,05). 
Density per Minute REM sle~p. The effects of the admini-
stration of clozapine and placebo upon the density per minute REM 
sleep are presented in Table 10 and significant findings are 
illustrated in Figure 9 (F(AXB) = 5,10; df 6,72; p<0,001). 
Closer examination of the data through simple main effects 
analysis revealed significant differences between the clozapine 
and placebo groups on the first (F = 4,36; df 1,84; p<0,05) as 
well as the second (F = 8,72; df 1,84; p<0,01) baseline nights 
and a significant difference over the laboratory recorded nights 
for the clozapine group <F = 7,03; df 6,41; p<0,001 ), but not for 
th e p I ace b o g r o u p ( F = 0 , 9 3 ; d f 6 , 4 I ; p> 0 , 2 5 ) . 
133 
Th~ Tukey HSD comparisons indicated that the density per minute 
REM sleep increased significantly on the third night of clozapine 
administration and persisted on the first night of clozapine with-
drawal. The mean density per minute REM sleep on the third night 
of clozapine administration was significantly greater than on 
e i the r the f i rs t ( p< 0, 0 I ) and second ( p< 0, 0 I ) base I i n e n i g ht s as 
wel I as the first night of clozapine administration. In addition, 
the mean density per minute REM sleep on the first night of 
clozapine withdrawal was significantly greater than on either the 
f i rs t ( p < 0 , 0 I ) an d sec on d ( p< 0 , 0 I ) base I i n e n i g h ts as we I I as the 
f i rs t n i g ht of c I oz a p i n e ad mi n i st rat i on ( p< 0, 0 I ) . 
% Motility. The effects of the administration of clozapine 
and placebo upon% motility are presented in Table 10 and 
significant f~ndings are i I lustrated in Figure 9 (F(AXB) = 4,90; 
df 6, 72; p<0,00 I). Closer examination of the data through 
simple main effects analysis revealed significant differences 
between the clozapine and placebo groups on the first (F = 5,09; 
df 1,84; p<0,05) as well as the second (F 10,01; df 1,84; 
p<0,01) baseline nights and a significant difference over the 
laboratory recorded nights for the clozapine group (F = 7,29; 
df 6,41; p<0,001), but not for the p I acebo group (f = 0,94; 
df 6,41; p>0,25). 
The Tukey HSD comparisons indicated that % moti I ity increased 
significantly on the third night of clozapine administration and 
that this increase persisted on the first night of clozapine 
withdrawal. The mean% motility on the, third night of clozapine 
administration was significantly greater than on either the first 
(p<0,01) and second (p<0,01) base I ine nights as wel I as on the 
f i rs t n i g h t o f c I o z a p i n e a d m i n i st r a t i on ( p< 0 , 0 I ) . In addition, 
the mean% motility on the first night of clozapine withdrawal 
was significantly greater than on either the first (p<0,01) and 
second ( p< 0, 0 I ) base I i n e n i g ht s as we I I as on the f i rs t n i g ht of 
clozapine administration (p<0,01). 
6.1.4 Sleep Stage Latencies 
Stage ·1 Latency. The administration of clozapine and 
placebo had no significant effect upon the latency to stage 
sleep (f(AXB). = 1,77; df 6,72; p<0,25) (Table II). 
The administration of clozapine and 
placebo had no significant effect upon the lat~ncy to stage 2 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Stage 4 Latency. The administration of clozapine and 
placebo had no significant effect upon the latency to stage 4 
sleep CFCAXB) = 0,91; df 6,72; p>0,25) (Table II). 
Latency t6 the Fir~t REM Period. The administration of 
clozapine and placebo had no significant effect upon the latency 
to the first REM period CFCAXB) = 0,85; df 6,72; p>0,25) 
CTab I e I I ) • 
Latency to th~ Sec6nd REM Pe~iod. The administration of 
clozapine and placebo had no significant effect upon the latency 
to the sec on d REM p e r i o d ( F ( AX B ) = I , 0 I ; d f 6 , 7 2 ; p> 0 , 2 5 ) 
(Table JI). 
Latency t6 the Third REM Period. The administration of 
clozapine and placebo had no significant effect upon the latency 
to the third REM period CFCAXB) = 1,44; df 6,72; p<0,25) 
(Table II). 
6. I .5 Sleep Stage lhtid&nce 
Num~er 6f A~~k~hihgs. The administration of clozapine and 
placebo had no significant effect upon the number of awakenings 
du r i n g s I e e p ( F (AX B) 0, 5 6; d f 6 , 7 2; p> 0, 2 5 ) (Tab I e I 2 ) . 
Number of Stag& 4 P~~iods. The administration of clozapine 
and placebo had no significant effect upon the number of stage 4 
periods during sleep CFCAXB) = 1,31; df 6,72; p>0,25) (Table 12). 
136 
NJ~ber of Stag& REM P~ri6ds. The administration of clozapine 
and placebo had no significant effect upon the number of stage REM 















































































































































































































































































































































































































































































































































































































































































































































































































































6. I .6 Sleep Cycle Duration 
Duration of th~ Fi~st Sl~~P Cytle. The administration of 
clozapine and placebo had no significant effect upon the duration 
of the first sleep cycle (f(AXB) = 1,80; df 6,72; p<0,25) 
(Table 13). 
Duration of the S~tond Sleep Cfcle. The analysis of 
variance yielded a significant variance ratio (f(AXB) = 2,82; 
df 6,72; p<0,05) (Table 13) as well as a significant F max.ratio 
{ 
( F 2,26; df 2,36; p<0,05). In view of the significant F max. 
test of homogeneity of variance, no further statistical analysis 
was carried out. 
6. I .7 Body M6V~~~ht Activity 
As previously described (section 5.5.4) the indices of body 
movement activity have been analysed for the first three hours, 
the second three hours, the first six hours of the record as wel I 
as for the entire night. 
Numb~~ 6f B6dy M6V~~~hts. The effects of the administration 
of clozapine and placebo upon the number of body movements are 
presented in Table 14 (F(AXB) 4 , O 3 ; d f 6 , 7 2 ; p< O , 0 I ) . Closer 
examination of the data through simple main effects analysis 
revealed a significant difference between the clozapine and 
placebo groups on the third night of drug administration (F = 5,92; 
df 1,84; p<0,05) and a significant difference over the laboratory 
recorded nights for the clozapine group (F 5,19; df 6,41; 
p<0,001), but not for the p I acebo group (f 1,13; df 6,41; p>0,25). 



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Tukey HSD comparisons indicated that the number of body movements 
was significantly reduced during the second three hciurs of the 
three nights of clozapine administration as wel I as during the 
second three hours of the first night of clozapine withdrawal 
<Table 15(a)). 
The analysis of variance of th~ fir~t ~i~ hours of the record 
yielded a significant variance ratio (F(AXB) = 3,49; df 6,72; 
p<0,001). Closer examination through simple main effects 
analysis revealed a significant difference over the laboratory 
recorded nights for the clozapine group (F = 5,49; df 6,41; 
p<0,001 ), but not for the placebo group (F 0,64; df 6,41; 
p>0,25). The Tukey HSD comparisons indicated that the number 
of body movements were significantly reduced during the first 
six hours on the first and third nights of clozapine adminiitra-
tion as wel I as on the first night of clozapine withdrawal 
<Table 15(b)). 
Number of Body MciVemerits pet Miriute of Sleep. The effects 
of the administration of clozapine and placebo upon the number 
of body movements/minute of sleep are presented in Table 14 and 
significant findings are illustrated in Figure 10 CF<AXB) = 4,90; 
142 
df 6, 72; p<0,001). Closer examination of the data through simple 
main effects analysis revealed significant differences between 
the clozapine and placebo groups on the first (F = 5,16; df 1,84; 
p < 0, 0 5 ) an d th i rd ( F = 6 , I 9 ; d f 6 , 7 2 ; p< 0, 0 5 ) n i g ht s of d rug 
administration and a significant difference over the laboratory 
r n co nJ n d n i CJ h t '. f n r H1 r) c I o 1 d p i n e rJ r o u p ( F 
p<0,001 ), but not for the placebo group (F 
p> 0, 2 5) . 
6,57; df 6,41; 
1,09; df 6,41; 
Table 15(a) Tukey HSD comparisons+ of the means of the seven 
laboratory recorded nights for the second three 
hours of the record on the number of body move-
ments (clozapine group). 
Experimental Base I i ne Clozapine 
Condition 
Nights 3 4 5 
3 - 0,83 7,03** 










6 7 8 9 
5,60** 7',63** 6,02** 3,99 
4,77* 6,79** 5, 18* 3, 16 
I, 43 0,60 I , O I 3,04 
- 2,03 0,42 I , 6 I 
- I , 6 I 3,63 
- 2,03 
-
Table 15(b) Tukey HSD comparisons+ of the means of the seven 
laboratory recorded nights for the first six 
hours of the record on the number of body move-
ments (c]ozapine group). 
Experimental Base I in e Clozapine 
Condition 
Nights 3 4 5 
3 - 0,03 4,98* 










6 7 8 9 
4,05 5,36** 4,94* 2,33 
4,09 5,39** 4,98* 2,37 
0,93 0,38 0,03 2,64 
- I, 30 0,89 1,72 
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LABORATORY RECORDED NIGHTS 
F_igure IO The mean number of body movements/mi.nute of sleep· 
for the clo2apine and placebo gfoups over the 
laboratory recorded nights. ·The mean number of 
body movements/minute· of sleep were markedly 
reduced during the administration of clozapine 
and values remained at low levels on the first 
n _i g ht of c I oz a p i n e w i th draw a I • N i g ht s 3- 4 an d 





The Tukey HSD comparisons indicated that the number of body move-
ments/minute of sleep was markedly reduced during the administra-
tion of clozapine and values remained at low levels on the first 
night of clozapine withdrawal (Figure 10). The mean number of 
body movements/minute of sleep on the first night of clozapine 
administration was significantly lower than on either the first 
Cp<0,01) or second Cp<0,01) base I ine nights. The mean number of 
body movements/minute of sleep on the second night of clozapine 
administration was significantly lower than on either the first 
( p< 0 , 0 I ) o r s e co n d C p< 0 , 0 5 ) b a s e I i n e n i g h ts w h e re a s t h e me a n 
number on the third night of cl~zapine administration was also 
significantly lower than on the first Cp<0,01) or second Cp<0,01) 
baseline nights. Fina 11 y, the mean number of body movements/ 
minute of sleep on the first night of clozapine withdrawal was 
s i g n i f i c a n t I y I owe r t h a n on t h e f i rs t b a s e I i n e n i g h t ( p< 0 , 0 5 ) . 
Movement Time. The administration of clozapine and placebo 
had no significant effect upon movement time CFCAXB) = 1,31; 
df 6,72; p>0,25) (Table 14). The within-night analyses also 
revealed no significant differences for the first three hours 
CFCAXB) = 0,78; df 6,72; p>0,25), the second three hours CFCAXB) 
0, 6 6 ; d f 6 , 7 2 ; p> 0, 2 5 ) as we I I as· the f i rs t s i x ho u rs C F CA X B) 
1,02; df 6, 72; p>0,25) of the record. 
6. I .8 Vi~ual Arialogue Stales 
The visual analogue scales (depression, anxiety, drowsiness and 
concentration ability) provided a sensitive index of transient 
feelings and moods (section 5.2.6). The subjects completed the 
above visual analogue scales in the morning approximately fifteen 
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minutes after awakening (section 5.3.7). As previously described 
(section 5.6. I), the visual analogue data were transformed to 
normalised data using a Z score transformation procedure. The 
visual analogue data are presented in Table 16. 
Depre~sion. The administration of clozapine and placebo 
had no significant effect upon depression CFCAXB) = 0,83; df 6,84; 
p> 0 , 2 5 ) C Ta b I e I 6 ) . 
Anxiety. The administration of clozapine and placebo had 
no significant effect upon anxiety CFCAXB) = I ,74; df 6,84; p<0,25). 
Drowsiness. The effects of the administration of clozapine 
and placebo upon drowsiness are presented in Table 16 CFCAXB) = 
4,85; df 6,84; p<0,001 ). Closer examination of the data through 
simple main effects analysis revealed significant differences 
between the clozapine and placebo groups on the first morning 
fol lowing drug administration CF= 14,995; df 1,84; p<0,001) and 
on the first morning following drug withdrawal CF= 11,65; df 1,84; 
p< 0 , 0 0 I ) , a n d a s i g n i f i ca n t d i f f e re n c e o v e r t h e I a b o rat o r y re co rd e d 
nights for both the clozapine CF = 10,44; df 6,84; p<0,001) and 
placebo CF = 3,04; df 6,84; p<0,01) groups. 
The Tukey HSD comparisons indicated that the administration of 
clozapine significantly increased the degree of drowsiness on the 
mo r n i n gs f o I I ow i n g th e f i rs t a n d .sec on d n i g h ts o f a d m i n i st rat i on 
whereas the administration of placebo significantly increased the 
degree of drowsiness on the morning following the second night of 
placebo administration. The mean value was significantly greater 
on the morn i n g f o I I ow i n g the f i rs t n i g ht of c I oz a p i n e ad mi n i st rat i on 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(p<0,01) baseline nights, the third night of clozapine administra-
t i on ( p< 0 , 0 5 ) as we I I as the f i rs t ( p < 0 , 0 I ) an d sec on d ( p< 0 , 0 I ) 
nights of clozapine withdrawal. In addition, the mean value on 
the morning following the second night of clozapine administration 
was significantly greater than the mean values on the mornings 
following the second baseline night (p<0,05) and the first night 
of clozapine withdrawal <p<0,01). The mean value on the morning 
fol lowing the third night of clozapine administration was signifi-
cantly greater than the mean value on the morning fol lowing the 
first night of clozapine withdrawal (p<0,05). Finally, the mean 
value on the morning fol lowing the second night of placebo 
administration was significantly greater than the mean value on 
the morning following the first baseline night (p<0,05). 
Concentration Ability. The effects of the administration 
of clozapine and placebo upon concentration abi I ity are presented 
in Table 16 (F(AXB) = 2,56; df 6,84; p<0,05). Closer examination 
of the data through simple main effects analysis revealed a 
significant difference between the clozapine and placebo groups 
on the morning following the first night of drug administration 
(F = 10,13; df 1,84; p<0,01) and a significant difference over 
the laboratory recorded nights for the clozapine group (F 3,79; 
d f 6 , 8 4 ; p< 0 , 0 I ) , b u t n o t f o r t h e p I a c e b o g r o u p ( F = 0 , 6 2 ; 
df 6,84; p>0,25). 
The Tukey HSD comparisons indicated that the abi I ity to concen-
trate was markedly reduced on the morning following the first 
night of clozapine administration. The mean value on the morning 
following the first night of clozapine administration was signifl-
cantly lower than the mean values on the mornings following the 
f i rs t ( p< 0 , 0 I ) an d sec on d ( p < 0 , 0 I ) b as e I i n e n i g ht s , th e th i rd 
night of clozapine administration (p<0,05) as well as the first 
(p<0,01) and second (p<0,05) nights of clozapine withdrawal. 
6.1.9 Sleep Log 
The sleep log provided information regarding the quality of the 
night's sleep, the mood shortly after awakening as wel I as 
psychological and physiological side-effects (section 5.2.8). 
The subjects completed the sleep log in the morning approximately 
fifteen minutes after awakening (section 5.3.7). The sleep log 
data are presented in Table 17. 
Quality of Sleep (Question six). The administration of 
clozapine and placebo had no significant effect upon the qua I ity 
o f s I e e p ( F ( A X B ) = I , 3 3 ; d f 6 , 7 2 ; p> 0 , 2 5 ) ( T a b I e I 7 ) . 
Mood Shortly Aftet A~akening (Question ~~Ven). The 
administration of clozapine and placebo had no significant effect 
upon the mood shortly after awakening (f(AXB) = 2,07; df 6,72; 
p< 0 , I 0 ) ( Ta b I e I 7 ) • 
Psychologic~I ~~d Physi61~gical Sid~~Eff~tts. The clozapine 
group reported numerous physiological side-effects such as nausea, 
difficulty in writing and speaking on the mornings following the 
three nights of clozapine administration but failed to report any 
psycholpgical side-effects (Table 17). No side-effects were 
reported on the mornings fol lowing the base I ine or drug withdrawal 
conditions. The placebo group failed to report any psychological 






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































6. I. I 0 Menta I Speed Test 
The mental speed test assessed the speed and accuracy of perfor-
mance (section 5.2.9). The subjects completed the mental speed 
test fifteen minutes after awakening (section 5.3.6). 
Number of Efr6rs. The administration of clozapine and 
placebo had no significant effect upon the number of errors 
produced on the menta I speed test CFCAXB) = 0,63; df 6, 72; 
p> 0 , 2 5 ) ( T a b I e I 8 ) • 
i 5 I 
Number of Prob le~~ Att~~pted. The effects of the administra-
tion of clozapine and placebo upon the number of problems attempted 
are presented in Table 18 CFCAXB) = 6,12; df 6,72; p<0,001). 
Closer examination of the data through simple main effects analysis 
revealed significant differences between the clozapine and placebo 
groups on the mornings following the first CF= 4,57; df 1,84; 
p<0,05), second CF= 4,25; df 1,84; p<0,05) and third CF= 4,211; 
df 1,84; p<0,05) nights of drug administration and a significant 
difference over the laboratory recorded nights for both the 
c I o z a p i n e ( F = I 2 , 5 4 ; d f 6 , 4 I ; p< 0 , 0 0 I ) a n d p I a c e b o ( F = 3 , 3 I ; 
d f 6, 4 I ; p< 0, 0 I ) groups • 
The Tukey HSD comparisons indicated that the number of problems 
attempted were dramatically reduced on the mornings following 
the three nights of clozapine administration. An increased 
number of problems were attempted on the mornings following the 
nights of placebo administration. The mean number of problems 
attempted on the morning following the first night of clozapine 
administration was significantly less than on the mornings 






























































































































































































































































































































































































































































































































































































































































































































as we! I as the ti rst (p<0,01) and second (p<0,01) withdrawal 
nights. In addition, the mean number of problems attempted on 
the morning fol lowing the second night of clozapine administra-
t i on was s i g n i f i cant I y I es s than on the morn i n gs f o I I ow i n g the 
first (p<0,01) and second (p<0,01) baseline nights as well as 
t h e f i rs t ( p< 0 , 0 I ) a n d s e con d ( p< 0 , 0 I ) w i t h d raw a I n i g h t s • 
Finally, the mean number of problems attempted on the morning 
fol lowing the third night of clozapine administration was 
significantly less than on the mornings following the second 
b a s e I i n e n i g h t ( p< 0 , 0 5 ) a s w e I I a s t h e f i rs t ( p < 0 , 0 I ) a n d s e co n d 
(p<0,01) withdrawal nights. 
The mean number of problems attempted on the morning following 
the second night of placebo withdrawal was significantly greater 
than those on the mornings fol lowing the ti rst (p<0,05) and 
second (p<0,05) baseline nights. 
6.1.11 The Activation Deactivation Adjective Check List 
The Activation Deactivation Adjective Check List measured 
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transient levels of mood (section 5.2.5). The subjects completed 
the above check I ist in the morning approximately fifteen minutes 
after awakening (section 5.3.7). The check I ist data are pre-
sented in Table 19. 
Ge~etal Activation. The effects of the administration of 
clozapine and placebo upon General Activation are presented in 
Tab I e I 9 ( F (AX B) = 3, 8 0; d f 6 , 7 2 ; p< 0, 0 I ) . Closer examination 
of the data through simple ~ain effects analysis revealed a 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































on the morning following the first night of drug withdrawal 
(F = 10,05; df 1,84; p<0,01) and a significant difference over 
the laboratory recorded nights for the clozapine group (F 6,91; 
df 6,41; p<0,001 ), but not for the placebo group (f = 0,67; 
d f 6 , 41 ; p> 0 , 2 5 ) . 
The Tukey HSD comparisons indicated that General Activation was 
markedly reduced on the morning following the first night of 
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clozapine administration (Table 19). The mean General Activation 
index on the morning following the first night of clozapine 
admi n i strati on was significant I y I ow er than on the mornings fo I I ow-
ing the first (p<0,01) and second (p<0,05) baseline nights as well 
as the first night of clozapine withdrawal (p<0,01). In addition, 
the mean General Activation index on the morning following the 
first night of clozapine withdrawal was significantly greater than 
on the mornings following the second <p<0,01) and third (p<0,01) 
nights of clozapine administration. 
High Activation. The administration of clozapine and 
placebo had no significant effect upon High Activation CFCAXB) 
= I , 7 4 ; d f 6 , 7 2 ; p< 0 , 2 5 ) ( Tab I e I 9 ) . 
DeattiVation Sl~ep. The effects of the administration of 
clozapine and placebo upon Deactivation Sleep are presented in 
Tab I e I 9 ( F (AX B ) = 2 , 8 6 ; d f 6 , 7 2 ; p< 0, 0 5 ) . Closer examination 
of the data through simple main effects analysis revealed a 
significant difference between the clozapine and placebo groups 
on the mo r n i n g f o I I ow i n g the f i rs t n i g ht of d rug ad mi n i st rat i on 
<F = 7,89; df 1,84; p<0,01) and a significant difference over 
the laboratory recorded nights for the clozapine group <F = 9,6&; 
..... 
df 6,41; p<0,001), but not for the placebo group CF 
d f 6 , 4 I ; p> 0 , 2 5 ) • 
1,20; 
The Tukey HSD comparisons indicated that Deactivation sleep was 
significantly increased on the mornings fol lowing the first and 
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second nights of clozapine administration. The mean Deactivation 
Sleep index on the morning following the first night of clozapine 
administration was significantly greater than on the mornings 
f o I I ow i n g t h e f i rs t ( p< 0 , 0 I ) a n d s e con d · ( p < 0 , 0 I ) b a s e I i n e n i g h t s 
as wel I as the first (p<0,01) and second (p<0,01) nights of 
clozapine withdrawal. In addition, the mean Deactivation Sleep 
index on the morning following the second night of clozapine 
administration was significantly greater than on the mornings 
f o I I ow i n g the f i rs t base I t n e n i g ht ( p< 0 , 0 5 ) an d f i rs t n i. g h t o f 
clozapine withdrawal (p<0,0[). Finally, the mean Deactivation 
Sleep index on the morning following the third night of clozapine 
administration was significantly greater than on the morning 
f o I I ow i n g the f i rs t n i g ht o f c I oz a p. l n e w i. th d raw a I . ( p< 0 / 0 1. ) . 
G&heral De~ctiV~tion. The administration of clozapine and 
placebo had no significant effect upon General Deactivation 
(F(AXB) = 0,28; df 6 1 72; p>0,25) (Tab le 19). 
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6.2 Di'scussion 
6.2.I Research St~~t~gy 
The nine consecutive night, double bl ind cross-over design employed 
in the present study was developed in order to determine the 
effects of the short-term administration of 25mg clozapine and 
placebo upon the sleep patterns of normal young adults (Touyz et 
al l975(a)). Many methodological inadequacies are inherent in 
contemporary sleep research designs (section 3.0) and the present 
study therefore employed the following strategies: 
(i) Two adaptation nights were used to ensure that the sub-
jects were adequately adapted· to the sleep laboratory environment 
as the "first night" effect (section 3.1.1) has been associated 
with a decrease in stage REM sleep and increases in total waking 
time, the number of stage shifts and the latencies to stage 4 and 
stage REM sleep (Agnew et al 1966; Mendels and Hawkins 1966). 
(ii) The effects of clozapine and placebo were evaluated 
independently of one another thus providing additional information 
as to the effects of placebo upon sleep parameters. 
(iii) The double blind procedure was employed in order to 
eliminate the experimenter effect <Orne 1962; Rosenthal 1965) as 
both the experimenter and subject were unaware as to whether 
clo2apine or placebo had been administered (section 3.3). 
(iv) The duration of time which the subject was permitted to 
spend in bed was control led in order to eliminate the increase in 
stags REM sleep which ac~ompanies extended sleep In the morning 
(Hartmann 1973(b); Johnson 1975(b)-personal communication) 
(section 3.5). 
(v) The subjects were of a similar age group and were 
medically healthy as slow wave sleep decreases with increasing 
age (Agnew et al 1967(a); Feinberg 1969; Wi 11 iams et al 1974) 
(section 3.3). 
(vi) The female subjects commenced the study on the fourth 
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day of their menstrual cycles to control for the increase in stage 
REM sleep reported to occur prior to menstruation (Hartmann 1966(a); 
Sheldrake and Cormack 1974) (section 3.3). 
(vii) Smaller portions of the night's data were analysed 
to ensure that all sleep stage alterations were detected (Kales 
et al 1976; Freemon 1972; Hartmann and Cravens 1973(a)) 
(section 3.6). 
A I imitation of the present study was the use of a I imited ·number 
of subjects. This was necessitated by the exorbitant cost of 
sleep research. However, the number of subjects used in the 
present investigation was wel I within the average number used in 
most sleep research programs. 
6.2.2 Total Sleep Time 
The short-term administration of 25mg clozapine resulted in a 
marked increase in the duration of total ~leap time on the first, 
and, to a much lesser extent, on the second night of administration 
(Figure 7). Clozapine administration, however, did not reduce the 
latency to stage I sleep (sleep onset) or the frequency and dura-
tion of awakenings during the night. The evidence therefore 
suggests that the administration of cloz~pine did not result in 
the subjects fal I ing asleep more rapidly. Neither did the clozapine 
group wake up on fewer occasions or for shorter durations during the 
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night. However, they did sleep for more prolonged periods of 
time. It is of interest to note that an attempt was made to 
control for the length of time the subjects spent In bed (section 
5.3. I), but attempts to awaken the subjects at the specified time 
on the first and second mornings after clozapine administration 
proved to be unsuccessfu I. 
It is not surprising that the administration of clozapine had no 
significant effect upon the latency to stage I sleep as the subjects 
who participated in the present study were selected on the basis of 
their healthy sleeping habits. The mean latency to stage I sleep, 
during the baseline condition, was found to be only 6,40 minutes 
and was well below the mean value of 18 minutes reported for normal 
subjects of a similar age.group by Williams et al (1974). The 
subjects fel I asleep rapidly without the administration of medica-
tion and the effectiveness of clozapine in reducing the latency to 
sleep onset should thus be investigated in subjects suffering from 
sleep onset insomnia. This type of insomnia is characterised by· 
sleep onset latencies of exceptionally long durations (Wi 11 lams 
et al 1974). 
It appears that the subjects developed a rapid tolerance to the 
drug since the duration of sleep returne~ to the pre-drug adminis-
tration baseline levels by the third night of clozapine 
administration. 
In general, therefore, the data showed that the short-term 
administration of 25mg clozapine resulted in an initial prolonga-
tion of sleep duration and that subjects developed a rapid 
tolerance to the drug. The finding that clozapine enhanced 
the duration of sleep is In accordince with the assumption that 
clozapine may have sleep inducing properties (Ruch et al 1976; 
Hemphi 11 et al 1974, 1975; Gross and Langner 1966, 1969; Angst 
et al 1971; Berzewski et al 1969). 
The administration of 25mg placebo had no significant effect upon 
total sleep time. This result is in harmony with the findings 
of Adam et al (1975, 1976). 
6.2.3 Major Sleep Stages 
The short-term administration of 25mg clozapine resulted in a 
marked decrease in stage 4 sleep on the second and third nights 
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of administration (Figure 8). The within-night analyses revealed 
that stage 4 sleep was suppressed during the first six hours of the 
record on both these nights as wel I as on the first night of 
clozapine withdrawal. These results are largely in agreement 
with earlier reports concerning the effects of benzodiazepines on 
sleep patterns. Benzodiazepines have been found to suppress 
stage 4 sleep much more consistently than stage REM sleep (Kales 
and Scharf 1973; Dement et al 1973(b); Kales et al 1970(d); 
Vogel et al 1972(b); Oswald et al 1973). The finding that the 
administration of 25mg clozapine significantly reduced stage 4 
sleep may have important therapeutic imp I !cations for the treat-
ment of disorders of slow wave sleep. Enuresis and somnambulism 
have been found to occur primarily, though not exclusively during 
slow wave sleep (Gastaut and Broughton 1964; Hawkins et al 1965; 
l?ierce et al 1961; Ritvo et al 1967; Jacobson et al 1965; 
Jacobson and Kales 1967),whereas night terrors (paver nocturnus) 
are known to occur ex~lusively .during stage 4 sleep (Gastaut and 
Broughton 1964). 
Indeed, the benzodiazep[nes have been used In the treatment of 
disorders associated with slow wave sleep. GI i ck et a I ( ·1 97 I ) 
successfully treated seven children, suffering from combinations 
of enuresis, somnambulism and paver nocturnus, with diazepam 
(2,50-5,0mg/night). Moreover, Fisher et al (1973) reported 
that seven patients suffering from paver nocturnus, showed a 
marked clinical improvement when treated with diazepam (5,0-20mg/ 
night). It thus appears that clozapine may play an important 
role in the treatment of disorders associated with slow wave 
sleep. However, since the long-term effects of the suppression 
of slow wave sleep have not yet been determined, such therapeutic 
intervention should be approached with caution. 
In sharp contrast to the marked suppression of stage 4 sleep, the 
short-term administration of 25mg clozapine had no significant 
effect upon stage REM sleep (Table 9). Many of the hypnotic 
drugs, which are presently prescribed for the treatment of 
insomnia, have been reported to suppress stage REM sleep (Oswald 
1968; Freemon 1972; King 1972). The withdrawal of these drugs 
after continuous administration, results in a rebound of stage 
REM sleep. This re~ound has been associated with an increased 
vividness in REM mentation with the subsequent occurrence of 
nightmares (Kales et al 1968(a), 1969(b), 1974, 1975), a phenome-
non that has often resulted In drug dependence. The finding 
that clozapine administration had no significant effect upon 
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stage REM sleBp appears therefore to have additional ~herapeutic 
lmpl !cations for the tre~tment of insomnia. 
·The short-term administration of 25mg placebo had no significant 
effect upon any of th~ major sleep stages <Table 9). This find-
ing is in accordance with earlier reports that the administration 
of placebo did not influence sleep patameters in normal subjects 
(Adam et a I 1975, 1976). The present study emp I eyed the doub I e 
blind procedure as well as in depth statistical analyses and has 
thus provided convincing evidence for the notion that the short~ 
term administration of placebo has no effect upon the sleep 
parameters of normal young adults. This finding may ~ot be 
applicable to insomniac subjects whose sleep has been reported 
to improve followipg the administration of a placebo (Nicolis 
and Silvestri 1967). 
6.2.4 REM lhdices 
The indices of stage REM sleep (section 5.4.2) have not been 
readily accepted by the sleep research community and have appeared 
infrequently in the published literature. A possible explanation 
for this tendency may be the large individual differences evident 
in many of these in.dices. Clausen et al (1974) reported that 
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the number of eye movements during REM sleep ''· .• varied considerably. 
among subjects, as indicated by the large individual ranges, large 
SD's and _si.g·n.ificant concordance across individuals .•..•• our data 
imply tha~ number of ey~ movements may more strongly reflect indi-
vi.dual characteristics" (Clausen et al 1974, p.515). Large 
individual differences are .evident in the present study resulting 
in the clozapin~ and placebo groups differing significantly from 
I 
one another on the first and second base I lne nights on the indices 
of mean burst length, density/minute of REM sleep and % moti I ity 
(Table 10). 
However, the administration of clozapine significantly increased 
the density/minute of REM sleep, the mean burst length and 
% moti I ity on the third night of administration. This increased 
activity persisted on the first night of clozapine withdrawal. 
In addition, the total number of bursts and the number of bursts/ 
REM period increased dramatically on the first night of clozapine 
withdrawal despite the fact that no significant reduction occurred 
during the administration of clozapine (Figure 9). 
163 
The implications of these findings are difficult to assess as the 
function of stage REM sleep has yet to be conclusively dete~mined. 
Dement et al (1970) commented that " ••• never before in the history of 
biology has so much been known about a phenomenon from the des-
criptive point of view while at the same time knowing so little 
about its function - its raison d'etre" CDement et al 1970, p.72). 
It has been tentatively suggested that the increased rapid eye 
movement activity may be associated with the remission of symptoms 
in psychotic patients (Blum and Girke 1973). The authors 
commented that '' •.• although no systematic investigations have been 
ca r r i e d .out , the g e n e r a I c I i n i ca I i mp res s i on i s that a rem i s s i on 
of psychotic symptoms coincides with •...•• the intensified dream 
a c t i v i t y " ( 8 I u m a n d, G i r k e I 9 7 3 , p • 8 0 ) • 
The validity of the possible isomorphic relationship between the 
profusion of rapid eye movements and visual imagery (scanning 
hypothesis) appears to be questionable (firth 1973, )974; Hauri 
and van de Castle 1973; Jacobs et al 1970; Koulack 1972; 
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Moskowitz and Berger 1969). Recent research, however, has indica-
ted that an increase in the profusion of rapid eye movements is 
associated " .•. with experiences in which the dreamer is an active 
participant, rather than thinking, reflecting, or passively 
observing events" (firth 1974, p.547). The evidence from the 
present study therefore suggests that the REM dream content became 
more active on the third night of clozapine administration and 
that this effect persisted on the first night of clozapine with-
drawal. This finding was responsible for eliciting REM dream 
reports on the third night of clozapine administration during the 
REM dream recal I investigation. Previous studies have not 
attempted to determine the effects of placebo administration upon 
REM indices such as those employed in the present study. The 
present finding that the administration of placebo had no signifi-
cant effect upon the indices of stage REM sleep is in accordance 
with the assumption that placebo administration does not influence 
sleep parameters <Adam et al 1975, 1976). 
6.2.5 Sleep Stage L~tencies 
The short-term administration of 25mg clozapine and placebo had 
no significant effect upon the latencies to stage I, stage 2 and 
stage 4 sleep as wel I as the latencies to the first, second and 
third REM periods. 
The finding that the administration of clozapine did not signifi~ 
cant I y reduce the I atency to stage. I or stage 2 s I eep imp Ii es that 
the subjects did not fall asleep more rapidly (section 6.2.2). 
This is not surprising as the mearr latency to stage I sleep, 
during the baseline condition, was well below the mean value 
reported by Wi I Ii ams et a I ( 1974). The I atenci es to both stage 
I and stage 2 sleep were statistically analysed as it has been 
suggested that stage 2 may be a more reliable Index of sleep 
onset than stage I sleep (Johnson 1975(a)). 
The administration of clozaplne markedly suppressed stage 4 sleep 
but had no effect upon Its onset latency. The evidence there-
fore suggests that the onset of stage 4 sleep was not delayed but 
that it was consistently suppressed throughout the night. Con-
firmation of this assumption has been provided by the finding that 
the within-night analyses ·revealed that stage 4 sleep was in fact 
suppressed throughout the first six hours of the record. The 
administration of clozapine had no significant effect upon the 
percentage of time spent in stage REM sleep and is therefore not 
surprising that the latencies to the REM periods were not signifi-
cantly affected (Table I l). 
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The finding that the administration of placebo had no significant 
effect upon the latencies to sleep stages as wel I as the latencies 
to REM periods provides further confirmation of the assumption that 
placebo administration does not Influence sleep parameters (Adam et 
al 1975, 1976). 
6.2.6 Sl~~p Stag~ lncld~hce 
The short-term ~dmlnistration of 25mg clozaplne had no significant 
effect upon either the number of awakenings or the .number of stage 
4 or stage REM periods (Table 12). The finding that the 
admlnlstratlon of clozapine did not significantly reduce the 
number of stage 4 periods provides f6tther confirmation for the 
finding that stage 4 sleep was consistently suppressed throughout 
the first six hours of the record, since the number of stage 4 
periods remained constant and the reduction in stage 4 sleep was 
therefore not .due to the suppression of one or more specific 
stage 4 periods. 
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The administration of placebo had no significant effect upon the in-
cidence of sleep stages and thus provides further confirmation 
of the assumption that placebo administration does not influence 
s I e e p pa r a mete rs (Ad am et a I I 9 7 5 , I 9 7 6 ) • 
6.2.7 Sleep Cycle Dur~tion 
The 11 90-minute sleep-dream cycle" is relatively stable and with 
a few exceptions 11 ••• no pharmacological agent and no illness or 
hormonal condition we have studied, produce a systematic change 
in cycle length" (Hartman 1968(a)). The administration of 
clozapine and placebo had no significant effect upon the duration 
of the first or second sleep cycles (Table 13). This evidence 
suggests that the administration of clozapine did not have a dis-
ruptive effect upon the infrastructure of the night's sleep as 
the duration from the end of one REM period to the end of the next 
remained constant. 
6.2.8 Body Mov~m~nt Attivity 
The short-term administration of 25mg clozapine significantly 
reduced the number of body movements which occurred on al I three 
nights of administration and this effect persisted on the first 
night of clozapine withdrawal (Table 14). The within-night 
analyses revealed that the number of body movements was predomin-
antly reduced during the second three hours of the record. The 
number of body movements per minute of sleep, an index which 
adjusted tor sleep duration, was significantly reduced on the 
three nights of clozapine administration as we! I as on the first 
night of clozapine withdrawal (figure 10). Movement time was 
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also reduced during the administration of clozapine but this effect 
tailed to reach statistical significance. 
In general, therefore, the data showed that the administration 
of clozapine resulted in a significant reduction in body movement 
activity. This finding may have important therapeutic imp I ica~ 
tions tor the treatment of insomnia, since it suggests that sleep 
was more restful <Oswald 1970(c)). 
The administration of placebo had no significant effect upon the 
body movement indices and is in accordance with the assumption 
that placebo administration has no effect upon sleep parameters 
(Adam et al 1975, 1976). 
6.2.9 Psychologital a~d Physiological Side-Ett~tts 
Psychologit~I Side-Etfetts 
"The ideal hypnotic agent would rapidly induce physiological 
sleep but produce no unwanted drowsiness or heavy-headedness upon 
awakening" (Greenblatt and Shader 1974, p.189). 
The short-term administration of 25mg clozapine resulted in a 
significant increase in drowsiness on the first, second and third 
mornings following administration <Table 16). This increase in 
drowsiness was accompanied by a significant impairment of perfor-
mance in a test of intellectual function on the three mornings 
following the administration of clozapine. General Activation 
168 
as wel I as the subjective index of concentration abi I ity were 
significantly reduced on the first morning fol lowing the administra-
tion of clozapine. In addition, Deactivation Sleep was signifi-
cantly increased'on the first and second mornings following 
administration <Table 19). In general, therefore, the data 
showed that the administration of 25mg clozapine resulted in 
specific "morning after" effects such as drowsiness and sleepiness 
as we I I as an i mp a i r me n t o f i n t e I I e ct u a I p e r f o rm an c e . This 
evidence appears to suggest that clozapine does not meet the 
criteria of an ideal hypnotic (Greenblatt and Shader 1974). 
However, most hypnotic agents, including the barbiturates and 
benzodiazepines, produce "morning after" side-effects such as 
drowsiness, heavy-headedness and the impairment of intellectual 
motor function (Greenblatt and Shader 1974) and clozapine appears 
to be no exception to the rule. Confirmation of the finding that 
clozapine produces "morning after" effects has been provided by 
an extensive c Ii n l ca I tri. a I of the drug in the treatment of psy-
c·hotic patients (Hemphi.11 et al 1975). The authors remarked 
that " ... because of the side-effects, especially sleepiness, it 
would be unwise to prescrlbe clozaplne, in the doses 1 we h.ave 
used, for outpati.ents until after one week's trial in hospital 
1
The doses varied from between IOOmg to 300mg per day. 
or under the supervision of a reliable person at home. Under 
no circumstances should the patient be allowed to drlve a car, 
look after children, or have responsibi I ities at home that carry 
ri.sks unti I continued tolerance has been demonstrated" (Hemphi 11 
et al 1975, p.2123). It should be emphasised, however, that the 
"morning after" drowsiness noted in the present study was of a 
less intense nature than that of the above study as a result of 
the low dose used. 
The short-term administration of 25mg placebo resulted in a sig-
nificant increase in drowsiness on the second morning fol lowing 
administration. This finding is in harmony with Beecher (1955) 
who reported numerous side-effects fol lowing the administration 
of placebo. This increase in drowsiness was reported despite 
the fact that no change in any of the sleep parameters were 
observed. The subjective ratings showed no change in anxiety or 
the quality of sleep and is in accordance with the findings of 
Adam et al (1975, 1976). 
Physiological Side~Etfects 
Many, non-specific side-effects such as slurring of speech, 
difficulty in writing, nausea, physical weakness and dryness of 
mouth were reported fol lowing the short-term administration of 
25mg clozapine <Table 17). These side-effects disappeared on 
the f i rs t morn i n g f o I I ow ( n g the w i th draw a I of c I oz a p i n e • The 
above side-effects resulted in a lower dose of clozapine 
(12,50mg/night) being used in the remaining series of experiments. 
The short-term administration of 25mg placebo produced no 
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physiological side-effects. The evidence points overwhelmingly 
in favour of the conclusion that the short-term administration of 
placebo has no significant effect upon sleep parameters and pro-
duces only minimal side-effects. Only one measure, namely the 
subjective estimation of drowsiness, Increased significantly on 
the morning fol lowing the second night of placebo administration. 
ln summary, the evidence suggests that the short-term administra-
tion of clozapine may have therapeutic imp I I cations for the 
treatment of insomnia and disorders of slow wave sleep. This 
conclusion was supported by the fol lowing findings: (I) Stage 4 
sleep was significantly suppressed on the second and third nights 
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of clozaplne administration (2) Total sleep time was significantly 
increased on the first and second nights of clozaplne administration 
despite the attempt to control for the duration of time spent in 
bed (3) The number of body movements was significantly reduced 
on al I three nights of clozapine administration (4) The number 
of body movements/minute of sleep was also significantly reduced 
on al I three nights of clozapine administration (5) The short-
term administration and withdrawal of 25mg clozapine/night had no 
significant effect upon stage REM sleep. However, the indices 
of stage REM sleep were significantly affected. The mean burst 
length, the density/minute REM sleep and% moti I ity were signifi-
cantly Increased on the third night of clozaplne administration 
and persisted on the first night of clozapine withdrawal. In 
addition, the total number .of bursts and the number of bursts/REM 
period increased significantly on the first night of clozapine 
withdrawal despite the fact that no significant reduction occurred 
during the administration of cloz~pine. Finally, p~ychological 
and physiological side-effects were reported and it thus appears 
that clozapine does not meet the criteria for an id~al hypnotic 
agent. However, further research on insomniac patients should 
be carried out to validate and extend the above findings. 
The short-term administration of 25mg placebo had no significant 
effect upon any of the sleep parameters and this result is in 
harmony with the findings of Adam et al (1975, 1976). The 
administration of placebo resulted in a significant increase in 
only one index, namely the subjective estimation of drowsiness 
on the second morning fol lowing administration. 
I 7 I 
7.Q THE LONG~TERM CLOZAPINE INVESTlGATlON 
7.1 Results 
The statistical procedures employed in this investigation involved 
the comparison of one group of subjects on base I ine, clozapine 
administration and withdrawal conditions on a given variable. 
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These were one factor designs where the subjects were monitored 
repeatedly and the appropriate ana)ysis employed was the one way 
analysis of variance with repeated measures (Winer 1962). This 
one way analysis of variance was fol lowed up by comparisons between 
eel I means using the Tukey HSD procedure which identified the 
direction of significant findings. However, where the overal I 
test of significance barely yielded a probabi I ity value of 0,05, 
the conservatively large confidence intervals employed by the 
pairwise comparison test CTukey HSO) yielded probability values 
greater than 0,05 and hence non significance. 
7.1.1 Total Sleep Time 
The administration of clozapine had no significant effect upon 
the duration of total sleep time CF= 0,41; df 7,35; p>0,25) 
<Tab le 20). 
7. I .2 Major Sleep St~ges 
As previously described (section 5.5.4), the major sleep stages 
were analysed for the first three hours, the second three hours, 
the first six hours of the record as wel I as for the entire 
night, expressed as a percentage of total sleep time. Stage 
awake was expressed as a percentage of total recording time. 
Stage Awake. The administration of cloz~pine had no 
sig~ificant effect upon the p~rcentage of time spent awake CF 
0,67; df 7,35; p>0,25) (Table 20). 
The within-night analyses also revealed no significant differen-
ces for the first three hours CF= 1,42; df 7,35; p<0,25) and 
the first six hours CF= 1,00; df 7,35; p>0,25) of the record. 
However, the administration of clozapine had a significant effect 
upon the second three ho~rs of the record CF 2,33; df 7,35; 
p<0,05). The Tukey HSD comparisons indicated that the mean 
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number of minutes spent awake during the second three hours of the 
third (night 8)(p<0,05) and eleventh (night 16)Cp<0,05) nights of 
clozapine administration was significantly lower than the mean 
number during the second three hours of the second baseline night 
(night A). The administration of clozapine thus reduced the 
number of minutes spent awake during the second three hours of 
the recording on the third and eleventh nights of administration. 
Stage I. The effects of the administration of clozapine 
upon the percentage of time spent in stage 
in Table 20 CF= 2,37; df 7,35; p<0,05), 
sleep are presented 
The Tukey HSD com-
parisons revealed that the mean p~rcentage of time spent in stage 
sleep was significantly lower on the third night of clozaplne 
administration (night 8) than the mean on the second baseline 
night (night 4)Cp<0,05), 
The within-night analyses revealed no significant differences for 
the first three hours of the record CF~ 1,50; df 7,35; p<0,25). 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































upon the second three hours (F = 3,91; df 7,35; p<0,01) and 
first six hours CF= 2,87; df 7,35; p<0,05) of the record. 
The Tukey HSD comparisons Indicated that the mean number of 
minutes spent in stage I sleep during the sec6nd three hours of 
the first baseline night (night 3)(p<0,05) and third (night 8) 
(p<0,01), seventh (night 12)(p<0,01) and eleventh (night 16) 
Cp<0,01 )nights of clozapine administration was significantly 
lower than those during the second three hours of the second 
baseline night (night 4). 
The Tukey HSD comparisons indicated that the mean number of 
minutes spent in stage I sleep during the fit~t ~i~ h6urs of the 
third night (night 8)(p<O,OI) of clozapine administration and 
the fifth night (night 25)(p<0,05) of clozapine withdrawal was 
significantly lower than those during the first six hours of the 
second baseline night (night 4). 
Stage 2. The administration of clo2apine had no signifi-
cant effect upon the percentage of time spent in stage 2 sleep 
CF= 1,12; df 7,35; p>0,25)(Table 20). 
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The within-night analyses also revealed no significant differences 
for the first three <F = 1,77; df 7,35; p<0,25) and six (F = 0,61; 
df 7,35; p>0,25) hours of the record. However, the administra-
tion of clozapine had a significant effect upon the second three 
hours of the record (F = 2,67; df 7,35; p<0,05). 
The Tukey HSD comparisons indicated that the mean .number of 
minutes spent in stage 2 sleep during th~ s~tdnd tht~~ h6Jrs of 
the eleventh night tnight 16) of clozapine administration was 
significantly greater than those during the second three hours 
of the fifth night tnight 25) of clozapine withdrawal Cp<0,05). 
Stage 3. The administration of clozapine haa no signifi-
cant effect upon the percentage of time spent in stage 3 sleep 
CF= 1,52;. df 7,35; p<0,25)(Table 20). The within-night 
analyses also revealed no significant differences for the fl rst 
three hours CF= 2, 15; df 7,35; p<O, 10), the second three hours 
C F = 0, 5 5 ; d f 7, 3 5 ; p> 0, 2 5 ) an d f i rs t s I x ho u rs ( F = I , 2 8; 
df 7,35; p>0,25) of the record. 
Stage 4. The administration of clozapine had no signifi-
cant effect upon the percentage of time spent in stage 4 sleep 
( F = 0, 9 6; d f 7, 3 5 ; p> 0, 2 5 ) (Tab I e 2 0) . The w i th i n - n i g ht . 
analyses also revealed no significant differences for the first 
three hours CF= I ,20; df 7,35; p>0,25), the second three hours 
CF= 1,23; df 7,35; p>0,25) and first six hours CF= 1,04; 
df 7,35; p>0,25) of the record. 
St~ge Sldw W~ve. The administration of clozapine had no 
significant effect upon the percentage of time spent in stage 
s I ow w a v e s I e e p ( F = I , 0 8 ; d f 7 , 3 5 ; p> 0 , 2 5 ) ( Ta b I e 2 0 ) . T h e 
within-night analyses also revealed no significant d[fferences 
for the first three hours CF= 1,41; df 7,35; p<0,25), the 
second three hours CF= 0,71; df 7,35; p>0,25) and first six 
hours (F = 0,76; df 7,35; p>0,25) of the record. 
Stage REM. The effects of the administration of clozapine 
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upon the percentage of ttme spent in stage REM sleep are presented 



























BASELINE CLOZAPINE ADMINISTRATION CLOZAPINE WITHDRAWAL 
3 4 8 12 16 20 21 25 
LABORATORY RECORDED NIGHTS 
The effects of the long-term administration of 
12,50m~ .clozapine upo~ the mean percentage of· 
time ~pent in stage REM sleep over .the · 
laboratory ~ecor~ed nights. 
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( F = 2 , 6 4 ; d f 7 , 3 5 ; p< 0 , 0 5 ) . T h e T u key H S D co mp a r i s on s f a i I e d 
to identify the direction of this finding. tnspection of the 
data showed that stage REM sleep was reduced during the adminis-
tration of clozapine (Figure ll)(Table 20). 
The within-night analyses revealed no significant differences for 
the first three hours <F = 0,56; df 7,35; p>0,25), the second 
three hours (F = 1,56; df 7,35; p<0,25) and first six hours 
CF= 1,66; df 7,35; p<0,25) of the record. 
7.1.3 REM Indices 
Mean REM Dur~tion. The administration of clozapine had no 
significant effect upon the mean duration of REM sleep <F 
df 7,35; p>0,25)(Table 21). 
0' 90; 
Total Numbet of B~r~ts. The administration of clozapine 
had no significant effect upon the total number of bursts <F = 
0,89; df 7,35; p>0,25HTable 21). 
Number of Bursts per REM P~riod. The administration of 
clozapine had no significant effect upon the number of bursts/REM 
period ( F = 0, 4 8; d f 7, 3 5; p> 0, 2 5 ) (Tab I e 2 I ) . 
M~an Burst Lerigth. The administration of clozapine had no 
significant effect upon the mean burst length CF= 1,05; df 7,35; 
p>0,25)(Table 21). 
D~risity per Miriute REM Sl~e£· The administration of 
clozaplne had no significant effect upon the density/minute REM 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































% Motllity. The effects of cfozaplne administration upon 
% motility are presented.in Table 21 CF= 2,58; df 7,35; p<0,05). 
The Tukey HSD comparisons failed to identify the direction of 
this significant finding. 
7. I .4 Sleep StaSe Lat~~ties 
Stage I Latency. The administration of clozapine had no 
significant effect upon the latency to stage I sleep CF= I, 15; 
d f 7, 3 5; p> 0, 2 5 ) <Tab 1 e 2 2 ) . 
Stage 2 Latency. The administration of clozapine had no 
significant effect upon the latency to stage 2 sleep CF= 0,95; 
df 7,35; p>0,25). 
Stage 4 Latency. The effects of the administration of 
clozapine upon the latency to stage 4 sleep are presented in 
Table 22 CF= 2,96; df 7,35; p<0,05). The Tukey HSD compari-
sons indicated that the mean latency to stage 4 sleep was signi-
ficantly longer on the first night of clozapine withdrawal 
( · n i g h t 2 I ) th an those on e i the r the th i rd ( n i g h t 8 ) ( p< 0 , 0 5 ) o r 
f i f tee n t h ( n i g h t 2 0 ) ( p< 0 , 0 I ) n i g h ts o f c I o z a p i n e a d m i n i s t rat i o n 
' as wel I as on the fifth night (night 25) of clozapine withdrawal 
( p<O I 05) . 
Latency to the First REM Period. The administration of 
clozapine had no significant effect upon the latency to the first 
REM period (F = 1,18; df 7,35; p>0,25) (Table 22). 
Latency to th~ S~ttind REM P~t(od. The administration of 
cloz~plne had no signlftcant effect upon the lat~ncy to the second 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Lat~hcy to the Thitd REM P~tiod. The administration of 
clo2apine had no significant effect upon the latency to the 
third REM period CF = I, 73; df 7,28; p<0,25). 
7. I .5 Sl~ep St~g~ tntid~hce 
Number of Aw~kenihgs. The administration of clozapine had 
no significant effect upon the number of awakenings during sleep 
( F = I , O 4 ; d f 7 , 3 5 ; p> O , 2 5 ) . C Tab I e 2 3 ) . 
Number of Stag~ 4 P~riods. The administration of clozapine 
had no significant effect upon the number of stage 4 periods 
during sleep CF= 1,33; df 7,35; p>0,25).CTable 23). 
Nu~b~r of Stag~ REM Peri6ds. The effects of the administra-
tion of clozapine upon the number of stage REM periods durin~ 
sleep are presented in Table 23 CF= 2,41; df 7,35; p<0,05). 
The Tukey HSD comparisons failed to reveal the direction of this 
significant finding. 
7. I .6 Sleep Cycle Dur~tion 
Duration of the First Sl~~P Cytle. The administration of 
clozapine had no significant effect upon the duration of the first 
sleep cycle CF= 0,85; df 7,35; p>0,25)(Table 24). 
D~r~tlon of the S~cond Sle~p Cfcle. The administration of 
clozapine had no significant effect upon the .duration of the 
second sleep cycle CF= 0,68; df 7,28; p>0,25)(Table 24). 
7.1.7 86dy Move~eht AttiVlty 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































movement activity have been analysed for the first three hours, 
the second three hours, the first six hours of the record as well 
as for the entire n.ight. 
Number of Body MoVem&~ts~ The effects of the administration 
of clozapine upon the number of body movements are presented in 
Table 25 (F = 2,42; df 7,35; p<0,05). The Tukey HSD comparisons 
failed to reveal the direction of this significant finding . 
. 
The within-night analyses revealed no significant differences for 
th e f i rs t th re e ho u rs C F = I , 9 4 ; d f 7 , 3 5 ; p< 0 , I 0 ) , the sec on d 
three hours CF= 1,50; df 7,35; p<0,25) as well as the first 
s i x h o u rs ( F = I , 8 I ; d f 7 , 3 5 ; p< 0 , I 0 ) o f t h e re co rd • 
Number of Body Mov&m&nts per Minute of Sleep. The effects 
of the administration of clozapine upon the number of body move-
ments/minute of sleep are presented in Table 25 and significartt 
findings are i I lustrated in Figure 12 (F = 2,50; df 7,35; p<0,05). 
The Tukey HSD comparisons failed to reveal the direction of this 
significant finding. 
Movement Time. The effects of the administration of clozapine 
upon movement time are presented in Table 25 (F = 3,19; df 7,35; 
p<0,05). The Tu key HSD comparisons fa i I ed to revea I the 
direction of this significant finding. 
The within-night analyses also revealed significant ~ifferences 
for the first three hours, second three hours as wel I as the fl-rst 
six hours of the record. The within-night analysis of the fitst 
thr&& hours yielded a significant variance ratio CF= 2,31; 
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The effects 6f the long-term ~dmlnistration of 
12,50mg clozapine. upon the mean number _of body 
move~~nts/mi.nu+e .of .sleep .over the la~oratory 




to reveal the direction of this significant finding. 
The within-night analysis of the ~et6nd thtee h60rs yielded a 
significant variance ratio CF= 3,06; df 7,35; p<0,05). The 
Tukey HSD comparisons indicated that the mean movement time on 
the third night (night 8) of clozapine administration was signi-
ficantly lower than the mean on the first night (night 21) of 
clozapine withdrawal Cp<0,05). 
The within-night analysis of the first six h6urs yielded a sign1-
ficant variance ratio CF= 2,49; df 7,35; p<0,05). However, 
the Tukey HSD comparisons failed to reveal the direction of this 
significant finding. 
7. I • 8 SI eep Log 
188 
The sleep log provided information regarding the quantity and 
.quality of the night's sleep, the mood shortly after awakening, 
psychological and physiological side-effects as well as the 
subjective assessment of the nature of the medication administered 
(Appendix 14). The procedure for scoring the sleep log is. 
described in section 5.5.5. 
in Tables 26, 27 and 28. 
The sleep log data are presented 
E~timated D0tatiori of Sleep Length (Question five). The 
effects of the administration of clozapine upon the estimated 
sleep duration are presented in Table 26 and significant findings 
are i 11 ustrated in Figure 13 (f = 3,01; df 4~20; p<0,05). The 
.Tukey HSD comparisons indicated that the mean estimated sleep 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































clozapine withdrawal than on the second five night period of 
ciozapine administration (p<0,05). 
Quality of.Sleep (Question six). The administration of 
clozapine had no significant effect upon the quality of sleep 
CF= 2,62; df 4,20; p<O,IO)(Table 26). 
Mood Shortly After Awakening (Question seven). The 
administration of clozapine had no significant effect upon the 
mood shortly after awakening (F = 2,03; df 4,20; p<0,25) 
(Table 26). 
Number of Side-Effects (Question ten). The effects of the 
administration of clozapine upon the number of side-effects 
reported are presented in Tabfe 26 and significant findings are 
i I lustrated in Figure 14 .(F = 5,26; df 4,20; p<0,01 ). 
191 
The Tukey HSD comparisons indicated that the number of side-effects 
reported increased dramatically on the mornings following the 
first five night period of clozapine administration and was 
followed by a progressive decline to baseline and withdrawal 
levels (Figure 14). The mean number of side-effects on the 
mornings fol lowing the first five night period of clozapine 
administration was significantly greater than the mean number on 
th e b a s e I i n e ( p< 0 , 0 I ) , th i rd f i ve n i g h t p e r i o d o f c I o z a p i n e 
administration (p<0,05) and withdrawal condition (p<0,01) . 
. The frequency of occurr~nce of individual side-effects are pre-
sented in Table 27. Side-~ffects ~uch as titedness, drowsiness 
and wanting to go ~ack to sleep were reported on base I ine and 
withdrawal conditions but increased markedly on the first five 
Table 27 The frequency of occurrence of individual side-effects 
during the long-term administration of 12,50mg 
c)ozapine. 
Experimental Base- Clozapine Administration C!ozaptne 
Condition Ii ne Withdrawal 
Side-Effects Nights Nights Nights Nights Nights 
Reported 1-5 6-10 I 1-15 16-20 21-25 
Dizzy 0 4 2 I I 
Nauseous 0 0 I 0 0 
Ti red 10 19 14 13 12 
Drowsy 10 17 15 12 13 
Exhausted 0 7· 3 4 5 
Feeling Faint 0 3 I 0 0 
Difficulty 
in writing 0 0 0 I 0 
Difficulty 
in talking 0 I I 0 0 
Mouth very 
dry I 9 I 3 I 
Mouth very 
moist I 3 I 3 0 
Want to go 
back to sleep 9 20 I I 9 6 
Fe It dizzy 
but fine when 
I lay down 0 I 0 0 0 
Felt dizzy 
even when 

























































Fi .. gure 14 , The effects of the long-term administration of 
.l2,,50mg c~6zaplne upon the me~n num~er 6f side-
effects rep·orted. , The mean .n·umber of side-· 
.effects reported significantly ·increased on the 
first five night p~riod (nights 6~10) of 
clozapine administration.· 
,193 
n\ght period of clozapine administration. 
P s y ch o I o g i ca I S i de - E f f e ct s CQ u es t i o n t we I v e ) . The subjects 
reported side-effects such as depression, apathy, tiredness, lack 
of vitality, resentfulness and the lack of mental and physical 
energy during the administration of clozapine (Table 28). 
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Drug Identification Rating (Question thirt~en). The effects 
of the administration of clozapine upon the drug identification 
rating scale are presented in Table 26 and significant findings 
are i 1 lustrated in Figure 15 (F = 5,86; df 4,20; p<0,01 ). 
The Tukey HSD comparisons indicated that the drug identification 
rating increased markedly on the mornings following the first 
five night period of clozapine administration. The values on 
the mornings following the second and third five night periods of 
clozapine administration remained elevated although not signifi-
cantly so. There was a dramatic reduction in the drug identifi-
cation rating when clozapine was withdrawn. The mean drug 
identification rating on the first five night period of clozapine 
administration was significantly greater than on the base I ine 
<p<0,05) or clozapine withdrawal Cp<0,01) periods. 
Stahf6rd Sleepih~ss St~le. The administration of clozapine 
had no significant effect upon the Stanford Sleepiness Scale 
(F = 2,39; df 4,20; p<O, 10) <Tab le 26). 
7.1 .9 Psychological A~~e~~~~nt 
The Bt[~f P~yth[~ft[t Ratlhg St~le. The administration of 
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FLgure 15 The effects .of the long-term ~dmin1str~tion of 
12,50mg clozaplne upo~ the mean drug identification 
ratih~. .Thi mean rating signific~nt)y· increased 
on the f i rs t f i v e n i. g h t · p e r i o d ( n Lg ht s 6- 1.0 ) of 
cloz~pine ~dministr~tion. · 
·19'6 
Rating Scale .(Table 2~). The dependent t test analysts fai le~ 
to identify a significant difference (~ =~0,42; df 5; p>0,05). 
The Taylor Manif~~t An~i~ty Scale. The administration of 
clozapine had no significant effect upon the Taylor Manifest 
Anxiety Scale <Table 29). The dependent t test analysis failed 
to identify a significant difference Ct =-1,41; df 5; p>0,05). 
7.1.10 Blood Parameters 
The administration of clozapine had no significant effect on 









The psychological assessment of the effects of 
the long-term administration of 12,50mg clozapine 
of 6 normal young adults (Means + S.E.) 
Pre- Post-
Experi menta I Experimental 
Condition Condition 
Psychiatric Rating Scale (mean 
18,67.::_0,33 18,83.::_0,54 
















Table 30 The effects of the long-term administration of 
l2,50mg clozapine upon the mean blood parameters 
of 6 normal young adults (Means+ S.E.) 
Pre- Post-







Mean number of white blood cells X 10 3/cubic millimeter 
clozapine 
group 7,73..:'.:_l,12 7,68..:'.:_2,74 0,04 5 >O, 05 
Mean number of red blood eel Is X 10 3/cubic centimeter 
clozapine 
group 
5,25..:'.:_0, 19 -0,28 









Mean corpuscular volume (cubic microns) 
clozapine 
group 86,67..:'.:_l,41 85,50..:'.:_2,08 0,76 
Mean corpuscular haemoglobin (mmg's) 
clozapine 
group 
28,83..:'.:_0,40 29,98..:'.:_0,77 -3,52 
5 > 0, 05 
5 >O ,O~ 
5 >0,05 
5 >O, 05 
5 >0,05· 
Mean corpuscular haemoglobin concentration (gm/IOOml) 
clozapine 
group 33,08..:'.:_0,69 34,28..:'.:_0,73 -5,72 5 >0,05 
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7.2 ·orscussi.on 
7.2. I R~~~a~ch ~t~~tegy 
The twenty five night single bl ind cross~over design employed in 
this second phase of the investigation was developed in order to 
determine the effects of the long-term administration of 12,50mg 
clozapine upon the sleep patterns of normal young adults. As a 
result of the many methodological inadequacies inherent in sleep 
research designs (section 3.0), the present study: 
Ci) comprised two adaptation nights to ensure that the 
subjects were adequately adapted to the sleep laboratory environ-
ment as well as to the experimenta/routine (section 3.1.1). 
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(ii) enabled the long-term ef ects of clozapine to be e_valua-
ted independently of any other drug thus avoiding any possible 
carry-over effects from one drug to the other (section 3.4). 
(iii) employed the single blind procedure as the experimenter 
was aware of the nature of the medication administered on each 
night of the investigation. 
(iv) was designed in ~uch a way as to permit the comparison 
between the effects of 25mg cloza~ine after three consecutive 
nights of administration with the effects of 12,50mg clozapine 
after the same duration of administration. 
(v) used subjects of a similar age group who were medically 
healthy (~ection 3.3}. 
(vi) employed precautionary measures such as blood analysis 
before the commencement and after the completion of the 
lnvestigation to ensure that the subjects particJpating in the 
study suffered no i I I effects after the long-term administration 
of 12,50mg clozapine. 
(vii) control led tor the duration of time which the subject 
was permitted to spend in bed and 
(viii) analysed smaller portions of the night's data 
(section 3.6). This procedure enabled changes in sleep patterns 
to be identified which would otherwise have remained undetected 
it only conventional analysis had been used. The within-night 
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analy5es of the ti rst and second three hours of the record; 
however, often produced non systematic and inconsistent data which 
resulted in difficulties in interpretation. 
A I imitation of the present study was once again the use ot a 
relatively smal I number of subjects. This was necessitated by 
th~ exorbitant cost of sleep research. However, the number of 
subjects used in the present investigation was wel I within the 
average number used in most sleep research programs. 
7.2.2 Tot~I Sleep Time 
The long-term administration of 12,50mg clozapine had no signifi-
cant effect upon the duration of total sleep time (Table 20). 
This finding is in marked contrast to the significant increase in 
total sleep time which occurred on the fitst and ~econd nights 
of clozapine administration .during the short-term investigation. 
This comparison should however be interpreted with caution as 
the first laboratory monitored night to be carried out in the 
present study, to det~rmine the effects of clozapine upon sleep 
parameters, was carried out on th~ third night of clozaplne 
administration. The evidence from the two s~udies combined 
susgests that the effect of clozapine administration upon sleep 
duration may be dose related. Research has yet to be 
carried out to ascertain whether the administration of 12,50mg 
clozapine wi I I enhance the sleep duration of insomniac subjects. 
Hartmann and Cravens ( 1973c-f) reported that the long-term. 
administration (60 days) of four drugs (amitriptyl ine 50mg/day, 
chlorpromazine 50mg/day, chloral hydrate 50mg/day and chlordiaz~-
poxide 50mg/day) significantly increased total sleep time in 
fourteen young healthy male adults despite the fact that an 
attempt was made to maintain a regular sleep schedule. The 
increases in total sleep time failed to reach statistical signi-
ficance after three to four weeks of administration. This 
finding suggests that the body developed a toletance to these 
drugs after chronic administration. Similarly the increase in 
total sleep time during the short-term administration of 
c+ozapine returned to baseline levels by the third night of 
administration. It should be noted, however, that the doses 
used in the Hartmann and Cravens (1973c-f) studies were double 
those used in the short-term clozapine investigation. 
7.2.3 M~jdt SI~~~ St~ges 
Although the long-term administration of 12,50mg clozapine had 
no significant effect upon the percentage time spent awake, the . . 
within-night analyses of the second three hours of the record 
revealed that the num~er of minutes spent awake was significantly 
reduced on the third and eleventh n.ights of clozapine 
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administration. This evidence provides some confirmation of 
the assumption that clozaplne has sleep inducing properties 
<Ruch et al 1976; Hemphi I I et al 1974, 1975). 
The analysis of the data of the entire night as wel I as the 
within-night analyses of the second three hours and first six 
hours of the record revealed that the administration of clozapine 
significantly reduced stage I sleep (section 7.1 .2). Stage I 
sleep has been reported to occur " .•• most often in the transition 
from wakefulness to other sleep stages or fol lowing body movemehts 
during sleep" (Rechtschaffen and Kales 1968, p.5). It is tenta-
tively suggested that the significant reduction in wakefulness and 
body movement activity resulted in the significant decrement in 
stage I sleep. The large individual differences, inherent in 
the within-night analyses data, resulted in the first and second 
base I ine nights differing significantly from one another during 
the second three hours of the record. 
Although the long-term administration of 12,50mg clozapine had 
no significant effect upon the percentage time spent in stage 2 
sleep, the within-night analysis of the second three hours of the 
record revealed that the num~er of minutes spent in stage 2 sleep 
was significantly increased on the eleventh night of clozapine 
administration. A tentative explanation for this finding appears 
to be that the increase in stage 2 sleep during the ~econd· three 
hours of the eleventh night of clozapine administration occurred 
as a compensatory response for the decrease in stage awake and 
stage I sleep on the s~me night. Stage 2 forms the bulk of 
sleep and It [s the~efore not surprising that stage 2 sleep 
compensated for the decrease in stage awake and stage 1 sleep. 
Two results in this investigation require particular attention: 
the first, the finding that the administration of l2,50mg 
clozapine had no significant effect upon stage 4 sleep; the 
second, the absence of a REM rebound despite the fact that a 
significant reduction in stage REM sleep occurred. 
In sharp contrast to the marked decrease in stage 4 sleep during 
the short-term administration of 25mg clozapine (Figure 8), the 
long-term administration of 12,50mg clozapine was found to have 
no significant effect upon stage 4 sleep. This long-term 
investigation included a laboratory recording night on the third 
night of clozapine administration so as to enable a comparison 
with the short-term investigation to be made. The evidence from 
the two studies combined suggests that the effects of clozapine 
upon sleep parameters are dose related. Evidence for this 
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assumption is provided by the finding that low doses of chlorpro-
mazine increased REM sleep, high doses suppressed REM sleep and 
intermediate doses had no significant effect (Lewis and Evans 1969). 
The second important point raised by the present investigation 
was a significant reduction in stage REM sleep during the long-
term administration of clozapine. This effect, however, barely 
reached statistical significance (Table 20). Moreover, the 
Tukey HSD comparisons failed to identify the direction of this 
finding (section 7.12). In addition, the abrupt withdrawal of 
clozapine, after fifteen nights of c~nsecutive administration, 
failed to result in a significant rebound of stage REM sleep. 
However, there was a sl.ight tendency for the percentage of time 
spent in stage REM sleep to be elevated above base I ine levels 
(Figure 11),but these values were wel I below the normal values 
associated with the rebound of stage REM sleep 1 (Oswald 1970(c)). 
These findings have important therapeutic implications for the 
treatment of insomnia as many of the hypnotic agents presently 
prescribed have been found to produce a REM rebound upon with-
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drawal after chronic administration (section 4.3). These inc I ude 
the barbiturates (Oswald and Priest 1965), nitrazepam (Oswald and 
Priest 1965; Haider and Oswald 1971 ), glutethimide and methy-
prylone (Kales et al 1970(e)), tricyclic antidepressants (Hartmann 
and Cravens 1973(c);· Toyoda 1964; Ritvo et al 1967; Chernik 
et al 1973(b)) and the monoamine oxidase inhibitors (Wyatt et al 
1969). Freemon (1972) reported that the " .•. REM rebound fqllow:-
ing the chronic use of a drug is one of the commonest causes of 
sleep disturbance" (Freemon 1972, p.127). This REM rebound is 
often accompanied by difficulty in falling asleep, an increased 
vividness in REM mentation as wel I as the occurrence of nightmares. 
7.2.4 REM Indices 
The long-term administration of 12,50mg clozapine significantly 
increased% moti I ity Cp<0,05)(Table 21 ), but had no systematic 
effect upon any of the other REM indices. This finding is in 
sharp contrast to the marked increase in % moti I ity Cp<0,001) 
and the density/minute of REM sleep Cp<0,001) as well as the 
increase in burst length Cp<0,05) during the short-term administra-
tion of 25mg clozaplne (Table 10). Two explanations for this 
1The percentage of time spent in stage REM sleep during the 
n.i ght Increases f rem 20.-25% to 45-50%. 
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findin9 are possible. 
The long-term administration of 12,50mg clozapine significantly 
reduced the p~rcentage of time spent in stage REM sleep (Table 
20) but had no effect upon the mean burst length. The duration 
of burst activity thus occupied a greater proportion of stage REM 
sleep and hence an increased% motility'. An alternative ex-
planation, for the I imited effect of the administration of 12,50mg 
clozaplne upon indices of stage REM sleep, may be that clozapine 
no longer exerted an antipsychotic effect at this dosage. It 
has been suggested that the remission of psychotic symptoms during 
the administration of clozapine appear to be associated with an 
increase in rapid eye movement activity (Blum and Girke 1973). 
The evidence suggests that the administration of low doses of 
clozapine (12,50mg/night) has I ittle or no effect upon rapid eye 
movement activity (Ta.ble 21 ). 
7.2.5 Sleep Stage Latencies 
The finding that the long-term ad~lnistration of 12,50mg clozapine 
did not significantly reduce the latency to stage I or stage 2 
sl~ep indicates that the administration of clozapine did not 
result in subjects falling asleep more rapidly. This finding 
is not surprising as the subjects had exceptionally short stage 
(5,33 minutes) and stage 2 (10 minutes) latencies under base I ine 
conditions. 
However, Hartmann and Cravens Cl973(b)(e)) reported that the 
long-term administration of 50mg chloral hydrate and 0,5mg reserpine 
1% moti 11ty is defined as the p~rcentage of REM periods 
occupied by bursts (Aserinsky 1971). 
, 
significantly reduced the latency to stage I sleep in normal 
young adults. lt should be noted, however, that the base I ine 
latency to stage I sleep was eleven minutes in the Hartmann and 
Cravens! (]973(b)(~)) s.tudy compared to the 5,33 minutes in the 
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present study. There was thus a greater proba~i I ity of a signi-
f icant reduction of stage latency in the Hartmann and Cravens' 
study than in the present investigation. The higher dose used 
in the Hartmann and Cravens' study may also have been partly 
responsible for the significant reduction in the latency to 
stage I sleep. 
The finding that the latency to stage 4 sleep was significantly 
increased on the first night of clozapine withdrawal is more 
difficult to interpret. It is tentatively suggested that qn 
increase in the duration of the first stage I, stage 2 or stage 3 
period occurred or alternatively minor increases in al I three 
sleep stages culminated in a significant increase in the latency 
to stage 4 sleep. The absence of statistical confirmation 
raises some doubt as to the validity of this explanation. 
7.2.6 Sl~ep Stag~ lhtid~hce 
The long-term administration of 12,50mg clozapine had no signi-
ficant effect upon the number of awakenings and stage 4 periods. 
This f lnding ls ln harmony with those of Hartmann and Cravens 
l1973lb)(c) who reported that the long-term administration of 
50mg amitriptyl [ne and 0,5mg reserpine had no systematic effect 
upon the number of awakenings in normal young adults. However, 
the long-term administration of clozapine had a significant 
effect upon the numb~r of stage REM periods Cp<0,05)(Table 23). 
The Tukey HSD comparisons failed to i dent I fy the di recti.on of 
this finding. There was a tendency, however, for the number of 
stage REM periods to increase on the first night of clozapine 
withdrawal (Table 23}. (t. appears I ikely therefore that this 
increase in the.number of stage REM peri.ods upon the withdrawa·I 
of clozapine may be some manifestation of the REM rebound 
phenomenon as there was a significant decrease in the percentage 
of time spent in stage REM sleep during the administration of 
clozapine (Figure l I). The significance of this finding is 
questionable as no significant increase in stage REM sleep 
(rebound) occurred during the withdrawal of clozapine. Hartmann 
and Cravens Cl973(b)(e) reported that the long-term administra-
tion of chloral hydrate had no systematic effect upon the number 
of stage REM periods whereas reserpine significantly increased 
the number of stage REM periods during drug administration. 
7.2.7 Sleep Cycle Dtir~tion 
The long-term administration of 12,50mg clozapine appears to 
have had I ittle or no effect upon the organisation of laboratory 
sleep as the duration from the end of one REM period to the end 
of the next remained constant. Clozapine thus appears to 
resemble chloral hydrate in this respect as the long-term admini-
stration of chloral hydrate had no systematic effect upon the 
duration of the sleep cycles in normal young a.dults (Hartmann and 
Cravens 1973(e). The long-term administration of amitripty)ine 
increases (Hartmann and Cravens (1973(c)), whereas reserpine 
decreases (Hartmann and Cravens Cl973(b)) the duration of the 
sleep cycles. 
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7.2.8 Body M6vem~ht Aetivlty 
The long-term administration of 12,50mg clozapine significantly 
reduced the number of body movements Cp<0,05), the number of 
body movements/minute of sleep Cp<0,05)(Figure 12) as well as 
movement time Cp<0,05)(Table 25). This effect was not as 
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dramatic as the m~rked decrease in the number of body movements 
Cp<0,01) and the number of body movements/minute of sleep (p<0,001) 
which occurred during the short-term administration of 25mg 
clozapine. The evidence from the two studies combined provides 
further support for the assumption that the effects of clozapine 
upon sleep parameters are dose related. The administration of 
clozapine thus reduces the number of body movements during sleep. 
This finding may have important therapeutic implications for the 
treatment of insomnia, since it implies that sleep was more_ 
restful (Oswald 1970(c); Hartmann and Cravens 1973(b)). 
C I oz a p i n e th us appears to have a s i mi I a r e f f e ct upon body move -
ment activity as chlordiazepoxide C50mg/night) which significantly 
reduced the number of body movements during long-term administra-
tion in normal youn-g adults (Hartmann and Cravens 1973(f)). The 
long-term administration of 50mg amitriptyl ine and chloral 
hydrate have no systematic effect upon the .number of body move-
ments during sleep and clozapine and chlordiazepoxide thus appear 
to be superior to these drugs in that they appear to produce a 
more restful sleep (Oswald 1970(c); Hartmann and Cravens 1973(b)). 
7.2.9 Blood Parameters 
The analyses of :blood parameters were carried out as a precautionary 
-
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measure as the adminlstratlon of large doses .of .cJozapine has 
been associated with the occurrence of agranulocytosls in clinical 
patients <Goodson 1976-personal communicatioh)(section 5·.3.9). 
The long-term administration of 12,50mg clozaplne had no signifi-
cant effect upon any of the blood parameters monitored. 
7.2.Ja Psyc~ological A~~~~~~~nt 
Sleep Log. The !Ong-term administration of 12,50mg clozapine 
had no systematic effect upon the estimated duration of sleep 
length (Table 26). The estimated duration of sleep length was, 
however, significantly redu~ed on the five night p~rlod of 
clozapine withdrawal (Figure 13). This finding appears to be 
consistent with the findings of Hartmann and Cravens· i·l~73(a)) 
who reported that in a study of asimilar nature 11 ... the nights 
after discontinuation of medication, especially several nights 
thereafter, were sometimes associated with feeling better, with 
feeling they were 'over the hump', and nearing the end of one 
more drug study period" (Hartmann and Cravens 1973(a) p.165). 
Thus here, the decrease in the estimation of sleep duration could 
have been associated with the excitement of completing the sleep 
research prog~am and receiving the substantial monetary 
compensation. 
The number of side-effects reported increased markedly on the 
morning fol lowing the first f.lve n.ight perio.d of .clozapine 
administration (Figure 14). The most prominent side-effects to 
be reported were tho~e w~ich characterised sleepiness ~uch as 
t'lredness, drowsiness, exhaustion and wanti~g to. go back to sleep 
<Table 27). Thi~ finding appeajs to b~ consistent with the 
finding of Hemphi 11 et .al .(1975) that " ••. sleepiness coloured 
the patient's response to the drugl for the f (rst few days and 
masked other effects" CHemphi I I et al 1975, p.2122). It is 
of interest to note that although the Stanford Sleepiness Scale 
revealed an increase in sleeplness during the flrst five night 
period of clozapine admlnistration (Table 26), this finding did 
' not r~ach statistical significance. It appears I iekly therefore 
that the Stanford Sleepiness Scale was a less sensitive index of 
sleepiness than the sleep log. 
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The subjects also reported side-effects such as depresslon, apathy, 
tiredness, lack of vitality, resentfulness and the lack of 
physical and mental energy (Table 28). Having drawn attention to 
these side-effects, it should be noted that 12,50mg clozapine was 
administered t6 hot~al subjects with h~althy sleeping habits for 
fifteen consecutive nights. Hartmann and Cravens Cl973(a)) 
reported that 11 ••• our studies convinced us that normal human 
subjects cannot tolerate a higher2 dose on a continuing basis .•. 
. • . • although 50mg/day 2 is a low dose in clinical terms, it is 
apparently the maximum dose tolerable for continued use by normal 
subjects" <Hartmann and Cravens l973(a) p.161). The evidence 
suggests that the side-effects reported in the present study may 
not occur ih in~6~ntac subjects as these subjects hav~ peculiar 
sleeping habits. However, further research on Insomniac subjects 
is required to provide the necessary ~onfirmatlon of this hypothesis. 
The drug identification rating increased markedly on the first 
five night period of clozapine administration <Figure 15). 
1
The dosage of clozapine varied between 100mg-300mg/day. 
2chlorpromazlne (50mg/day). 
This 
finding indicated that the subjects were ab!A to correctly 
assess the nature of the medication Ci.e.c1ozapine) on these 
five nights. The data, however, indicated that the subjects 
were far less accurate in their assessment of the nature of 
the medication on the second and third five night periods of 
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clozapine administration (Table 26). This finding is consistent 
with the finding of Hemphill et al (1975) that " ..• tolerance and 
norma I sleep patterns were estab Ii shed after a week" CHemph i 11 
et al 1975 p.2122). The evidence favours the conclusion that 
a rapid tolerance to clozapine may develop. This finding may 
turn out to be the major limitation in the use of clozapine as 
an hypnotic agent over an extended period of time. Many 
hypnotic drugs have been found to become relatively ineffective 
after chronic administration (Johns 1975; Kales and Kales 1973) 
and the present finding appears to indicate that further research 
on insomniac subjects is required to determine whether the admini-
stration of 12,50mg c16zapine wi I I enhance sleep duration over an 
extended period of time. 
P~ycholdgic~l As~~~~~~nt 
The long-term administration of 12,50mg clozapine had no signifi-
cant effect upon the Brief Psychiatric Rating or the Taylor 
Manifest Anxiety scales and its effect was thus restricted to its 
s I eep inducing proper-ties. This finding is consistent with the 
finding that '' ••. there was no evidence in any case that clozaplne 
had a thymoleptic effect, or was a mood elevator or a direct 
psychostimulantll (Hemphill et al 1975 p.2123). 
In summary, the evidence suggests that the long-term ~dministration 
of l2,50mg clozapine may have important therapeutic imp I I cations 
for the treatment of insomnia. This conclusion was supported 
by the fol lowing findings: Ci) The number of minutes spent aw~ke 
.during the ~econd three hours of the record on the third and 
eleventh nights of clo2apine administration was significantly 
reduced. Ci i) The percentage of time spent in stage I sleep was 
significantly reduced. Ci ii) The number of body movements which 
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occurred during sleep was significantly reduced. (iv) The number 
of body movements/minute of sleep was significantly reduced. 
(v) Movement time was sigriificantly decreased and Cvi) There was 
no evidence of a stage REM rebound, despite the fact that a smal 
but significant reduction in the percentage of time spent in 
stage REM sleep occurred, during the administration of clozapine. 
The finding that a rapid tolerance to clozapine may develop, may 
turn out to be the major I imitation in the possible use of 
clozapine as an hypnotic agent over an extended period of time. 
Further research on insomniac subjects should however be carried 
out to determine whether the administration of 12,50mg clozaplne 
wi I I enhance sleep duration over an extended period of time. 
8.0 THE REM DREAM RECALL INVESTIGATlON 
8. I Res u Its 
8. I. I Dream Repd~t R~ti~S St~les 
The effects of the administration of clozapine and placebo upon 
the dream report rating scales are presented in Table 31. In 
al I but one instance (Active Participation), 'no significant 
differences were obtained. 
'The analysis of variance of the Active Participation Scale 
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yielded a significant variance ratio <F = 8,16; df 2,10; p<0,01). 
The Tukey HSD comparisons indicated that the Active Participation 
rating decreased on the withdrawal of clozapine. The mean 
Active Participation rating was significantly lower on the recor-
ded clozapine withdrawal night (night 24) than the mean on the 
rec o rd e d b as e I i n e n i g h t ( n i g ht I 0 ) ( p< 0 , 0 5 ) a n d the rec o rd e d 
clozapine administration night (night 17)(p<0,05). 
8.1.2 Sleep Log Indices 
The administration of clozapine and placebo had no significant 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































8.2. I Re~~arch St~ategy 
This study comprised a four night single blind, cross-over design. 
Each of the four re~ord1ng nights were within a space of six days 
of one another. This intermediate period permitted the subjects 
to recover from any possible REM rebound incurred by laboratory 
awakenings (Hartmann and Cravens 1973(a). The major I imitation 
of the present study was that any immediate withdrawal effect, 
which might have occurred within the spacA of five days, would 
have remained undetected. It appears I ikely however that only 
I imited withdrawal effects occurred as the administration of 
12,50mg clozapine had no systematic effect upon REM dream content 
as measured by the standard rating scales used <Table 31) .. 
Only one adaptation night was effected as al I of the subjects 
participating in the present phase of the investigation, had taken 
part in a previous sleep study in this series of experiments. 
8.2.2 Dream Rating Scales 
The short-term administration of 12,50mg clozapine had no system-
atic effect upon REM dream content. This finding appears to be 
consistent with the previous finding that the administration of 
12,50mg clozapine had no systematic effect upon the indices of 
stage REM sleep (Table 21). 
"There is evidence that even if individual EM's do not 
represent the dreamer tscanning' his world, profusion 
of EM's is associated with experiences in which the 
dreamer Is an active pa~ticipant, rather than thinking, 
reflecting, or passively observing events" 
(Firth 1974 p.547). 
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The present finding appears to be in marked contrast to most 
hypnotic agents which have been found to produce an increased 
vividness in REM mentation on withdrawal characterised by the 
occurrence of nightmares (Kales et al 1969(b), 1974; Oswald 
and Priest 1965). This evidence further indicates that clozapine 
Cl2,50mg) may have an important role to play in the treatment of 
insomnia, but again, further research on insomniac subjects is 
necessary to substantiate this hypothesis. 
8.2.3 Sleep Log Indices 
The short-term administration of 12,50mg clozapine had no signifi-
cant effect upon the qua I ity arid quantity of the subject's dream 
experiences recalled upon awakening at home. This additional 
information proved to be invaluable as discrepancies between 
laboratory REM dream reports and dream experiences recalled at 
home, have been reported to occur (Weisz and Foulkes 1970). 
Hal I and Van de Castle ( 1966) concluded that: 
Dreams reported at home differed in content from dreams 
reported after REM period awakenings in the laboratory. 
The major difference was that of dramatic quality. 
Home dreams tended to be more dramatic, laboratory 
dreams more prosaic. 
<Hall and Van de Castle 1966 p.48). 
Thus, in the present study two I ines of evidence, namely the 
laboratory REM dream reports and dream experiences recalled at 
home, have been brought together to determine the effects of the 
short-term administration of 12,50mg clozapine upon dream content. 
The findings of the present study thus provide further confirma-
tion for the conclusion that the short-term administration of 
12,50mg clozapine has no signif1cant effect upon the REM dream 
content. 
9.0 CONCLUSlONS 
The findings of the short-term, long-term and REM dream recal I 
investigations have been discussed in the relevant sections and 
in this section the major findings are high I ighted again and the 
results from the numerous indices are synthesised. 
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A major aim of the present study was an attempt to assess the 
effects of the short-term administration of 25mg clozapine upon 
the ~leep patterns of normal young adults. This investigation 
revealed that the short-term administration of clozapine markedly 
suppressed stage 4 sleep which remained at low levels even when 
clozapine had been withdrawn. It is tentatively suggested that 
the decrease in stage 4 sleep was produced in such a mannar as 
not to permit homeostatic restoration within the first two days 
of clozapine withdrawal. The significant reduction in stage 4 
sleep appears to have important therapeutic imp) ications for the 
treatment of disorders of slow wave sleep. 
In addition, the short-term administration of 25mg clozapine 
appears to have important therapeutic imp I ications for the treat-
ment of insomnia. This conclusion was supported by the following 
findings: (i) Total sleep time was significantly increased on the 
first and second nights of administration despite the fact that an 
attempt was made to control for the time spent in bed. (ii) The 
number of body movements was significantly reduced on al I three 
nights of clozapine administration. (iii) The number of body 
movements/minute of sleep was significantly reduced on al I three 
nights of clozapine administration. (iv) The short-term 
admlnlstration and withdrawal of 25mg clozapine/night had no 
significant effect upon stage REM sleep. 
However, the indices of stage REM sleep were significantly 
affected. The mean burst length, the density/minute REM sleep 
and% moti I ity were significantly Increased on the third night 
of clozap1ne administration and this increase persisted on the 
first night of clozapine withdrawal. In addition, the total 
number of bursts and the number of bursts/REM period increased 
significantly on the first night of clozapine withdrawal. It 
was tentatively suggested that these findings may have. reflected 
the antipsychotic properties of clozapine (Blum and G1rke 1974). 
Finally, numerous psychological and physiological side-effects 
were reported and these findings may represent a major I 1m1tat1on 
of the possible use of clozapine as an hypnotic agent. 
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The second major aim of the present study was an attempt to 
determine the effects of the short-term administration of a placebo 
upon the sleep patterns of normal young adults. Controversy 
exists in the I iterature at present as to whether the administra-
tion of placebo influences sleep parameters (Davis and Hartmann 
1973 (a)(b); Zung 1973; Adam et al 1975, 1976). The present 
investigation revealed that the administration of placebo had no 
systematic effect upon any of the monitored sleep parameters. 
This finding, however, does not appear to hold true for psycho-
logical parameters as the administration of placebo significantly 
increased the subjective estimation of drowsiness on the morning 
following the second night of administration. 
The third major aim of the present study was to determine the 
effects of the long-term administration of 12,50mg clozapine 
upon the sleep patterns of normal young adults. The evidence 
from this experiment suggested that clozapine may have important 
therapeutic implications for the treatment of insomnia. This 
conclusion was supported by the fol lowing findings: ( i ) The 
number of minutes spent awake during the second three hours of 
the record on the third and eleventh nights of clozapine admini-
stration was significantly reduced. (ii) The percentage of time 
spent in stage I sleep was significantly reduced. (iii) The 
number of body movements which occurred during sleep was signifi-
cantly reduced. (iv) The number of body movements/minute of 
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sleep was significantly reduced. (v) Movement time was signifi-
cantly decreased and (vi) There was no evidence of a stage f3EM 
rebound, despite the fact that a smal I but significant reduction 
in the percentage of time spent in stage REM sleep occurred during 
the administration of clozapine. 
There was some evidence, however, that indicated that a rapid 
tolerance to clozapine may develop. This finding may prove to 
be the major I imitation in the possible use of c)ozapine as an 
hypnotic agent over an extended period of time as many hypnotic 
drugs have been found to become relatively ineffective after chronic 
administration (Johns 1975, Kales and Kales 1973). The present 
findings should be validated and extended on insomniac subjects to 
determine whether the administration of 12,50mg cl6zapine would 
enhance sleep duration over an extended period of time. 
The fourth major aim of the present study was an attempt to explore 
the effects of the short-term administration of 12,50mg clozapine 
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upon REM dream content. The withdrawal of 12,50mg clozapine 
after three nights of consecutive administration was found to 
have no systematic effect upon the REM dream content. This 
finding was in marked contrast to most hypnotic agents which 
have been found to produce an increased vividness in REM menta-
tion upon withdrawal (Kales et al 1973). This increased 
vividness has often been associated with the occurrence of night-
mares (Kales et al 1969(b), 1974; Oswald and Priest 1965; 
Hartmann 1973(a)). This finding provides further confirmation 
of the previous assumption that clozapine may have important 
therapeutic implications for the treatment of insomnia. 
In the present study a start has been made in an attempt to deter-
mine the effects of clozapine upon the sleep patterns and REM 
dream content of normal young adults. Kales and Kales (1975) 
have aptly portrayed the importance of rigorous research strategies 
in the evaluation of hypnotic drugs before they are placed on the 
medical market. 
11 Insomnia is one of the most common symptoms treated 
by the physician, and pharmacologic agents are the 
most frequent method of treatment. Because of a 
number of shortcomings in the evaluation and promo-
tion of hypnotic drugs, the physician is often 
provided insufficient and misleading information 
resulting in a general misuse of these drugs". 
(Kales and Kales 1975 p.826). 
The present study employed a multiplicity of measures including 
sleep stage percentages, indices of stage REM sleep, sleep stage 
tncidence, sleep stage latencies, sleep cycle duration, body 
movement indices as wel I as the assessment of psychological and 
physiological side-effects. This study required a total of 
2190 hours of recording ov0r a total of 219 nights. This 
comprehensive assessment of the effects of clozapine upon the 
sleep patterns of normal young adults indicates that clozapine, 
in addition to its proposed wide variety of uses, may be of use 
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2 Activation Deactivation Adjective Check List 
3 Brief Psychiatric Rating Scale 
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APPENDIX I 
TAYLOR MANIFEST ANXIETY SCALE 
do not ti re quickly 
2 am troubled by attacks of nausea 
3 believe I am more nervous than most others 
4 have very few headaches 
5 work under a great deal of tension 
6 cannot keep my mind on one thing 
7 worry over money and business 
8 I frequently notice my hand shakes when I 
try to do something 
9 blush no more often than others 
10 have diarrhoea once a month or more 
I I worry quite a bit over possible misfortunes 
12 practically never blush 
13 am often afraid that I am going to blush 
14 have nightmares every few nights 
15 My hands and feet are usually warm enough 
16 I sweat very easily even on cool days 
17 Sometimes when embarrassed, I break out in 
a sweat which annoys me greatly 
18 hardly ever notice my heart pounding and 
am seldom short of breath 
19 feel hungry almost al I the time 
20 am very seldom troubled by constipation 
21 have a great deal of stomach trouble 
22 have had periods in which I lost sleep 
over worry 
23 My sleep is fitful and disturbed 
24 I dream frequently about things that are 
best kept to myself 
25 am eas i I y embarrassed 
26 am more sensitive than most other people 
27 frequently find myself worrying about 
something 
28 l wish l could be as happy as others 
seem to be 
29 am usually calm and not easily upset 
30 cry easl ly 
31 feel anxiety about something or someone 
almost al I the time 
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32 l am happy most of the time 
33 It makes me nervous to have to wait 
34 I have periods of such great restlessness 
that I cannot sit long in a chair 
35 Sometimes I become so ~xcited that I find 
it hard to get to sleep 
36 I have sometimes felt that difficulties 
were pi I ing up so high that I could not 
overcome them 
37 I must admit that I have at times been 
worried beyond reason over something that 
really did not matter 
38 
39 
have very few fears compared to my friends 
hav~ been afraid of things or people that 
know could not hurt me 
40 certainly feel useless at times 
41 find it hard to keep my mind on a task 
or job 
42 am usually self-conscious 
43 am inclined to take things ha rd 
44 am a high-strung person 
45 Life is a strain for me much of the 
time 
46 At times I think I am no good at al I 
47 I am certainly lacking in self-confidence 
48 I sometimes feel that I am about to go 
to pieces 
49 I shrink from facing a crisis of 
difficulty 




ACTIVATION DEACTIVATION ADJECTIVE CHECKLIST 
Name Date and Time 
(Please include A.M. or P.M.) 
Each of the words on the next sheet describes feelings or mood. 
Please use the I ist to describe your feelings ·~t this ~o~ent. 
It the word definitely describes how you feel at the moment you 
read it, circle the double check Cvv) to the right of the word. 
For example, if the word is, relaxed, and you are definitely 
feeling relaxed at the moment, circle the double vv as follows: 
relaxed fj v ? no. 
This means you definit~ly f~el ~elaxed at the m6~ent. 
If the word only slightly applies to your feelings at the 
moment, circle the single check as follows: 
relaxed vv G) ? no. 
This means you feel slightly relaxed at the moment. 
If the word is not clear to you or you cannot decide whether or 
not it a~plies to your feelings at the moment, circle the 
question mark as to11ows: relaxed vv v CD no. 
This means you cannot decide whether you are relaxed or not. 
If you clearly 
at the moment, 
relaxed vv v 
This means you 
decide the word does not apply to your feelings 
circle the no as follows: 
? §. 
are definit~ly not relaxed at the ~o~ent. 
Work rapidly. Your first reaction is best. Work down the 
first column, then go on to the next. Please mark all words. 
This should take only a few minutes. 
-Now please turn the page and begin working-
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@ v ? no definitely feel 
vv 0 ? no feel sli.ghtly 
vv v 0 no cannot decide 
vv v ? § definitely do not feel 
carefree vv v ? no aroused vv v ? no 
serious vv v ? no fearful vv v ? no 
peppy vv v ? no Ii ve I y vv v ? no 
pleased vv v ? no st i I I vv v ? no 
placid vv v ? no self-centered vv v ? no 
leisurely vv v ? no wide-awake vv v ? no 
sleepy vv v ? no skeptical vv v ? no 
jittery vv v ? no activated vv v ? no 
intense vv v ? no sad vv v ? no 
grouchy vv v ? no ful I-of-pep vv v ? no 
energetic vv v ? no affectionate vv v ? no 
egotistic vv v ? no quiet vv v ? no 
calm vv v ? no concentrating vv v ? no 
suspicious vv v ? no sluggish vv v ? no 
ti red vv v ? no overjoyed vv v ? no 
regretful vv v ? no quick vv v ? no 
stirred up vv v ? no nonchalant vv v ? no 
warm-hearted vv v ? no quiescent vv v ? no 
vigorous vv v ? no clutched-up vv v ? no 
engaged-in-thought vv v ? no Wakeful vv v ? no 
at rest vv v ? no rebe I I i ous vv v ? no 
elated vv v ? no active vv v ? no 
drowsy vv .v ? no blue vv v ? no 
witty vv v ? no def lant vv v ? no 
INSTRUCTIONS 
APPENDIX 3 
BRIEF PSYCHIATRIC RATING SCALE 
tOveral I and Gorham) 
Insert General Scoring Sheet and Code 01 under 
Sheet .Number. -
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This form consists of 18 symptom constructs, each 
to be rated on a 7-point scale of severity ranging 
from "Not present" to "Extremely severe". It a 
specific symptom is not rated, mark "O" =Not 
Assessed. 
Mark the column headed by the term which best 
describes the patient's present condition. 
USE A N0.2 LEAD PENCIL. BE SURE TO MAKE MARKS HEAVY AND DARK. 
ERASE COMPLETELY ANY MARKS YOU WISH TO CHANGE. 
0 = Not assessed 
I .. Not present 
2 Very Mild 









Mark on right half of ~taring ~h~et on ~bw sp~tified 
Row 
No. 








De g re e o f co n c e r n o v e r p re s e n t b o d i I y h e a I t h . -t 
Rate the degree to which physical health is 
perceived as a problem by the patient, whether 
complaints have a reali.stic basis or not. 
Worry, fear, or over-concern for present or 2 
future. Rate solely on the basis of verbal 
repo~t of p~tient's own subjective experiences. 
Do not infer anxiety from physical signs or 
from neurotic defense mechanisms. 
Deficiency in relating to the interviewer and 
to the interviewer situation. Rate only the 
degree to which the patient gives the 
impression of fai I ing to be In emotional con-
tact with other people- In the interview 
situation. 
Degree to which the thought processes are 
confused, .disconnected 6r disorganized. Rate 
on the basis of Integration of the verbal 
products of the patient; do not rate on the 
.basis of patient's subjective impression of 













Over-concern or remorse for past behavior. 
Rate on the basis of the patient's subjective 
experiences of gui It as evidenced by verbal 
report with appropriate affect; do not infer 
gui It feelings from depression, anxiety or 
neurotic de1enses. 
Physical and motor manifestations of tension, 
"nervousness", and heightened activation 
level. Tension should be rated solely on 
the basis of physical signs and motor 
behavior and not on the basis of subjective 
experiences of tension reported by the patient. 
Unusual and unnatural motor behavior, the type 
of motor behavior which causes certain mental 
patients to stand out in a crowd of normal 
people. Rate only abnormality of movements; 
do not rate simple heightened motor activity 
he re. 
Exaggerated self-opinion, conviction of unusual 
abi I ity or powers. Rate only on the basis of 
patient's statements about himself or self-in-
relation-to-others, not on the basis of his 
demeanor in the interview situation. 
Despondency in mood, sadness. Rate only de-, 
gree of despondency; do not rate on the basis 
of inferences concerning depression based upon 
general retardation and somatic complaints. 
Animosity, contempt, bel I igerence, disdain for 
other people outside the interview situation. 
Rate solely on the basis of the verbal report 
of feelings and actions of the patient toward 
others; do not infer hosti I ity from neurotic 
defenses, anxiety nor somatic complaints. 








II.SUSPICIOUS- Belief (delusional or otherwise) that others II 
NESS have now, or have had in the past, malicious 
or discriminatory intent toward the patient. 
Oh the basis of verbal report, rate only those 
s~spicions which are currently held whether 




Perceptions without normal external stimulus 
correspondence. Rate only those experiences 
which are reported to have occurred within 
the last week and which are described as 
distinctly different from the thought and 




.STANFORD SLEEPINESS SCALE 
Please record the scale value of the statement which best 
describes your state of sleepiness. 
I. Feeling active and vital; alert, wide awake. 
2. Functioning at a high level, but not at peak; 
able to concentrate. 
3. Relaxed; awake; not at f u I I alertness; responsive. 
4 . A Ii tt I e foggy; not at peak; Jet down. 
5. Fogginess; beginning to lose interest 
awake; slowed down. 
6. Sleepiness; prefer to be lying down; 
woozy. 






i n remaining 
fighting sleep; 
lost struggle to 
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APPENDlX 5 
LARSON INTERVIEW SCHEDULE 
through your mind just What before I cal led you? 
~ 
(If something) Would you tell 
me about it? (Spontaneous 
C I f nothing, don't 
or don't know 1 remember, 
Report) 
~ 
Was there any visual imagery? Would you think for a moment 
~ 
or so and see if anything comes 
back to you? i 
(If yes) Would 
i~~ please ~cribe 
At the time you had 
these images, did 
you fee I you were 
really seeing them 
protrayed, or were 
you aware that it 
was just a mental · 
image passing 
through your mind? 
(i.e., did it seem 
real, or did it 
real lyseem to be 
happening?) i 





You may go 
back to 
sleep now. 
Can you remember 
anything now? 
~ 
(If something) (If nothing) 
l 
OK, would you say that you felt 
there was a mental experience 
but you forgot it, or did it seem 
that there just wasn't anything at 
al I to recal I? i 
Is there anything else? 
i 
OK, thank you, you may go back to 
sleep now. 
OK, thank you, you may 
go back to sleep now. 
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0 - - No re ca I I 
I -- No re ca I I 
2 -- Recall 
3 -- Re ca II 
4 -- Re ca I I 
5 -- Recall 
6 -- Reca I I 
7 -- Recall 
APPENDIX 6 
DREAMLIKE FANTASY SCALE 
Feels mind was blank. 
Feels he was experiencing something, 
but forgets what. 
Conceptual (no sensory imagery), 
everydayish content. 
Conceptual, bizarre content. 
Perceptual (sensory imagery), non-
hal lucinatory (didn't believe 
experience was real), everydayish 
content. 
Perceptual, nonhal lucinatory, 
bizarre content. 
Perceptua I, ha I I uci natory (be Ii eved 
events he imagined were really 
happening), everydayish content. 




PHYSICAL AGGRESSION SCALE 
0 none 
hitting in fun, I ike hard slap on back 
trivial property destruction 
any case where actions not ostensibly involving 
aggression seem to you to involve it 
2 threats and counterthreats by gesture, posture, word 
carrying a weapon, being in war, if no specific 
agg. cited 
accidental and extensive damage of property of others 
one isolated bit of defensive behavior--one action of 
restraint (press: being apprehended for purposes of 
restraint, confinement only) 
**perception but denial of vague, unspecified threats--
he might do something bad or something bad might happen 
to him 
3 perception of hostile threat, but minimization or 
den i a I of same. Ex**" You mi g ht th i n k that he 1 d h i t her 
but ..• " or (press) "You might think he'd be in danger but ... " 
or *accidental kl 11 ing or injury to other, not S-caused is 
scored as need for s if it is indicated that he is guilty 
.about it 
mild type episode--e.g., one slap 
or contemplation of accidental death or terminal illness 
OT another person or self 
or accidental non-fatal injury to others/self 
or defensive role in aggressive sequence--more than I 
TSolated act · 
or intentional and extensive destruction of property of 
others/self 
4 perception of possibi I ity of 6 act, but denial. Ex**"You 
might think that he would kl 11 her, but he is actual ly •.. "etc. 
or attack upon others: intentional, offensive, violent, 
though some provocation has been offered 
or accidental killing of other or self (press includes being 
"kl I I e d" by d i seas e an d n at u r a I forces as we I I as be i n g 
ki 11 ed by another person by accident) 
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5 contemplat[on of or threat of commlttfng an act I [sted 
as 6 
or any major incident of aggression which seems quite 
unprovoked 
particularly violent episode, sustained in character 
6 ki 11 ing another person, intentionally, whether described 




MANIFEST SEXUALITY SCALE 
The Manifest Se~ual lty Scale 
Instructions to judges: 
I. Since extremely overt sexual behavior (petting, intercourse) 
is rare in dreams, liberal interpretations are to be made 
of sexual "behavior", so that scores of 3-6wi11 be 
moderately frequent for any set of dreams from normal 
subjects. 
2. Where several scores apply, give the highest score except 
when a dream appears to be highly symbolic overal I, but 
has, in addition to the symbolism, some casual sexual 
interaction (e.g., boy talking to girl). Here, give a 
score on the basis of the symbolism (l·-2) rather than on 
the basis of the overt behavior (3-4). 
The. scale. 
0 = none 
=sexual feeling, interest, concern, ascribed to others 
with no overt sexual behavior OR 
,j 
symbolic sexual behavior protrayed In others. A 
representative but not Inclusive I 1st of sexual symbols 
fol lows. Score If these or other symbols can be 
considered, on the basis of dream context, as "probably" 
sexual in any particular case. 
(Male symbols 
pole, key, pen, 
r1fle, gun, sword, 
cigarette, cigar, 
pipe, snake, horse, 
dog, tree, conical 




such as box, door, 
window, vase, glass, 
pot--, kitten, flower, 







instrument, any back 
and forth repetitive 
motion, wild/crazy 
driving in car as 
when out of cont ro I , 
bumping, contact 
symbols; soil, 
infect; shoot wtth 
gun, etc.) 
2 se.xual feeling, interest,· concern ascribed to self 
with no overt sexual behavior OR 
syrri~dl'ic sexual behavior portrayed iri ~elf ••• 
3 =mild "erotic" behavior (dating, flirting, teasing, 
being ·with--tn other than st~ict bus(nessl ike · 
setting--, playing with, joking with, having fun 
or pleasurable casual social interaction with, member 
of opposite sex of approximately equivalent age) 
ascribed to oth~rs · 
4 mi Id "erotic" behavior( ..• ) ascribed to self 
5 strongly "erotic" behavior (spending night with, 
sleeping (with), having intercourse with, petting, 
kissing, fondling, grabbing, touching, bumping, 
or having any bodily contact with, going to bed with, 
in bedroom or sleeping quarters of, member of 
opposite sex of approximately equivalent age; 
pregnancy; implicitly or explicitly having babies or 
marrying (but not necessarily being a parent or being 
married)) ascribed to others 
Note: sleeping in experiment is not counted, 
unless some erotic touch is added to the typical 
laboratory situation 
6 strongly "erotic" behavior( ... ) ascribed to self 
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APPENDIX 9 
ACTIVE PARTICIPATION SCALE 
Dreamer is not present in dream; seems to be exerting 
no control over its action; is not on scene even as 
passive spectator. 
2 Dreamer is present in dream only to extent of being 
passive spectator. 
3 Dreamer is present as participating character but his 
role is entirely or almost entirely passive (recipient 
of others' actions rather than initiator). 
4 Dreamer is present as participating character in 
moderately active role; not the overriding determiner 
of dream events, however. 
5 Dreamer is present in active role and seems to be 




THE VERBAL AGGRESSION SCALE 
0 none 
mi Id teasing mocking or you sense some hostile-type 
tension in conversation with other 
2 derogation of objects associated with person Ex**"Your 
car is a mess". (Some objects, e.g., clothing, may 
be so much a part of the self that an attack on them is 
more properly considered an attack on the person wearing 
them). 
3 derogation of persons associated with a person. 
Ex**"Your mother is a dope" 
4 direct derogation of behavior or beliefs of other. 
In one-sided form, "criticisms", etc. In two-sided form, 
"arguments", etc. 
Score 5, if extended, particularly violent, etc. 
Score 3, if incident is mild, without any apparent 
etc. 
I 1-w i I I 
5 mi Ider than 6 but stronger than 4, in that abusiveness is 
sti 11 evident as is focus of attack on other as a person 




APPENDIX I I 
THE HEDONIC TONE SCALE 
very pleasant 
2 moderately pleasant 
3 slightly pleasant 
4 neither pleasant nor unpleasant; can't tel I 
5 slightly unpleasant 
6 moderately unpleasant 
7 very unpleasant 
APPEND l.X 12 
01.STORTION SCALE 
How distorted or fantastic was it (that is, to what degree 
were you thinking or were you, or other people, or objects 
behaving in ways which would seem strange if they occurred 
in waking life)? 
extremely distorted 
2 quite distorted 
3 fairly distorted 
4 somewhat distorted 
5 a little bit distorted 
6 not at al• distorted 
This becomes a six point distortion scale by reversing the 
numbers preceding the response alternative C I = not at al 
distorted, 6 = extremely distorted), and employing these 
reversed numbers as weights. 
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APPENDIX 13 
THE SHORT-TERM INVESTIGATION SLEEP LOG 
For Each Night of Sleep Day and Date 
(Evening) Lab. Night I 2 3 4 5 6 7 8 9 
Questions I - 3 refer to day before sleep period. (Date above). 
(I) Any Naps? 
study)? 
Alcohol? Medication of any kind (except for this 
If YES please describe. 
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(2) Any unusual activities or occurrences that might have 
influenced your sleep (e.g. physical exercise, upsetting news, 
sexual intercourse, exams, major changes in daily routine 
etc.)? 
(3) Time to bed. 
(4) Time you got up this morning? 
(5) How much sleep do you think you had? 
For Questions 6 and 7 use the fol lowing rating system: 
5 much better 
4 a I ittle better 
3 same as usual 
2 a I ittle worse 
much worse than usual 
(6) How wel I did you sleep compared to the way you usually sleep? 
(7) How do you feel this morning? 
(8) Did you dream at all last night? If yes, please describe 
briefly including mood in dream and any unusual features. 
(9) Do you feel sick in any way whatever? 
Any unusual physical feelings? lf YES please describe. 
( I 0) Any u n us u a I psycho I o g i ca I fee I Ing s th i s morn i n g or du r i n g the 
past day? 
More or Less depressed, anxious, or angry than usual? 
lf YES please describe. 
Question 11 to be answered from night 5 only. 
(II) lf you answered YES to questions 9 or 10, do you think that 
it may be due to +he sleeping pi I I you are taking or is it 
explainable in other ways? 
APPENDIX 14 
THE LONG-TERM INVESTIGATION SLEEP LOG 
S LEEP S T U D Y 
Thank you once again for taking part in this study. You are 
being paid R85.00 for your participation. The reason for this 
is that I would I ike you to be as co-operative and honest as 
possible. It is essential for you to take your sleeping pi 11 
each night. Just keep in mind that a great deal of time, effort 
and money has been put into this study and your co-operation wi I I 
result in its success. The most vital aspects on your part is 
to take your pi 11 each night, complete the sleep log every morn-
ing, and to arrive at the laboratory on time on the required 





Dep~rtm~nt 6f P~yth616gy. 
Te I: 698531 ext. 532 
447221 
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HOME SLEEP LOG 
· rnsTRUCT IONS 
Read the questions carefully and answer them to the best of 
your abi I ity. 
Be quite sure not to leave any out. 
Complete this log shortly after you have woken up. 
Department of Psychology, 
University of Cape Tdwn. 
SURNAME: 
INITIALS: 
DATE LAST NIGHT: 
Day of week yesterday: 
Code No. of pill: 
Did you take your pi 11 last night? 
What time did you take your pill? 
What is the time now? 
Last night was the ...•... night I have taken a pi I I. 
Signature. 
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Questions I ~ 3 refer to day before sleep perlod. (Date on front 
page). 
(I) Any Naps? 
s.tudy)? 
Alcohol? Medication of any kind (~xcept for this 
lf YES please describe. 
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(2) Any un~sual activities or occurrences that might have 
influenced your sleep (e.g. physical exercise, se.xual inter-
course, upsetting news, exams, changes in daily routine etc.)? 
(3) Time to bed? 
(4) Time you got up this morning? 
(5) How much sleep do you think you had (hours)? 
For Questions 6 and 7 use the fol lowing rating system: 
5 = much better 
4 = a I ittle better 
3 = same as usual 
2 a I ittle worse 
I much worse than usual 
( 6 ) How w e I I d i d y o u s I e e p comp a re d to t h e w a y yo u u. s u a I I y s I ee p ? 
(7) How do you feel this morning? (please elaborate if possible). 
(8) Did you dream at al I last night? If YES please describe your 
dream from beginning to en~ in as much detai I as possible, 
including mo6d or ~ny unusual features. If you only remember 
parts of your dream then write these down. How many dreams 
did you have? Include any drawings you might wish to make. 
(9) Do you feel sick in any way? 
Please describe. This is an important aspect of the study 
and it would be appreciated if you would write down any 
unusual physical feelings. If you answered yes, do you 
think it may be due to the sleeping pi I I you are taking or 
is it explainable in other ways? 
( 10) Are any of the symptoms I isted below relevant to your present 
state? Answer YES, NO, or NOT APPLICABLE. Please complete 
al I the categoriei. ff you answered YES to any category, do 
you think it may be due to the sleeping pi 11 you are taking 
or is it explainable in other ways. · · 
( i ) 
( i i ) 
( i i i ) 
( i v) 
( v) 
(vi ) 







diffi6ulty in writing 




(xi i ) 
Cx i l i ) 
difficulty in talking 
mouth very dry · 
mouth very moist 
want to go back to sleep 
felt dizzy but fine when 
felt dizzy even when lying 
lay down 
down 
C.11) If you answered yes to any category in .question (10) please 
elaborate and explain if possible what could ~ave taused it? 
Also if any feeling not listed, describe. 
(12) Any unusual psychological feelings this morning or during 
the past day? More or less depressed, anxious, or angry 
than usual? If Yes please describe. 
For Question 13 use the fol lowing rating system: 
2 sleeping tablet 
=cannot decide 
0 placebo 
(13) Do you think you had a sleeping tablet or a placebo (lnert 
compound) last night? 
(14) In as much detai I as possible describe how you arrived at 
your decision in question 13. 
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( 15) Judging by the way you slept last night and feel this morning, 
would you recommend the sleeping tablet you took last night 
to a friend? Describe. 
(16) Any information you feel that could be relevant to the present 
study (not yet discussed). 
APPENDIX 15 
THE REM DREAM RECALL INVESTIGATION SLEEP LOG 
HOME LOG 
(To be completed each morning upon waking) 
I • DATE NAME 
2. Please indicate by a mark on the fol lowing I ine the amount 
or quantity of your last night's dreaming. An average 
night should mean a mark in the centre 
Dreaming a 11 
the time 
Little or 
no dreami n:::i 
3. Please indicate by a mark on the fol lowing I ine the quality 
of your last night's dreaming. An average night should mean 
a mark in the centre 
Very everydayish, 
ordinary dreaming 
Very vivid, · 
bizarre dreaming 
4. How distorted or fantastic was your dreaming last night, 
that is, to what degree were you thinking, or were you, or 
other people or objects behaving in ways which would seem 
strange if they occurred in waking I ife 
I. extremely distorted 
2. quite distorted 
3. fairly distorted 
4. somewhat distorted 
5. a I ittle bit distorted 




MENTAL SPEED TEST 
SURNAME: 
NIGHT IN LAB: 2 3 4 5 6 7 8 9 
DATE: 
Complete as many of the problems as accurately as possible in 
the given time. 
5+ 7. I+ 7. 3+2. 5 +4. 3+4. = 5+4. 
4+4. 4 + I. 9 +3. = 3+2. 9 +5. = I +6. = 
7+ I. 9 +3. = 5+5 2 +2. I +3. 2 +3. = 
7+6. = 4+3 = 6+9 4+3. 5+0 = 
,. 7+4 
1+2 3+9 4+) 5 +8. 3+6. 3+4 
4+2 = 4+6 5+2 7+7 = 7+1 8+3 = 
6 +I = 6+7 = 6+3. 4+5 '= 8+0. "' 6+9. O!! 
4+0 3+3 = 3+1 6+7 2+0 ::. 5+1 
6+8 = 5+ I. = 9+0 8+9. 4+7 = 8+5. 
9 +2. = 9+1 3+0 3+5. = 9+3. 0+3 = 
5+2. 9 + 7. 5+2. 6+2 1+9 "' 5 + 7. = 
4 +8. ::. 9 +9. 5+6. 3+5. 5+4 = 5 +2. 
4+3 7+7 3+5. 2+2 5+0 = 8+8 = 
5+7 6+3 ·- 9+5. 9 +5. = 8+7 = 3+2 = 
3+2. 9+2 4+5. 7+1 6+9. 6+4 = 
2 + I. = 8+1 3+5. 9+9 6+ 7. 9+9 
3+9. "' 2+7 7+4 2+2 7+8 = 9+1 
6+6 8+9 = 8+0 8+8 6 +I. 2 +5. 
4+3 I+ I 7+0 . 8+4. 8+3. 6+5 
2 +2. = 5+4 8+3 6+5 4+3 5+8 
5+9. = 5+5 9+0. 4+6 4+5 5+6 -
4+3 7+4 = 2 +.5 3+6 3+6. 1+6 
5+) = 6 +I 3+3. 2 +I 2+1 3+7 
I +8. = 6+9 1+8 8 +O. 8 +O. = 3+6 = 
8+1 2 +8. 2 +9. 7+1 7+1 8+8 
5+9. 1+3 6 +8. I +0. 1+0. = 5+4 = 
7+8 7+2 4+5 7+4 0+6. 2+4 
8+ I. 5+7 I +6. 5 +2. 7+4 = 6+4 = 
3+3. 8+3. 9 +5. 8+3 5+2 l+O 
9 +2. 8+6 7+6 4+5 0+9. 7+1 
8 + I. 4+4 5+6 9+4 8+3 6 +O. 
9 +9. 3+5 = 7+5 4+6 4+5. 3+7 
2+6. 5+9 8+2. 8+6. 9+4. 4+7 
I +8. I + I. 6+6 3+2 4+6. = 3+8. 
2+5 7+4. 5+9. 2+7. 8+6. 7 +3. 
7+4. 8•5 3+7 6+ I. 3+2. 3+2. = 
9+2 9 + 7. 5 +4. = 4+4 2+ 7. 9+7 
l.+9. 8+8. = 4+5. 5+8. 6+1 = 7+4 
3+ I. = 3+ L 5+2 l.+9. 4+4. = 5+6. 
2+3 5 +4. 9 + 7. 2+3 5 +8. 4+9. 
I .+5. 7+6. 9 +5. 1+6. I +9. 4+3. = 
3+4 7+8. I +O. 5+4 2 +3. I +6. 
9 +8. 9+4 I + I. 4+3. I +6. = 4+8 = 
_) 
APPENDIX 17 
PRINTOUT OF THE Z SCORE TRANSFORMATION PROGRAM 
LIST 
100 DIM XC20J 
110 PRINT 
120 PRINT " Z SCORE TRANSFORMATI OMS" 
130 PRINT 
140 PRINT 
150 PRINT "NO OF SCORESCMAX=20>" 
160 INPUT N 
170 PRINT ''NEw MEAN.1SDEV" 
180 INPUT Ml.1Sl 
190 PRINT "INPUT DATA" 
200 PRINT 
202 LET M2=52=0 
210 FCR 11=1 TON 
220 INPUT XCilJ 
230 LET M2=M2+XCI1J 
240 LET S2=S2+XCI1Jt2 
250 NEXT Il 
260 LET S2=SQRCCS2-M2t2/1\J)/CN-l>> 
270 LET M2=M2/l\J 
280 PRINT "OLD MEAN=";MlH"OLD SDEV=";S2 
290 PRINT 
300 PRINT "Z SC ORES & NEW SC <RES" 
310 FOR Il=l TON 
315 IF 52=0 THEN 335 
320 LET Z=CXCI1J-M2>/S2 
330 LET Y=Sl*Z+Ml 
331 GOT0340 
335 LET Z=0 
336 LET Y=Ml 
340 PRINT z,y 
350 NEXT Il 
360 PRINT 
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